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Resumen 
En esta tesis doctoral el objetivo ha sido estudiar la nanomecánica de 
proteínas de superficie celular involucradas en la adhesión de 
patógenos a células humanas. Concretamente se han estudiado las 
proteínas que utiliza Escherichia coli uropatogénica para unirse al 
tracto urinario, y el receptor CD4 de los linfocitos T que es empleado 
por el Virus de la Inmunodeficiencia Humana (VIH) para unirse e 
infectar a estas células del sistema inmune. 
 Ambos procesos infecciosos han sido estudiados en profundidad 
desde diversos campos del conocimiento como la Medicina, la 
Biología, la Química y la Física, empleando diversas técnicas que han 
aportado información útil para el desarrollo de tratamientos médicos. 
Sin embargo, y pese a todos los avances logrados, estas enfermedades 
aún hoy suponen un desafío para la comunidad científica y médica. Las 
infecciones del tracto urinario son muy comunes y recurrentes entre la 
población. Aunque en muchos casos se resuelvan de manera favorable, 
el problema de la resistencia a antibióticos es cada vez mayor y ya hoy 
supone un problema grave de salud pública. Las cepas patogénicas 
están adquiriendo resistencia a cada vez más antibióticos, y 
tratamientos que antes funcionaban han dejado de hacerlo. 
Complicaciones derivadas de una infección del tracto urinario pueden 
desembocar en graves problemas de salud que en última instancia 
pueden provocar la muerte. En el caso del VIH los avances científicos 
han permitido transformar una enfermedad mortal en una enfermedad 
crónica, mejorando sensiblemente la calidad de vida de las personas 
que viven con la infección. No obstante a día de hoy no existe una cura 
para esta enfermedad de distribución mundial, de la que cada año 
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alrededor de un millón de personas se contagia. La enorme capacidad 
del virus para eludir al sistema inmune y para, de hecho, utilizar y 
destruir a las mismas células que deberían combatirlo lo convierten en 
un desafío para la Medicina. 
 Si bien estos dos patógenos son diferentes existen paralelismos 
entre ambos que además son exportables a otros casos. 
Independientemente de la etiología de cada caso, todo proceso 
infeccioso comienza por el reconocimiento y la adhesión del patógeno 
a la superficie de la célula que infecta. Para esto las bacterias y los virus 
utilizan moléculas expuestas tanto en sus propias superficies como en 
las de las células a las que se unen, siendo mayoritariamente proteínas 
las moléculas que median el anclaje específico entre los actores 
involucrados. Una vez superado este primer escollo del proceso 
infectivo el patógeno puede proceder con su ciclo de vida y expandirse, 
infectando nuevas células usando mecanismos similares y, en 
consecuencia, deteriorando la salud del huésped.  
 Tanto en el caso de E. coli uropatogénica como en el del VIH, el 
patógeno debe unirse a sus células diana de manera específica y superar 
obstáculos que se oponen a su adhesión física, tales como condiciones 
químicas adversas o la respuesta del sistema inmune. Entre estas 
dificultades se encuentran las fuerzas mecánicas, un ámbito muy 
inexplorado pero a la vez crucial tanto para el éxito como para el 
fracaso de una infección. El diseño y el uso de medicamentos que 
alteren mecánicamente a las proteínas empleadas durante la adhesión 
patogénica podría suponer un avance ante los desafíos que tiene que 
afrontar la Medicina moderna. A la luz de esta nueva aproximación 
orientada a alterar mecánicamente proteínas involucradas en 
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enfermedades humanas nace el campo de la Mecanomedicina o 
Mecanofarmacología, una nueva forma de estudiar y de tratar 
patologías donde un componente mecánico juega un papel importante. 
Debido a que las fuerzas mecánicas intervienen en este proceso, 
creemos que la adhesión patogénica constituye un ámbito de acción 
apropiado para el desarrollo de este nuevo campo. 
 El estudio desde este nuevo punto de vista cobra sentido cuando 
se atiende a las peculiaridades de la infección del tracto urinario. En su 
ruta de ascenso desde la uretra, E. coli debe avanzar por el tracto 
urinario y permanecer unida al epitelio en contra del flujo de orina. En 
ausencia de mecanismos de adhesión sería expulsada durante la 
micción y por ello, de entre un arsenal de factores, dispone de 
estructuras filamentosas denominadas pili o fimbrias que le sirven para 
unirse de manera específica a las células del epitelio urinario. Existen 
distintos tipos de fimbrias pero las empleadas por este organismo en el 
tracto urinario inferior son las denominadas de tipo I. Estos filamentos 
poseen diversas propiedades biomecánicas que le otorgan a la bacteria 
una adaptación extraordinaria para poder prosperar y resistir en este 
nicho tan adverso de la anatomía humana. Una cualidad muy 
interesante de estas estructuras, que pueden llegar a medir varias micras 
de longitud, es el modo en el que están organizadas y ensambladas. 
Estos filamentos están compuestos de cientos de proteínas dispuestas 
linealmente, en el que cada unidad de proteína está conectada a la 
siguiente mediante interacciones débiles de tipo hidrofóbico y puentes 
de hidrógeno. De manera que estas largas cadenas de proteínas 
conectadas, empleadas como anclajes que deben resistir estrés 
mecánico, mantienen su integridad mediante interacciones en 
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apariencia débiles pero que se han demostrado como unas de las más 
resistentes de la naturaleza.  
 Ante el creciente problema de resistencia a antibióticos, atacar 
los pili podría suponer una alternativa válida para impedir la adhesión 
bacteriana en primer lugar. En este sentido comprender las propiedades 
nanomecánicas de las proteínas que componen el pilus así como el 
proceso de biogénesis de este puede ser el comienzo para diseñar 
nuevos tratamientos que alteren la estabilidad mecánica de estos 
filamentos, o bien el proceso de ensamblaje y secreción del pilus en la 
superficie de la bacteria. 
 En el caso del VIH la adhesión se produce preferencialmente a 
los linfocitos T del sistema inmune, y para esto utiliza un receptor 
propio de la membrana del linfocito denominado CD4. La partícula 
vírica expone en su superficie un complejo proteico formado de dos 
glicoproteínas que median tanto la adhesión como la posterior fusión 
del virus con la célula. Una de estas proteínas se une de manera 
específica pero no covalente a CD4, estableciendo el anclaje en la 
superficie de la célula. Posteriormente esta misma glicoproteína 
reconoce a un segundo receptor de membrana en la célula y tras su 
unión se desencadena el proceso que conduce a la fusión del virus con 
la célula.  
 Los esfuerzos realizados para encontrar una vacuna efectiva 
contra el VIH han sido frustrados debido a la naturaleza del virus.  El 
VIH dispone de una serie de ventajas que le permiten eludir al sistema 
inmune, tales como la glicosilación de las dos únicas proteínas que 
expone en su superficie así como de su alta tasa de mutación, lo que se 
traduce en la rápida generación de variantes de estas proteínas. Esto 
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convierte a la lucha del sistema inmune contra este patógeno en una 
carrera de fondo en la que el virus es siempre más rápido. Además la 
habilidad para integrarse en el genoma de las células y permanecer 
escondido en estas lo hace indetectable hasta que vuelve a reaparecer 
para infectar nuevas células. La interacción con el receptor CD4 es 
clave y es la primera que conduce a una infección exitosa. El posterior 
proceso de unión a un segundo receptor en la membrana del linfocito 
supone el acercamiento del virus a la membrana mientras está unido a 
CD4, lo que implicaría que CD4 debería ser una molécula flexible que 
permitiera esta aproximación. Diversos cambios estructurales y 
químicos ocurren en las moléculas involucradas en la infección, y las 
fuerzas mecánicas de nuevo no están exentas en este proceso. Una 
partícula vírica unida al receptor CD4 está sometida a movimiento 
Browniano, de manera que el virus podría ejercer fuerzas en CD4 que 
le permitirían estirar a esta molécula para así acercarse al segundo 
receptor de membrana. Obviamente el rango de fuerzas en las que esto 
se podría producir tiene que ser muy bajo, de lo contrario el virus 
podría separarse de CD4 y alejarse de la superficie celular. En este 
sentido un delicado equilibrio de fuerzas podría inducir la extensión y 
la contracción mecánicamente inducida de CD4, pero sin comprometer 
la unión del virus. Aunque las fuerzas aquí tengan un papel menos 
conspicuo que en el caso de la infección del tracto urinario, también 
pueden ser decisivas y por lo tanto soluciones a la infección por el VIH 
pueden ser encontradas desde un abordaje mecanofarmacológico. 
Comprender la nanomecánica de CD4 así como el efecto de ciertos 
factores que se conoce que afectan a esta molécula, podría ser el primer 
paso para diseñar terapias orientadas a combatir al VIH desde el primer 
paso de la infección. Bloquear el proceso de infección en este punto 
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supondría evitar la infección por completo. Aunque no supusiera una 
cura definitiva para aquellas personas que padecen la infección, 
limitaría su propagación en estos pacientes y además podría ser 
utilizado como medida profiláctica para prevenir nuevas infecciones. 
 Conociendo este contexto nuestro planteamiento ha sido abordar 
estos dos procesos de adhesión desde un punto de vista mecánico, 
explorando cómo las fuerzas y ciertas modificaciones químicas afectan 
mecánicamente a las proteínas involucradas. Para ello en esta tesis se 
ha empleado la espectroscopia de fuerza atómica para aplicar fuerzas a 
moléculas únicas y así poder determinar su comportamiento mecánico 
bajo diferentes condiciones.  
 En primer lugar nuestro objetivo fue determinar la estabilidad 
mecánica de las proteínas que componen el pilus tipo I de E. coli 
uropatogénica. Se diseñaron proteínas quiméricas en las que se 
preservó la interacción nativa que mantiene a cada proteína del pilus 
unida a su predecesora mediante la creación de permutantes circulares. 
La espectroscopia de fuerza en este caso nos permite aplicar fuerzas y 
explorar la resistencia mecánica de estas proteínas y de sus 
interacciones recreando la misma geometría que tendría lugar en el 
proceso in vivo cuando una bacteria es empujada por el flujo de orina y 
el pilus anclado al epitelio es estirado longitudinalmente. Nuestros 
experimentos de fuerza han demostrado la altísima resistencia mecánica 
de estas proteínas, cuyos valores van desde los 500 pN para la proteína 
que está más representada en el pilus tipo I, hasta los 100 pN en la 
última proteína del pilus que media la adhesión al epitelio urinario. De 
manera muy significativa observamos que la estabilidad mecánica de 
estas proteínas es jerárquica y está relacionada con la arquitectura del 
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pilus, siendo las proteínas más débiles a medida que se aproxima el 
final del pilus. Además detectamos el efecto mecánico que tiene un 
puente disulfuro muy conservado en estas proteínas, cuya presencia 
incrementa sustancialmente la estabilidad de estas proteínas. Esta parte 
de la investigación verificó la enorme estabilidad mecánica de estas 
proteínas, de lo resistente que es la interacción no covalente entre 
proteínas del pilus y de lo importante que es la presencia del puente 
disulfuro en cada una de ellas para garantizar la integridad mecánica de 
cada una de las proteínas. 
 En la segunda parte de esta investigación decidimos estudiar el 
proceso de biogénesis del pilus tipo I. Estudiamos el plegamiento y 
maduración de una de las proteínas del pilus tipo I a nivel de molécula 
única y en presencia de los factores que la ayudan en este proceso. La 
espectroscopia de fuerza en este caso es útil para recrear las 
condiciones de desplegamiento y estiramiento que tiene la proteína 
cuando está siendo exportada al periplasma bacteriano, compartimento 
desde donde estas proteínas son incorporadas y secretadas durante el 
ensamblaje del pilus. Nuestros primeros hallazgos en presencia de la 
chaperona que ayuda a estas proteínas a plegarse y a ser incorporadas 
en el pilus, demostraron que ésta solo actuaba sobre aquellas proteínas 
que presentaran su puente disulfuro ya formado, discriminando a 
aquellas que carecen de este enlace. Teniendo en cuenta la diferencia en 
la estabilidad mecánica de estas proteínas dependiendo de si poseen o 
no el puente disulfuro formado, este mecanismo de selección por parte 
de la chaperona garantizaría la incorporación al pilus de únicamente 
proteínas que presentaran el puente disulfuro y que por lo tanto tuvieran 
una alta resistencia mecánica. El siguiente descubrimiento que hicimos 
fue que, en presencia de la enzima oxidorreductasa que induce 
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precisamente la formación del puente disulfuro, el plegamiento de esta 
proteína fue incluso mayor que con la chaperona. Este dato arroja una 
nueva perspectiva al proceso de biogénesis del pilus pues hasta ahora se 
creía que la chaperona era la única encargada de plegar a las proteínas 
del pilus y que la oxidorreductasa solo inducía la formación del puente 
disulfuro. De nuestra investigación concluimos que la oxidorreductasa 
se encarga de ambas cosas y que entrega a la chaperona proteínas 
prácticamente plegadas y listas para su incorporación en un pilus de 
nueva generación. En este escenario la chaperona se encargaría de 
estabilizar el plegamiento de las proteínas que la oxidorreductasa le 
proporciona, evitaría procesos de agregamiento o polimerización 
temprana en el periplasma y escoltaría a las proteínas del pilus hasta la 
plataforma de ensamblaje del pilus tipo I en la membrana externa 
bacteriana. 
 Desde una perspectiva farmacológica, atacar la integridad 
estructural del pilus o atacar a los factores encargados de la maduración 
de sus proteínas podrían ser el camino para combatir las infecciones del 
tracto urinario ocasionadas por E. coli. 
 En la segunda parte de esta tesis decidimos explorar la 
nanomecánica de los dos primeros dominios del receptor CD4, 
CD4D1D2. Obtener información sobre las fuerzas a las que despliegan 
estos dos dominios supone un primer avance para comprender si es 
factible que el VIH pueda inducir su extensión mecánica. Es por esto 
que caracterizamos el desplegamiento de estos dos dominios aplicando 
rangos de fuerzas y velocidades de estiramiento que fueran 
representativos del contexto fisiológico en el que se produce la 
infección. Una partícula vírica unida a CD4 puede ejercer fuerza sobre 
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este pero en ningún caso puede alcanzar los niveles de estrés mecánico 
a los que se tienen que enfrentar por ejemplo las proteínas del pilus 
bacteriano. Cuando sometimos a CD4D1D2 a los diferentes protocolos 
de aplicación de fuerza observamos siempre una jerarquía en el orden 
de desplegamiento de estos dos dominios, desplegando siempre 
primero el domino D2 seguido a continuación del dominio D1. 
Sorprendentemente las fuerzas de desplegamiento de D2 son mayores 
que las de D1, y sin embargo despliega primero al contrario de lo 
esperable. Esta característica se reprodujo en cualquiera de las 
condiciones testadas y la justificamos en base a la estructura de estos 
dos dominios, que comparten una hebra β. Esto supone que cuando se 
les somete a fuerza el dominio D2 despliega y deja desprotegido al 
dominio D1, cuya estabilidad mecánica se ve comprometida una vez la 
fuerza es transmitida a través de este elemento estructural compartido.  
 El desarrollo de un modelo matemático que relaciona física de 
polímeros con grado de infectividad por VIH nos permitió extrapolar, 
en base a unos experimentos previos que utilizaron variantes de distinta 
longitud de CD4, que la posibilidad de que algunos dominios de CD4 
se desplieguen durante la unión del virus es factible. A mayor longitud 
de CD4 mayor es la infectividad por VIH, lo que se relaciona con la 
flexibilidad de CD4 y con la capacidad del virus de explorar áreas más 
grandes de la superficie celular en busca del coreceptor que necesita 
para perpetrar la infección de la célula.  
 Nuestro siguiente paso fue estudiar el efecto que un anticuerpo 
denominado Ibalizumab, conocido por su potente efecto inhibidor de la 
infección por VIH, sobre la nanomecánica de CD4D1D2. La mayor 
parte de los contactos intermoleculares que se establecen entre este 
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anticuerpo y CD4 se localizan en el dominio D2, y se ha demostrado 
que las interacciones proteína-proteína pueden tener un efecto positivo 
en la estabilidad mecánica de las moléculas involucradas. Dado que el 
origen del efecto inhibitorio de Ibalizumab no ha sido hallado nosotros 
hemos planteado la posibilidad de que este anticuerpo pueda volver 
rígido a CD4 tras su unión, reduciendo su flexibilidad y quizás 
impidiendo que CD4 pueda ser extendido mecánicamente por la 
partícula vírica. Descubrimos que efectivamente Ibalizumab altera la 
nanomecánica de CD4 y que las fuerzas requeridas para su 
desplegamiento son mayores, sugiriendo que este efecto estabilizador 
puede ser el responsable de la inhibición de la infección y apoyando 
nuestra hipótesis de que el desplegamiento de CD4 facilita los 
siguientes eventos previos a la fusión del virus a la célula. 
 Finalmente quisimos estudiar el efecto que la oxidorreductasa 
tioredoxina puede tener en la regulación de los puentes disulfuros de 
CD4. Esta y otras enzimas encargadas de la regulación tiol-disulfuro 
son secretadas por la célula y afectan al estado de oxidación de los 
puentes disulfuro de CD4 y otras proteínas. De hecho las reducciones 
de puentes disulfuro del dominio D2 de CD4 y de las proteínas 
superficiales del VIH han sido señaladas como prerrequisitos 
necesarios para la consecución de la infección. Estos enlaces covalentes 
limitan la extensión mecánica de los dominios de CD4, y sólo la 
reducción química de estos por enzimas podría permitir mayores 
extensiones de CD4. Nuestros experimentos de fuerza sobre CD4D1D2 
en presencia de tioredoxina demostraron que los puentes disulfuros de 
estos dos dominios solo son reducidos después de haber sido estirados 
mecánicamente. En ambos dominios estos enlaces están ocultos en el 
interior hidrofóbico de sus estructuras, de manera que solo después del 
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desplegamiento de cada dominio se hacen accesibles para la 
tioredoxina. Dado que la reducción del puente disulfuro de al menos 
del dominio D2 parece necesaria para que se produzca la infección, 
nosotros planteamos que la partícula del VIH puede inducir el 
desplegamiento mecánico de algunos dominios de CD4 y este hecho 
puede hacer que la tioredoxina pueda acceder a los puentes disulfuros 
de estos dominios, reduciéndolos, y permitiendo que el virus pueda 
extender incluso más a CD4, mejorando sus oportunidades de encontrar 
al coreceptor de membrana. 
 Con este conjunto de factores vemos el comportamiento del 
receptor CD4 como el de un amortiguador, que se expande y se contrae 
debido a los movimientos del virus que tiene unido en su extremo. El 
VIH tendría la ventaja de, permaneciendo unido, ejercer fuerzas bajas 
que desplieguen y plieguen a los dominios de CD4 mientras se produce 
el encuentro con el coreceptor de membrana que finalmente conduce a 
la fusión del virus. Junto con los cambios químicos que tienen lugar en 
CD4, esto puede facilitar su flexibilidad e incrementar las 
probabilidades de encontrar a su coreceptor.  
 A la luz de los datos de estas investigaciones proponemos a la 
investigación mecanofarmacológica como una estrategia de futuro para 
tratar enfermedades cuyo origen yace en el malfuncionamiento de un 
componente mecánico. En esta tesis se ha estudiado el proceso de 
adhesión de patógenos y creemos que esta parte de la infección donde 
las fuerzas mecánicas juegan un papel relevante puede ser atacada 
mecánicamente. En el caso de la infección del tracto urinario debilitar 
sus estructuras de adhesión o deteriorando las propiedades 
biomecánicas de estas puede ser el camino para combatir esta 
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enfermedad. En el caso de la adhesión del VIH, hacer más estable al 
receptor CD4 e impedir su extensión mecanoquímica puede ser el 
punto de partida para estudiar si esta opción tiene relevancia a nivel 
fisiológico y puede convertirse en un nuevo tratamiento efectivo para 
prevenir la infección, tanto de nuevas células como de nuevos 
individuos. 
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Abstract 
The role of mechanical force in physiology is becoming increasingly 
recognized as an important factor in the human health. Mechanical 
force affects the function, the organization and the remodeling of 
organs and tissues in the human body, which are processes triggered by 
events occurring at the single-molecule level. In the same way 
mechanical forces are actively present during disease, and their 
involvement is calling the attention of the scientific and medical 
communities. Among diseases, the pathogenic infections are not 
exempt of mechanical forces, especially during the pathogen 
attachment to human tissues where surface proteins from both the 
pathogen and the host interact with each other. Currently, the 
traditional treatments against infections are facing the challenge of the 
bacterial antibiotic resistance and the lack of a cure for some 
pathogenic diseases of worldwide spread. In this sense, the 
pharmacological targeting of the mechanical attachment of the 
pathogen at the single-molecule level is seen to be a new approach to 
fight infections. This new point of view enables the design and 
discovery of new drugs, and the new fields of Mechanomedicine and 
Mechanopharmacology provide a suitable framework for the 
development of new treatments against pathogenic attachment. 
Although the last years have witnessed an increasing knowledge 
regarding single-molecule mechanics, little is known about the 
mechanical features of the proteins used by pathogens for attachment. 
Hence, basic research is needed to unravel the mechanics of these 
molecules and to provide a basis from where a pharmacological 
treatment can be developed. 
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 With this goal, my thesis has focused on the study of the 
nanomechanics of cell-surface proteins involved in viral and bacterial 
adhesion. Specifically I have studied the proteins used by 
uropathogenic Escherichia coli to attach to the urinary tract, and the 
human protein receptor CD4 used by Human Immunodeficiency Virus 
(HIV) for recognizing and infecting immune cells.  
 We hypothesized that bacterial proteins display a high 
mechanical resistance based on their adhesion function in the urinary 
tract. For the CD4 protein it was hypothesized that its mechanical 
extension is related with the Human Immunodeficiency Virus infection 
since this process requires the spatial rearrangement of many elements 
for bringing the virus closer to the cell membrane. Many disciplines 
and techniques are involved in this thesis but the most important 
technique applied for the direct manipulation of single protein 
molecules is single-molecule force spectroscopy. 
 In the first part of this thesis the mechanical resistance of the 
proteins that build the attachment organelle of uropahogenic 
Escherichia coli was studied. This extracellular structure is called type 
I pilus, a filamentous appendage composed of hundreds of proteins 
used during urinary tract infection. We found that pilus proteins show 
not only a remarkable resistance to mechanical unfolding but also that 
they follow an unfolding hierarchy pattern tightly connected to their 
position in the pilus structure. Our results reveal that conserved 
disulfide bonds in each of the pilus proteins are a crucial feature for 
their mechanical stability. Besides unraveling its nanomechanical 
architecture, the biogenesis of the pilus was studied wherein we 
recreated in vitro the same events that take place during the maturation 
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and folding of the proteins previous to their incorporation into the pilus. 
During our investigation we found that the enzyme DsbA involved in 
disulfide bond creation during the first step of pilus proteins maturation 
shows an additional pronounced chaperone effect, which helps to fold 
to pilus proteins in a greater extent than the putative real chaperone of 
this system. With these findings we provide for the first time a detailed 
description at the single-molecule level of the type I pilus mechanical 
architecture and biogenesis. 
 In the second part of this work the nanomechanics of the 
lymphocyte T cell-surface protein CD4 were studied. The CD4 protein 
is used by the Human Immunodeficiency Virus particle to attach to 
these cells. The subsequent events for viral infection require the 
approaching of the particle to the cell membrane to interact with other 
proteins meanwhile attached to CD4. We have discovered that the first 
two domains of CD4, D1D2, are able to unfold at low forces. We 
suggest that this is the range of forces that a viral particle could produce 
due to thermal motion. In this scenario CD4 would act as a shock 
absorber in which its domains can unfold at low forces by the virus, 
therefore increasing the length of the tether and allowing the virus to 
explore the cell membrane looking for the other proteins required for 
viral fusion. Also the regulation by oxidoreductase enzymes of the 
disulfide bonds of CD4 during HIV infection is important for the 
infectivity of the virus. We demonstrated that only the mechanical 
unfolding of CD4D1D2 makes possible the access of the 
oxidoreductase enzyme to the buried disulfide bonds, supporting the 
idea that the viral particle could unfold CD4 in vivo. A mathematical 
model was developed based on the infectivity of cells expressing 
engineered variants of CD4 showing different tether lengths. The 
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infectivity increases with the length of the tether, and the model allows 
interpreting that the in vivo infection would require the extension of 
CD4. Finally the effect of Ibalizumab, an antibody known to be a good 
neutralizer of HIV infection was tested. This antibody’s epitope is 
placed between CD4D1 and CD4D2 domains and the exact mechanism 
for its potent neutralizing effect is unknown. We have found that the 
mechanical stability of CD4D1D2 is increased in the presence of 
Ibalizumab, suggesting that the binding of the antibody hinders the 
extension of CD4 by the virus and this avoids the subsequent events of 
the infection. This supports again that the mechanical extension of CD4 
is mandatory for successful virus infection. Altogether our results 
suggest that CD4 mechanochemical extension may play a critical role 
during HIV infection. 
 In the light of these findings, we think that our results could 
help to develop new therapeutic strategies oriented to alter the 
nanomechanics of proteins involved in pathogenic attachment, in the 
context of the new fields of Mechanopharmacology and 
Mechanomedicine. In the case of bacteria, the use of molecules which 
disrupt the strength of the pilus proteins would circumvent the current 
limitations of traditional antibiotic treatments. For HIV, we suggest that 
an increased mechanical stabilization of CD4 receptor induced by 
antibody binding could prevent the infection or diminish its chances of 
success. 
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Chapter 1: Introduction 
In this first chapter the impact of pathogenic infections in the human 
health are addressed, with a special mention of the two issues covered 
in this thesis: uropathogenic Escherichia coli and HIV-1 attachment. 
Several examples of how forces affect different physiological processes 
are presented, and placed in the context of how some diseases have a 
mechanical malfunction origin that lies at the molecular level. The 
concepts of Mechanopharmacology and Mechanomedicine are also 
presented in this chapter as a potential tool for approaching these 
pathologies. 
 
1.1 Human pathogenic infections 
Pathogen infections are one of the main causes of morbidity and 
mortality in human populations worldwide. In 2015 the third cause of 
death was caused by lower respiratory infections, accounting for 3.2 
million deaths. Diarrheal diseases and tuberculosis produced each 1.4 
million deaths the same year. Although the mortality has been reduced 
during the last years, pathogen infections remain as one of the main 
public health issues1. 
Among the pathogens affecting the human health, the bacterial 
infections are increasingly becoming of public concern because of the 
appearance of antibiotic resistant strains (Fig. 1.1). The amount of 
deaths related with antimicrobial resistance (AMR) in the European 
Union (EU) is estimated to be about 25,000 per year, meanwhile in the 
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United States of America (US) it is about 23,000 deaths per year. In 
low and middle income countries the statistics are not so clear, but 
taking as an example Thailand the numbers are 3 to 5 times larger than 
in the EU or the US, although its population is 5 times smaller2.  
Urinary tract infections (UTIs) represent one of the most 
common bacterial infections, causing from mild cystitis to a severe 
uroseptic shock3. Despite of both women and men can be infected, 
traditionally UTIs have been considered a female disease since 
approximately 50 % of the women will suffer this infection at least 
once along their lives. Moreover, the 25 % of women that experience a 
cystitis episode will experience recurrent infections (rUTI) in the next 
months after the first outbreak4. Several microorganisms can produce 
UTIs (Proteus spp., Staphylococcus saprophyticus, Klebsiella spp., 
Candida spp., Enterococcus spp., etc.) but the main one is the 
uropathogenic Escherichia coli (UPEC)3.  
 
Figure 1.1. World 
year estimation of 
deaths caused by 
several diseases. It 
is estimated that in 
2050 the number of 
deaths related with 
AMR will increase 
from the current 
700,000 to 10 
million. Graph 
adapted from 
reference5. 
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Besides the threat posed by resistant bacterial pathogens, the 
viral infections are also the focus of the international medical 
community. As an example, the Influenza virus is annually responsible 
of 3-5 million severe cases and around 250,000 - 500,000 deaths6. The 
recent Ebola virus outbreak in West Africa caused more than 11,000 
deaths creating an emergency situation which the international 
community failed to contain, due to the rapid spread and the high 
virulence of the virus and the precarious health systems of the affected 
countries7.   
Despite of these viruses calling the attention of the public 
periodically, Human Immunodeficiency Virus (HIV) highlights above 
them because of its worldwide spread and the absence of a cure for it. 
Currently it is not anymore included in the top 10 cause of death list 
elaborated by the World Health Organization, although in 2016 caused 
1 million deaths (Fig. 1.2). In the same year 1.8 million people got 
infected and it is estimated that around 36.7 million live currently with 
the infection8. Despite of its broad distribution approximately 70% of 
the people living with the infection are in Sub-Saharan Africa, being 
the first cause of death in this region of the planet9.  
HIV produces the Acquired Immunodeficiency Disease 
Syndrome (AIDS), a condition based on the destruction of the immune 
system of the host which makes the patient more susceptible to 
infections, cancers and other diseases easily fought by people with a 
healthy immune system10. Huge efforts have been done in order to find 
a cure for this infection; however because of the nature of the virus it 
has been elusive to develop a successful treatment. Currently the 
antiretroviral therapy has proved to be successful converting a deadly 
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disease into a chronic one, but the increase in the life expectancy of 
infected people has increased the chances and the number of new 
infections too11.  
 
Figure 1.2. Estimated number of people dying from HIV-related causes, 2016 by World 
Health Organization (WHO) region. Adapted from reference12. 
 
1.2 The pathogen attachment as a therapeutic 
target 
The medical treatments employed for fighting back pathogenic 
infections are focused on interfering with the life cycle of the pathogen. 
For example antibiotics interfere with the ability of bacteria to 
synthesize proteins, DNA, cell wall components, etc13. The main 
antiretroviral drugs used against HIV infection block the replication of 
the virus at different stages of its life cycle11. In the case of bacteria the 
antibiotics are becoming useless against resistant strains. There is no 
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cure for HIV, its ability to integrate into the human DNA and hiding in 
latent cellular reservoirs makes its eradication impossible14.  
Independently of the differences of each case, in both the 
infection starts once the bacteria cells or viral particles establish contact 
with the surface of the target cells. This contact implies the recognition 
of specific features of the cell surface which serve as an anchor for viral 
and bacterial proteins used for the attachment. A reasonable approach 
to treat these diseases could be to interfere and target the proteins used 
by the pathogens to attach to human cells15,16. Disrupting the first step 
of the infection would avoid the infection itself, reducing the risks to 
the health and also reducing the costs derived from medical treatments.  
 
1.3 Forces at the nanoscale in biological systems 
1.3.1 Mechanobiology and mechanotransduction 
Avoiding the successful attachment of the pathogen is a promising 
target for new therapeutic approaches, however it is important also to 
broaden the way biological processes are studied and seen. Until 
recently the importance of mechanical forces on many biological 
processes which involve from single molecules to organs has received 
little attention. Tissues like bone or skin are exposed to different 
mechanical stresses, meanwhile others are able to exert forces like the 
heart in every beat or the skeletal muscles every time we walk. In many 
biological events mechanical forces are present, and viral and bacterial 
attachment is not an exception. 
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The study of how physical forces affect cells and tissues and 
how these processes are related to certain diseases are questions 
approached by Mechanobiology, a field at the edge of Physics, Biology 
and Bioengineering17. Individual cells in tissues adopt their correct 
morphology through the modification of their own shape, but they are 
also affecting the development of their surroundings including other 
cells. These processes implicate both the generation and the detection 
of physical disturbances in and from the surrounding media. For 
example the T cells of the immune system are exposed to several 
mechanical stresses along their lifetime, from the rigid substrates of the 
thymus to the fluid flow of the blood circulation18. Cells mechanically 
sense their microenvironment through protein complexes, being able to 
respond to the mechanical information with changes at the molecular 
level, a process known as mechanotransduction17,19,20. These 
mechanical stimuli sensed by the cell have a response that can be 
detected at the tissue level like bone grow and remodeling, wound 
healing or blood clotting. The mechanosensing of the environment and 
the mechanotransduction of signals encompasses feedback interactions 
among external structures like the extracellular matrix (ECM), surface 
proteins like integrins, and internal complexes like the cytoskeleton17.  
Many proteins are involved in processes of force generation and 
resistance. For example cadherins are transmembrane proteins involved 
in the adhesion between cells, contributing to the stability of both 
epithelial and non-epithelial tissues. These cadherins interact with 
cytoplasmic and cytoskeletal proteins, connecting the cytoskeleton of 
adjacent cells through specialized interactions named adherens 
junctions20,21. Another interaction related with force detection and 
generation are the focal adhesions, which are highly dynamic 
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complexes involved in cell motility and adhesion which connect the 
cell’s cytoskeleton with the ECM through integrins. These are only a 
few examples of force-bearing and force-producing complexes of the 
cell, where a number of proteins intervene not only as mechanical 
scaffolds but also as chemical and force effectors. An interesting issue 
is the elucidation of how the mechanical stimuli are sensed by cells. 
Proteins are the effector molecules of the cells, so the proteins involved 
in sensing and/or transducing physical signals could experience 
conformational changes upon mechanical stress application. 
 
1.3.2 Protein unfolding under physiological conditions 
The mechanotransduction of signals implies conformational changes of 
the involved effector proteins, which could include their partial or 
complete mechanical unfolding. In the above mentioned focal 
adhesions the linkage between the cytoskeleton and the membrane 
integrins is made by a protein called talin. This protein recruits another 
protein called vinculin for the stabilization of the focal adhesion. 
However the binding sites for vinculin are hidden in the folded talin. In 
a interesting set of single molecule experiments it was demonstrated 
that the mechanical unfolding of talin exposed these cryptic binding 
sites allowing for the recruitment of vinculin (Fig. 1.3). The in vivo 
stabilization of focal adhesions through vinculin binding to 
mechanically unfolded talin could be triggered by the contraction of the 
actin cytoskeleton, exerting forces in the range of the applied ones in 
these experiments21–23. The total or partial mechanical unfolding of 
ECM proteins such as collagen, fibronectin or laminin is related with 
cellular responses such as cell differentiation, proliferation and 
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angiogenesis24. The relevance of protein unfolding in vivo has been also 
reported in several cellular processes like the translocation of proteins 
through membranes or the protein degradation by ATP-dependent 
proteases25. 
 
Figure 1.3. Model for force-dependent regulation of vinculin recruitment at focal 
adhesions and anchoring the actin network. (A) In the focal adhesion the ECM is connected 
to the cytoskeleton through transmembrane proteins called integrins. In the cytoplasmic side of 
integrins, a protein called talin bridges them with the actin filaments. (B) The contraction of the 
actomyosin cytoskeleton triggers the unfolding of the talin protein bound to the integrins and 
the cytoskeleton. (C) The mechanical unfolding of talin exposes its vinculin’s binding sites 
(VBSs) recruiting vinculing molecules. Adapted from reference26. 
One of the most studied molecules from the mechanical point of 
view has been titin, the giant muscle protein. Titin is the biggest known 
protein of the human proteome, being composed of hundreds of 
domains that connect the M-line with the Z-disc in the sarcomere, the 
contraction unit of the skeletal muscle (Fig. 1.4).  
Single molecule techniques have been extensively used for 
unraveling the mechanical properties of this protein and its implication 
during muscle stretching27–34. The findings done along these last years 
support the idea that some of the domains of this protein could unfold 
during muscle stretching, although this is a source of big debate33,35. 
These unfoldings would expose cryptic sites in titin susceptible of 
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modification36,37, and titin would also contribute not only passively in 
the elasticity of the muscle but also generating a restoring force during 
the refolding of its domains38,39.  
These examples in which protein mechanical unfolding occurs 
as part of the normal life cycle of tissues and cells, strongly support the 
need and the importance of studying the effect of forces in biological 
processes.  
 
1.3.3 Mechanomedicine, a mechanical approach to diseases 
All these findings highlight that protein mechanical unfolding is part of 
the normal physiological performance. But in the same way, the 
malfunctioning of some of these proteins is directly linked to some 
pathologies in which physical forces play a crucial role. Many human 
diseases originate as a consequence of alterations in the 
mechanotransduction of cells and tissues and the alteration of the 
mechanical properties of the effector proteins responsible of these 
processes. For example changes in the composition, stiffness and 
architecture of the ECM is found in cancer tissues, increasing the 
proliferation and survival of tumor cells. In another example, abnormal 
levels of the protein talin are observed in several types of cancers. 
Another diseases in which these changes are relevant are fibrosis, 
asthma, atherosclerosis, heart disease among others17,23,40. Since forces 
are an important factor in disease, understanding the mechanics of the 
proteins involved in these pathologies could be an alternative strategy 
for the design of new pharmacological treatments. 
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 A multidisciplinary framework where Biology, Chemistry, 
Physics and Medicine meet is mandatory for investigating these force-
related diseases. Mechanomedicine and Mechanopharmacology appear 
as new fields for approaching pathologies where an altered mechanical 
feature leads to disease. But not only from the research point of view, 
Mechanomedicine and Mechanopharmacology could provide tools for 
the development of new therapies. The design of drugs able to alter the 
mechanical behavior of proteins involved in these pathologies is part of 
the issues covered by this field. On the one hand it is known that the 
binding of some molecules like antibodies to protein epitopes leads to 
the mechanical stabilization of the last41,42. On the other hand 
posttranslational modifications can weaken the mechanical stability of 
some proteins like titin36, cytoskeletal structures like the intermediate 
filaments43, and hybrid protein-DNA structures like nucleosomes44. 
Depending on the specific mechanical origin of the problem it is 
possible to adjust strategies oriented to treat the disease. 
 As in many diseases, the infective process involves more 
aspects than biochemical changes. The pathogen attachment to target 
cells is submitted to forces at the nanoscale, involving cell and 
pathogen surface single molecules. Protein unfolding under these 
circumstances may be a crucial factor for a successful infection, and the 
mechanical disruption or alteration of the proteins involved during the 
attachment process could be mechanically targeted as a 
pharmacological treatment.  
 With this hypothesis, this thesis is aimed to provide a 
description of the nanomechanics of the proteins used by UPEC to 
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attach to the urinary tract, and by HIV to bind to lymphocytes T-cells 
(Fig. 1.4). 
 In the next two chapters the main features of UPEC and HIV-1 
biology and attachment will be presented. To unravel the mechanics 
underlying these processes at the molecular level, and to identify the 
strengths and weaknesses of the main actors mediating attachment, can 
constitute the starting point for the designing of new therapeutic 
strategies in the context of Mechanomedicine. 
 
Figure 1.4. UPEC and HIV-1 attachment to target cells. (Left side) UPEC uses filamentous 
structures called pili or fimbriae to attach to epithelial cells from the urinary tract. These pili are 
made of hundreds of proteins subunits which are secreted from the outer membrane (OM) of 
the bacteria. E. coli image from Manu Forero (DOI:10.1371/journal.pbio.0040314). (Right 
side) HIV-1 particles have macromolecular structures on their surfaces which interact with 
lymphocyte T- cells surface receptors called CD4, in the first step of the infection. Image of 
HIV particles on the surface of a cell from Cynthia Goldsmith (https://www.pixnio.com/). 
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Chapter 2: Type I pilus 
In this chapter UPEC type I pilus is presented, with a special focus on 
its architecture, mechanical properties, and its biogenesis. Before 
approaching the appendage features, a brief explanation of how UTIs 
develop is given in order to better understand the mechanical 
challenges that UPEC faces during uroepithelium attachment.  
 
2.1 UPEC-UTI etiology 
Escherichia coli is a Gram-negative bacterial organism which lives in 
the mucous layer of the mammalian colon. The human gastrointestinal 
tract is invaded by this bacteria a few hours after being born, 
establishing a long-term symbiotic relationship with its host45,46. The 
human intestinal microflora is composed of many microorganisms but 
E. coli constitutes the most abundant facultative anaerobe, being one of 
the most successful competitors in this niche. E. coli rarely causes 
diseases, unless the host is immunosuppressed or the gastrointestinal 
barriers are compromised.  
 Despite of the benefits of this relationship some E. coli clones 
have acquired virulence factors that confers them the ability of 
colonizing and thriving into new niches causing several diseases46. The 
virulence factors enable the bacteria to replicate and to disseminate 
inside of a host by means of subverting or eluding the immune system 
of the host47. These virulence factors are encoded in genetic elements 
that can be distributed among different bacteria strains through 
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horizontal gene transfer. This exchange of genetic material leads to the 
creation of new combinations of virulence factors that arm the bacteria 
with an array of resources that allow them to successfully develop an 
infection in the host. The most successful combinations of virulence 
factors lead to the appearance of pathotypes. The E. coli pathotypes are 
strains able to cause diseases to healthy hosts and there are three main 
clinical syndromes derived from the infection with these pathotypes: 
enteric or diarrhoeal disease, sepsis or meningitis, and UTIs. UPEC is 
the pathotype responsible for about 70-80 % of the UTIs48–50, and it 
constitutes the most common extraintestinal infection46.  
Depending on the anatomical part of the urinary tract colonized 
by UPEC, UTIs are classified in lower and upper infections. Lower 
UTIs are confined to the bladder, producing cystitis. Cystitis could be 
asymptomatic and sometimes it can be resolved without medical 
treatment. When symptoms are present the main ones are: frequency, 
urgency, suprapubic pain, haematuria (red blood cells in the urine) and 
dysuria (pain during micturation)49. The upper UTI is known as 
pyelonephritis and it affects the kidney. Besides symptoms such as loin 
pain, haematuria and cystitis; the more general severe effects are fever, 
vomiting and septic shock. Fig. 2.1 shows a scheme summarizing the 
main features of both cystitis and pyelonephritis. Other UTIs include 
asymptomatic bacteriuria (high count of bacterial cells in the urine), 
urethritis, and prostatitis4,49. 
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Figure 2.1. Clinical features, causative microorganisms, and virulence mechanisms in 
cystitis and pyelonephritis.  Adapted from reference4. 
 
2.2 The onset of the infection 
The UTI probably starts with the colonization of the periurethral area 
by an uropathogenic strain coming from the gastrointestinal tract. Then 
the strain starts its ascension through the urethra to the bladder. 
Anatomical differences between genders favor the infection in women, 
since the urethral opening is in the vicinity of the rectum and the 
shorter urethra facilitates the bladder invasion4,49,50. Once in the urinary 
tract, UPEC faces the difficult physical and chemical conditions 
imposed to any organism trying to colonize this niche. Any organism 
occupying the urinary tract is exposed to the harsh chemical 
environment created by the low pH and the high osmolality of urine. 
Moreover, the bladder is frequently emptied of urine generating a 
physical stress on any loose cell. The unidirectional flow of urine 
generates shear forces that challenge the ability of remaining attached 
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to the uroepithelium to any organism ascending from the urethra51. In 
order to invade and colonize the urinary tract, UPEC displays its 
virulence factors. Among these virulence factors it is possible to find 
several molecules secreted by UPEC like α-hemolysin, cytotoxic 
necrotizing factor 1 (CNF-1), and the autotransported protease Sat46. 
These virulence factors are toxins that target the uroepithelium, 
interfering with several cellular processes. But as it was noted before, 
UPEC faces the forces generated by urine flow standing against its 
ascending route to the bladder and the kidneys. This mechanical stress 
is countered by the presence of virulence factors specific for the 
attachment to the uroepithelium called pili.  
 
2.3 Pili  
The pili or fimbriae are extracellular filamentous appendages 
protruding from the surface of Gram-negative and positive bacteria and 
archaea. They are used for: adhesion, host recognition, biofilm 
formation, and secretion of proteins or DNA.  In Gram-negative 
bacteria there are five different classes of pili that differ both in their 
function and in their assembly mechanism, being categorized according 
to this second feature52.  These categories are: chaperone-usher (CU) 
pili, curli, type IV pili, type V pili, and type IV secretion pili53. Among 
these five assembly systems, UPEC uses the CU-pathway for pilus 
biogenesis. UPEC uses these CU generated pili for the specific 
recognition and attachment to certain sugars present in the 
uroepithelium (Fig. 2.2).  
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Figure 2.2. Type I pili UPEC attachment to the bladder epithelium of mice. (a) Scanning 
Electron Microscopy image of the bacteria cells (yellow) attached to the mice bladder (blue). 
Bar 3 µm. (b) Freeze-dry/deep-etch Electron Microscopy image where the type I pili are 
resolved as long filaments surrounding the bacteria surface and interacting with the bladder 
epithelium. Bar 0.5 µm. Adapted from reference54. 
UPEC is able to express two types of pilus depending on which 
anatomical part is attached to. In the bladder the type I pilus is 
expressed, meanwhile in the kidney the type P pilus is chosen. These 
systems are tightly regulated at the genetic expression level, and when 
a bacterium ascends from the bladder to the kidney the pilus type 
expressed on its surface changes from the type I to the type P. In both 
cases the pilus is made of hundreds of proteins that form a micrometer-
size chain in whose tip is placed a lectin protein able to recognize and 
bind to sugars present in the uroepithelium. In this thesis the focus has 
been put on the type I pilus, the virulence factor used by UPEC for 
bladder invasion.  
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2.4 Type I pilus architecture 
2.4.1 Pilus structure 
The type I pilus is formed by four different proteins called Fims or 
pilins: FimA, FimF, FimG and FimH. These four subunits form a 
filamentous structure of up to ~2 µm of length and ~7 nm of diameter 
that can be divided in two parts: the pilus rod and the pilus tip.  
 
Figure 2.3. UPEC attachment to the uroepithelium with type I pili. (a) UPEC cell attached 
to the uroepithelium through one pilus type I (blue dashed square) meanwhile being pushed by 
the urine flow. (b) Close look to the blue dashed square highlighted in (a). Type I pilus is 
composed of the pilus rod made of hundreds of FimA subunits, and the pilus tip made of the 
array FimF-FimG-FimH. The lectin domain of FimH (FimHL) recognizes and binds to 
mannosylated glycoproteins present in the epithelium such as uroplakin 1a. 
 The vast majority of the pilus is composed by hundreds of 
copies of the protein FimA, constituting the pilus rod. In the pilus rod 
the chain of FimA subunits adopt a quaternary structure that generates a 
right-handed helix configuration, a feature that confers to this rod a 
spring-like behavior. At the distal end of the pilus rod the pilus tip 
composed by the array FimF-FimG-FimH is placed (Fig. 2.3). The 
distal end protein FimH has a lectin domain in its N-terminal part that 
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recognizes and binds to mannosylated glycoproteins present in the 
uroepithelium55,56. 
 
2.4.2 Subunit association in the pilus chain 
The Fim proteins are very similar between each other, being incomplete 
immunoglobulin (Ig)-like domains which lack the C-terminal seventh 
(or G) β-strand. FimA, FimF and FimG have an extra N-terminal β-
strand made of 10-20 amino acids which task is to complement the 
previous domain in the pilus. FimH slightly differs from the rest 
because it is composed of two domains: the C-terminal domain shares 
the same incomplete Ig-like structure of the other pilins (termed here as 
FimHP) meanwhile the N-terminal one is a lectin domain (termed as 
FimHL) involved in the adhesion to the uroepithelium. The absence of 
the C-terminal β-strand generates a deep hydrophobic groove in each 
pilin domain that makes them unstable, and only a β-strand donated by 
another subunit or by a chaperone can stabilize these protein domains57.  
Hence, in the type I pilus the subunits associate head to tail to 
each other forming a chain, where each Fim subunit donates its N-
terminal β-strand to the incomplete fold of the previous one. This 
connection between subunits is known as donor-strand interaction. In 
the pilus rod, each FimA donates to another FimA. In the pilus tip, 
FimF receives the β-strand from the last FimA subunit of the pilus rod. 
Then FimF donates its β-strand to FimG (Fig. 2.4), and finally FimG 
donates to the pilin domain of FimH57.  
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Figure 2.4. Donor-strand interaction between FimF and FimG. FimF N-terminal β-strand 
complements the fold of FimG. Pilin proteins lack the 7th β-strand causing a deep hydrophobic 
groove in its fold that makes them unstable. Lower panel shows the insertion of FimF β-strand 
in the hydrophobic groove of FimG from a longitudinal point of view. FimF displayed as a 
cartoon representation, FimG atoms shown as van der Waals spheres (PDB 4J3O). 
 
This feature defines one of the most remarkable qualities of the 
type I pilus, since this whole filament is assembled through non-
covalent interactions between hundreds of proteins. It is surprising that 
the integrity of the structure used by UPEC to attach to the urinary tract 
relies on apparently weak interactions, precisely when in this 
environment they are frequently challenged by the shear forces 
generated by the urine flow. 
 
Type I pilus 
38 
 
2.4.3 Pilus mechanical features 
Force-induced transition from low to high affinity for mannose binding: 
the catch-bond 
The type I pilus properties have been extensively studied. As a 
virulence factor it attracts the attention of the medical community since 
it can be a potential target for drug therapy instead of the traditional 
treatments with antibiotics. A good alternative approach could be to 
disrupt these structures used for attachment and colonization of the 
urinary tract. Since the beginning the focus was put on the receptor-
ligand interaction of the lectin domain of FimH with the sugars present 
in the uroepithelium. FimH binds to mannose-containing glycoproteins 
present on the surface of the bladder cells, like the protein uroplakin 
1a4,58,59. The recognition and binding of FimH to the glycoprotein D-
mannose has been deeply documented, studied and submitted to 
research focused on interfering with this bond58,60–66. It is common to 
think that when a pulling force is applied to separate two molecules 
(here FimH and mannose), the probability of breaking this bond will 
increase with the force applied67. These are known as slip-bonds, but 
the interaction between FimH and D-mannose is a special type of bond 
known as a catch-bond. In catch-bonds the strength of the interaction 
increases with force: FimH changes from a low to a high affinity state 
for D-mannose when a tensile force is applied to the bond68.  
 The attachment of UPEC to the urinary tract is optimized for 
avoiding being washed out during micturition but also it is optimized 
for maximizing the spreading of the infection and the colonization of 
the ascending route. In the absence of flow this loose attachment 
permits the bacterial cells to roll over the epithelium establishing new 
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infection focus. When the shear force induced by the urine flow push 
the cells, the bacteria pili that act as tethers are stretched, and finally 
this stretching force is transmitted to the bond between FimH and D-
mannose. Under this last circumstance, a spatial rearrangement induced 
by force between the lectin and the pilin domains of FimH increases the 
affinity for the sugar. The pilin domain acts as a negative allosteric 
regulator of the lectin domain bond with mannose, and tensile force 
separates both domains causing the lectin
 
to clamp tightly the mannose 
ligand yielding a long-lived and resistant interaction (Fig. 2.5). In the 
absence of force, in the pilus tip both domains adopt a hooked shape 
stabilized by weak inter-domain interactions. On the contrary FimG 
and FimF do not have these inter-domain interactions neither between 
them neither with FimH pilin domain and they act as a highly flexible 
hinge region between the rigid pilus rod and FimH, allowing for this 
hook conformation of the tip to explore the epithelium64,69–72.  
 
Figure 2.5. Catch-bond mechanism between FimH lectin domain and mannose. (a) 
Transition from the free (1) to the low-affinity bound state (2) of FimH-mannose. In the 
presence of shear forces (3), a conformational rearrangement between the lectin and the pilin 
domain of FimH increases the strength of the receptor-ligand bond. (b) Force dependence of 
the bond lifetime of slip-bonds (grey) and catch-bonds (brown). In slip-bonds the probability of 
receptor-ligand dissociation increases with the tensile force, meanwhile in catch-bonds the 
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strength increases with the force up to an optimum level and then it decreases again. FimH 
lectin domain-mannose binding exhibits this force-induced increase in lifetime72. 
 
Pilus rod uncoiling under shear stress 
Besides the optimization of the binding between FimH and the 
epithelium, the type I pilus also displays an additional mechanism for 
optimizing its attachment. The pilus rod composed of hundreds of 
FimA subunits adopts a quaternary structure in which the protein chain 
forms a rigid right-handed helix55. The biomechanical properties of the 
rod has been studied in single-molecule force experiments which 
demonstrated that this structure is able to uncoil under force and recoil 
when the force is reduced73–75. Under high shear stress this uncoiling 
mechanism of the rod increases the length of the pilus several times and 
it extends the lifetime of the catch-bond, protecting the bacterium from 
the detachment. When the stress is low enough the pilus experiences an 
entropic contraction of the chain followed by the recoiling of the helix 
rod, making possible the movement of the bacteria against the fluid 
flow (Fig. 2.6). This behavior depicts the pilus as a shock-absorber that 
extends and contracts depending on the flow, reducing the drag force 
experienced by the bacteria. Pili are present in a high number on the 
bacteria surface, and each of them acting as a damper would 
redistribute the stress in all of them, avoiding the overstress on 
individual pilus73,76,77. 
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Figure 2.6. Pilus rod uncoiling and retraction. Pilus rod helix configuration uncoils and 
extends after tensile force application. When the mechanical stress ceases, the retraction of the 
extended rod occurs in two phases. In the first one the extended rod behaves as an entropic 
spring, quickly retracting. In the second one the FimA subunits stack and coil again in a helical 
configuration at lower speed. Adapted from reference76. 
 
2.5 Type I pilus biogenesis 
The pili are placed in the outer plasma membrane (OM) of the bacteria 
where a transmembrane protein called Usher or FimD serves as a 
platform for their assembly. The pilus assembly is a complicated 
multistep process that takes place in several cellular compartments and 
involves the action of many proteins. The final destination of the pilus 
proteins is the extracellular space, but before they need to be exported 
from the cytoplasm to the periplasm through the inner plasma 
membrane (IM). Once in the periplasm and after the Fims have been 
folded and maturated, FimD incorporate these proteins to the nascent 
pilus and it expels them to the extracellular space through the OM.   
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2.5.1 Exportation to the periplasmic space 
This complex process starts with the Fim proteins being synthesized in 
the bacterial cytoplasm as pre-proteins. These pre-proteins have an N-
terminal signal peptide that labels them for being exported to the 
periplasm. The translocation to the periplasmic space through the IM 
depends on the Sec secretion system. The Sec translocase is made of 
three components: the chaperone SecB, the translocation ATPase SecA, 
and the membrane protein complex SecYEG. The pre-proteins are 
translocated into the periplasm in an unfolded and extended state 
through the pore made by the SecYEG complex78. Once in the 
periplasm, the immature Fims are subjected to a maturation process that 
involves the formation of a disulfide bond through the oxidation of the 
lateral chains of two cysteine residues, very well conserved not only in 
the type I pilus subunits but also in other pili79. This disulfide bond 
formation is managed by the Dsb system in the periplasm, whose main 
actors are the soluble periplasmic protein DsbA and the IM protein 
DsbB.  
 
2.5.2 Disulfide bond formation by DsbA 
DsbA is an oxidoreductase involved in redox reactions taking place in 
the periplasm. DsbA is part of the thioredoxin-superfamily and like the 
enzymes of this family it possesses a catalytic motif CXXC (two 
cysteine residues separated by another two different amino acids) 
whose cysteine residues alternate between oxidized (disulfide-bonded) 
and reduced (free thiols) state.  
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 Meanwhile the SecYEG complex translocates the Fim protein, 
part of the chain appears in the periplasmic side of the IM and then an 
oxidized DsbA can interact with it. Then one of the free thiols of the 
Fim proteins performs a nucleophilic attack on DsbA disulfide bond, 
breaking the bond between Cys30 and Cys33, and forming a mixed 
disulfide bond with Cys30. Afterwards, the remaining free thiol of the 
Fim protein attacks the mixed disulfide formed between DsbA and the 
Fim protein, releasing a reduced DsbA and the disulfide bonded Fim 
protein. DsbA oxidized state is restored by the reduction of one of the 
CXXC motifs of the IM protein DsbB. Later on the reoxidation of 
DsbB is performed by an oxidized quinone, restarting the Dsb system 
for a new cycle of substrate oxidation (Fig. 2.7)80–83.  
 
Figure 2.7. Fim protein exportation to the periplasm and disulfide bond formation. (1) A 
FimA preprotein is translocated to the periplasmic space through the SecYEG complex, placed 
in the inner bacterial membrane (IM). (2) A thiol group from one of FimA cysteines attacks an 
oxidized DsbA enzyme, forming a transient disulfide bond between DsbA and FimA. (3) The 
thiol group from FimA’s second cysteine attacks this intermediate, forming a disulfide bond 
between FimA cysteines and releasing a reduced DsbA. (4) DsbA is later oxidated by the 
transmembrane protein DsbA, restoring its disulfide. An ubiquinone is the final acceptor of the 
electrons, restoring the cycle for the next DsbA’s substrate. 
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2.5.3 Folding of pilus subunits by the chaperone FimC 
As it was mentioned above the four Fim proteins are incomplete Ig-like 
domains lacking the C-terminal β-strand. This absence creates a deep 
hydrophobic groove in their fold that makes them thermodynamically 
unstable unless they are complemented by the donation of the N-
terminal β-strand from their cognate subunit, this is the following 
protein in the pilus assembly (FimH-FimG, FimG-FimF, FimF-FimA, 
FimA-FimA). Nevertheless this complementation between subunits 
does not occur until they are incorporated into the growing pilus in the 
OM platform FimD. After disulfide bond formation induced by DsbA, 
the chaperone FimC gets into action. This chaperone is made of two 
connected Ig-fold domains which form a 45º angle between each 
other52. FimC stabilizes the fold of pilus proteins by donating its G1 β-
strand, which is inserted between the A’ and F strands of the pilin 
domain, running in a parallel orientation respect to the second (Fig. 
2.8).  
 This process is called donor strand complementation (DSC) and 
it takes place for all the pilin domains in the periplasm84. The pilin 
domains’ hydrophobic groove contains five conserved pockets termed 
P1-P5, which are filled during DSC with FimC’s G1 strand P1 to P4 
residues (three alternating bulky hydrophobic residues and a fourth 
hydrophilic amino acid). FimC helps pilin subunits to reach a 
semifolded metastable state through DSC which makes them competent 
for assembly into a growing pilus. Besides, FimC protects the pilin 
subunits from proteolytical degradation, prevents the aggregation with 
other subunits present in the periplasm, and escort the pilus subunits to 
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the OM polymerizing catalyst FimD/Usher, the platform in charge of 
pilus assembly and secretion84–89.  
 
Figure 2.8. DSC of FimA. (a) Scheme of the incomplete Ig-fold of FimA with the G1 
complementary strand donated by FimC running parallel to FimA F-strand. FimA domain, as 
FimF and FimG do, has an N-terminal strand for complementing the previously assembled 
subunit in the pilus. (b) Cartoon representation of the FimA-FimC complex, highlighting the 
parallel orientation of FimC G1-strand and FimA F-strand. Donor N-terminal strand from 
FimA is not present in this structure. (c) QuickSurf representation of FimA fold (lacking the N-
terminal strand) with its F-strand depicted as a cartoon and FimC G1-strand depicted as a 
yellow ribbon, with its P1-P4 residues depicted as red lines. The right figure has been rotated 
vertically 90º to emphasize how G1-strand fits into FimA hydrophobic groove (PDB: 4DWH). 
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2.5.4 Pilus assembly and secretion in FimD 
The final destination of the pilin-chaperone complexes is the OM 
protein FimD. FimD is a five-domain OM protein composed of one N-
terminal periplasmic domain (NTD), a transmembrane β-barrel domain 
forming the secretion pore, one periplasmic plug domain that seal the 
secretion pore, and two periplasmic C-terminal domains (CTD1 and 
CTD2) (Fig. 2.9)90.  
 
Figure 2.9. FimH-FimC complex recruitment in FimD. FimD is composed of five 
periplasmic domains and one transmembrane domain. The plug domain occludes the 
transmembrane pore when FimD is inactive. The NTD receives incoming pilin-chaperone 
complexes and transfer them to CTD1 and CTD2 for DSE reaction with the next protein in the 
assembly and latter translocation. Here FimH lectin domain is already inside of the pore and the 
pilin domain is in DSC state with FimC (PDB: 3RFZ). 
 The architecture of the pilus is crucial for the attachment of the 
bacteria, thus a mechanism should control the correct order of pilus 
subunits incorporaton into the pilus. FimH is the tip end subunit so it 
should be incorporated the first, followed by FimG, FimF and then 
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hundreds of FimA subunits. FimD NTD is the primary binding site for 
pilin-chaperone complexes recruitment, and the affinity for this domain 
varies among the four different complexes91. It has been demonstrated 
that FimH-FimC complex shows the highest affinity for FimD NTD, 
explaining why it occupies the first position in the pilus92. However the 
binding affinities of the other complexes do not correlate with their 
order of assembly into the pilus. The order of assembly is determined 
by the favorable exchange of FimC G1 complementary strand by the N-
terminal β-strand of the incoming subunit to the FimD platform. This 
process is termed donor-strand exchange (DSE) and it is kinetically 
favored when the incoming subunit donates the cognate β-strand (this is 
FimG after FimH, FimF after FimG and so on)93. FimD greatly 
increases the rate of this reaction by bringing closer all the involved 
elements, and by their correct positioning for optimal DSE94. The 
complementation through antiparallel DSE produces a strong 
thermodynamic stabilization of the Ig-fold, maintained by hydrophobic 
effects and an extensive hydrogen bond network between the donated 
strand and the A and F-strand of the fold95–97.   
 After FimH-FimC complex recruitment the plug domain of 
FimD is moved out to the periplasmic space, allowing the lectin 
domain of FimH to introduce inside of the pore (Fig. 2.9). Then FimH-
FimC is transferred to the CTDs of FimD, which provide a high-
affinity binding site for the complex. The periplasmic compartment is a 
very crowded space and probably the NTD of FimD is constantly 
submitted to incoming complexes which would be randomly 
incorporated into the pilus. But in order to continue with the pilus 
translocation the next complex should contain the correct subunit for 
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DSE with FimH-FimC waiting complex in the CTDs. When a new 
complex arrives to NTD, the donor β-strand of the subunit is placed in 
such a way that its P5 residue is close to the FimH P5 pocket. The 
FimC G1 strand from the FimH-FimC complex only occupies FimH’s 
P1 to P4, leaving free this fifth pocket available for the P5 residue of 
the incoming donor β-strand. The DSE reaction can only take place if 
there is a correct steric fit between FimH P5 hydrophobic pocket and 
the P5 residue of the next recruited subunit, being this correct surface 
complementarity what finally determines the order of assembly. After 
P5 residue correctness is addressed, a process of zip-in-zip-out takes 
place where the incoming β-strand invades the hydrophobic groove and 
progressively substitutes FimC G1 strand. 
 After FimH-FimC positioning in the CTDs, a FimG-FimC 
complex in the NTD proceeds with the DSE with FimH-FimC. The 
donor β-strand is inserted in an antiparallel fashion respect to the F 
strand completing and resembling the canonical fold of the pilin 
domain. After DSE the chaperone is released from FimH, leaving free 
the CTDs for the transfer from the NTD of the FimG-FimC complex. 
At the same time FimH translocates through the FimD pore to the 
extracellular space. This translocation is supported by the high-affinity 
of the CTDs for the complexes, which compete with NTDs for their 
binding. An additional support is given because of the presence of a 
helical pathway inside the pore which imposes a rotation of 110º to 
each extruded subunit. This generates a rotational uplift through the 
pore, facilitating this rotation the transfer of the next complex from the 
NTD to the CTDs (Fig.2.10). The free NTD is available for the 
recruitment of the next complex, this time FimF-FimC, and so on for 
the next pilins in the assembly52,56,95,98–104. 
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Figure 2.10. Pilus tip assembly in FimD. (a) In this moment of the pilus biogenesis, both 
domains of FimH has been translocated to the extracellular space. FimG is inside the pore and 
FimF is forming a complex with FimC, waiting for an incoming FimA-FimC complex at the 
NTD for receiving the donor-strand of FimA. (b) Detail of the intersubunit complementation. 
FimG donor-strand fills the fold of FimH pilin domain, meanwhile FimF donor-strand does the 
same on FimG (PDB: 4J3O). 
 It has been demonstrated that subunit translocation only requires 
the pilus subunits, the FimC chaperone, and FimD for efficient 
polymerization of pili in vitro, being independent of the cellular energy. 
There is no ATP in the periplasm and no chemical gradient along the 
OM, thus the competition between the CTDs and the NTD for the pilin-
chaperone complex and the helical pathway imposed inside the pore are 
proposed as the driving-force pushing the secretion of the pilus94,105. 
Besides these two proposed mechanisms for protein translocation, 
Brownian motions probably also contribute to the secretion of the pilus. 
However Brownian motions do not impose directionality, so the pilus 
should be coming in and out of FimD pore with no net extrusion to the 
extracellular space52. It has been proposed that some rearrangements in 
the pilus subunits take place after being secreted through the pore, such 
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as an angle change between the lectin and the pilin domain of FimH 
(Fig. 2.11). Both domains are aligned when bound to the CTDs, but 
after complete extrusion through the pore both domains display a 37.5º 
angle between each other that would prevent their backward motion. 
The rotation imposed through the pore plus the quaternary structure 
adopted by the pilus rod through FimA subunits interactions would 
give directionality to the pilus growing, but it could not be discarded 
the role of  the plug domain of FimD as a ratchet that avoids the pilus 
to slide back90,95. 
 
Figure  2.11. Conformational changes guaranteeing pilus extrusion. FimH lectin and pilin 
domain form a 37.5º angle between each other, a change happening after translocation (both are 
aligned meanwhile being extruded, see Fig. 2.8). Besides, every subunit is 110º 
counterclockwise rotated meanwhile traversing the pore. This imposed helical pathway make 
subunits to wind, and in the case of FimA to form a helical rod (PDB: 4J3O). 
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Chapter 3: CD4 receptor and 
HIV 
In this chapter the main features of HIV-1 infection are explained. The 
focus is on the cell-surface receptor CD4, the protein used by this virus 
to establish the first interaction leading to infection. The chemical 
regulation of CD4 and the HIV-blocking activity of an anti-CD4 
antibody are also shown. 
 
3.1 HIV historical perspective 
AIDS was identified for the first time in 1981, when a group of young 
adult people got sick and died from opportunistic infections easily 
fought by the immune system. The people affected by this disease 
suffered from slimness and had a weak appearance, besides showing 
purple lesions on their skin due to a rare type of cancer called Kaposi’s 
sarcoma. Later in 1982 the infectious origin of AIDS was determined, 
which occurs as a consequence of the exposition to contaminated body 
fluids or blood. The disease was rapidly spreading worldwide 
becoming an epidemic, and cases appeared among the previously 
believed non-risk groups. The origin of the immunodeficiency was 
found out to be rooted on the diminished levels of CD4 T-cells present 
in the blood of the affected people106.  In 1983 it was identified a new 
human retrovirus in a sample taken from a patient that later on 
developed AIDS, and it was linked to the human T-cell leukemia virus 
family (HTLV)107. One year later two independent investigations 
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related this retrovirus, termed as HLTV-III, to lymphadenopathy-
associated retroviruses (LAV) regarding morphological and biological 
criteria. Isolated serum from AIDS patients reacted with antigens 
present in HLTV-III, suggesting this retrovirus was the etiological 
agent of AIDS108–111. In 1986 this pathogen was named as the human 
immunodeficiency virus (HIV)112. 
 Two HIV types have been identified, termed as HIV-1 and HIV-
2, closely related to simian immunodeficiency viruses (SIVs). Both 
HIV types have an African zoonotic origin, when the simians’ 
pathogens crossed to the human species because of the direct 
exposition of hunters to chimpanzee blood and mucosal secretions. 
Both HIV-1 and HIV-2 cause AIDS, but HIV-2 is restricted to West 
Africa and it is less virulent and transmissible than HIV-1. There are 
four groups of HIV-1, each one representing a different transmission 
event (M, N, O and P). The M group is worldwide distributed and it is 
divided in nine subtypes (A-D, F-H, J, and K) predominating the C and 
B subtypes9,11,113,114. The main transmission mode of HIV-1 is through 
sexual contact, and since the onset of the pandemic 35 million people 
have died from AIDS-related diseases and 76 million people have 
become infected6. 
 
3.2 HIV-1 tropism 
HIV, as SIV does, belongs to the lentivirus genre. These viruses’ viral 
particles are characterized for a lipidic envelope that encloses a protean 
capsid core where the viral genome and proteins involved during 
infection are stored (Fig. 3.1)115. These viruses target the host’s 
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immune system, preventing their eradication by the same immune cells 
they infect. The HIV-1 (from now referred as HIV) targets the 
monocyte/macrophage lineage and lymphocyte T-cells establishing 
persistent infections. The immunodeficiency originates from the 
infection and depletion of CD4+ helper T cells involved in the adaptive 
immune response, being these cells the main target of HIV.  
 
Figure 3.1. HIV-1 structure. HIV virion particle is made of a lipid bilayer envelope which 
displays on its surface the heterotrimeric protein complexes Env. Each Env complex is made of 
three gp41 subunits associated with another three gp120 subunits. These two proteins have a 
crucial role during cell attachment and infection. Inside the virus are stored several proteins and 
enzymes involved during inside-cell infection process besides a protein capsid which encloses 
the viral RNA genome. Inspired from Thomas Splettstoesser work (www.scistyle.com). 
Representation is not at scale. 
3.2.1 HIV cell infection at a glance 
In order to infect cells HIV free-virion must adhere to the surface of the 
cell. Cell recognition and adhesion relies on a viral surface glycoprotein 
complex termed Env. Env binds sequentially to CD4 surface receptor 
and then to a membrane chemokine coreceptor which can be either 
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CCR5 or CXCR4. This second interaction with the coreceptor triggers 
conformational changes on HIV Env glycoprotein inducing membrane 
fusion between the cell and the virus, liberating the viral capsid into the 
cell.  
 Once in the cell cytoplasm the viral capsid is uncoated and the 
single stranded RNA genome is released for reverse transcription into 
double stranded DNA by an error-prone reverse transcriptase enzyme. 
Viral DNA is then transported to the cell nucleus where it integrates 
into a chromosome. Using host cell machinery the HIV genome is 
transcribed, translated, and post processed in order to generate new 
virions that finally bud out from the cell, releasing new infective 
particles to the extracellular space for viral expansion inside the host 
(Fig. 3.2).  
 
Figure 3.2. HIV-1 life cycle. (1) HIV-1 infection starts with the binding of the virion to a CD4 
receptor present on the surface of a CD4+-T cell. This attachment is done through the viral 
surface glycoprotein gp120 from an Env spike. (2) This same glycoprotein interacts with a 
surface coreceptor meanwhile attached to CD4. (3) Conformational changes in the viral Env 
spike leads to the formation of a pore on the host cell surface and the fusion of both 
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membranes, releasing the content of the virion into the cell cytoplasm. (4 y 5) Viral single-
stranded RNA is reverse transcribed into double-stranded DNA. (6) Viral DNA genome is 
transported to the cell nucleus and it is inserted into the cell genome. (7 y 8) The inserted viral 
genome is transcribed and translated to assembly new infective virions that finally bud out from 
the cell surface. Inspired from reference11. Representation is not at scale. 
 
3.2.2 Cell-to-cell infection 
Although HIV primary targets CD4+ helper T cells, antigen presenting 
cells (APCs) such as dendritic cells or macrophages can also become 
infected by HIV since they express the receptors required for Env viral 
protein binding, but in lower levels. Besides cell-free virion infection 
HIV has the ability to propagate and infect immune system cells 
through cell-cell interactions. These interactions are a natural 
mechanism among immune system cells, but HIV hijacks them to 
spread. Lymphocyte cells are constantly searching and identifying 
antigens present in the blood stream and in the lymphatic system. 
During the adaptive immunity response T-cell receptors (TCR) 
displayed on the surface of CD4 T-lymphocytes, recognize peptides 
presented by an APC in the major histocompatibility complex class II 
(MHC-II). MHC-II molecules are placed on the surface of APCs and 
the MHC-II/TCR interaction is further stabilized through CD4 receptor 
binding to MHC-II, forming what is termed as the immunological 
synapse.  The recruitment of CD4 to the MHC-II/TCR intercellular 
complex besides a stabilization role also triggers the onset of cell 
signaling for T-cell activation. Cell-to-cell transmission can occur 
during antigen recognition by T cells of APCs like dendritic cells, 
which can capture and internalize HIV virion. The virus containing 
dendritic cell (but maybe not infected) transmits the virus to the T-cell 
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through a process called trans-infection that requires the formation of 
what is termed virological synapse between the two cells.  This viral 
synapse is the membrane cell-to-cell contact area characterized by the 
recruitment of CD4 and the coreceptor, highlighting again the 
importance of these two membrane receptors for HIV entry. 
 However as it was noted before the preferential target of HIV 
are the CD4+ T-cells, and the dissemination of the virus through T-
cell/T-cell interactions has proven to be highly efficient for HIV 
spreading. In the viral synapse between two T-cells the infected cell 
displays the viral Env glycoprotein, which interacts with the CD4 
receptor present in the uninfected T-cell. Although this interaction is 
crucial for the successful infection, other surface adhesion molecules 
such as ICAM-1, ICAM-3 and LFA-1 facilitate the adhesion between 
cells. The Env-CD4 interaction yields a time lasting adhesion that 
reorganizes the viral production of the infected cell close to the cell-cell 
contact surface. The viral particles are then internalized by the non-
infected cell into an endocytic compartment where the virions are 
finally maturated into a fusion-competent state116,117. 
 
3.3 HIV entry key components 
HIV entry requires three essential components: viral Env, CD4 
receptor, and any of the coreceptors. HIV can attach to cells through 
several different auxiliary molecules present on the cell surface but 
viral and cell membrane fusion will not be triggered until the 
recruitment of CD4 and coreceptor molecules, making their presence 
indispensable for HIV entry (Fig. 3.3). 
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Figure 3.3. HIV-1 adhesion and entry. HIV Env spikes are made of two proteins, called gp41 
and gp120. The last one mediates the attachment to CD4D1 domain and later to a surface 
coreceptor. This two interactions of gp120 trigger structural changes in the Env spike that leads 
to the release of a fusion peptide from gp41 which generates a fusion pore for membranes 
fusion. Inspired from reference118. Representation is not at scale. 
 
3.3.1 Env spikes 
Env is the membrane glycoprotein of HIV and the unique viral 
antigenic protein exposed. It is first synthesized in the endoplasmic 
reticulum as a precursor termed gp160. After folding and extensive 
glycosylation, gp160 forms trimers stabilized through non-covalent 
interactions. These trimers travel to the Golgi compartment where they 
are cleaved into two subunits called gp120 and gp41, generating a 
trimer of heterodimers (three gp120/gp41 dimers)119. After maturation 
these Env trimers are transported to the cell surface where they are 
incorporated into the budding virions.  
 Env trimers protrude out of the viral envelope generating what 
is termed viral spikes. In these spikes gp41 is the transmembrane 
protein and gp120 the exterior subunit. The gp120 glycoprotein 
mediates the sequential binding of the virus to CD4 and then to the 
coreceptor, meanwhile gp41 is involved in the fusion of the viral 
envelope with the host cell membrane.  
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The gp41 subunit is composed of three major domains: a C-
terminal cytoplasmic domain, a transmembrane domain and an 
extracellular domain. This last domain contains, among other important 
sequences, the fusion peptide that penetrates and destabilizes the cell 
membrane to form the fusion pore. This fusion peptide is buried in the 
viral spike, and the binding of gp120 to CD4 and the coreceptor 
triggers conformational changes that expose it. The most apical part of 
Env is the gp120 glycoprotein. Its structure is made of five variable 
loop domains (V1-V5) and five constant domains (C1-C5). The 
sequence variability of the V domains originates from genetic changes 
like mutations and recombination and together with the heavy 
glycosylation of gp120, it prevents the recognition from the immune 
system. The CD4 binding site in gp120 is disseminated within the C1, 
C3 and C4 domains, which are far from each other in sequence but in 
close proximity in the folded structure. In the bound state CD4 contacts 
26 residues of gp120 triggering a large conformational change in gp120 
that exposes the coreceptor binding surface placed in V3 region. V3 
region shows dominant epitopes that are recognized by neutralizing 
antibodies, but its exposition only occurs after CD4 binding. Postposing 
the exposition until CD4 binding limits the time in which V3 epitopes 
can be targeted, and also it limits its availability due to the proximity to 
the cell surface which sterically prevents antibody access120. 
 
3.3.2 CD4 receptor 
CD4 is a cell-surface glycoprotein present in CD4+ T-lymphocytes, 
macrophages and dendritic cells. It is composed of four extracellular 
immunoglobulin domains, numbered from the N-terminal most exterior 
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domain as D1 and the closest one to the cell membrane as D4. All 
domains with the exception of D3 contain disulfide bonds, and both D3 
and D4 contain one glycosylation site. Besides the extracellular part 
CD4 also possesses a single transmembrane domain and a cytoplasmic 
C-terminal tail (Fig. 3.4)121.  
 During the adaptive immunity response the TCR recognizes and 
binds to antigenic peptides bound to the MHC-II presented by APCs. 
The T-helper cell is activated due to the recruitment of CD4 receptor 
which binds to MHC-II in a different site than TCR does it. The 
cytoplasmic tail of CD4 is associated to the tyrosine kinase Lck, which 
would be brought into close contact to the cytoplasmic side of the CD3-
TCR complex leading to their phosphorylation initiating a cascade 
signal that leads to T-cell activation122,123.  
 
Figure 3.4. CD4 extracellular structure. The extracellular domain of CD4 is composed of 
four domains. D1 and D2 are colored different from D3-D4 because of the D1 role during HIV 
binding and because of the role of D2 as a promising target for antibody recognition to prevent 
HIV infection (D2). Disulfide bonds are highlighted in yellow van der Waals spheres, 
meanwhile the glycosylation sites are represented with green beads (PDB: 1WIP). 
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3.3.3 Chemokine receptor CCR5 or CXCR4 
CCR5 and CXCR4 chemokine receptors are seven-transmembrane 
domains coupled to G-proteins. Both present an extracellular N-
terminal tail, three intracellular and three extracellular loops, and a C-
terminal cytoplasmic extension119,124. Chemokines are a group of small 
peptide molecules which act as chemoattractants and activators of 
phagocytes. The chemokine interaction with their receptors triggers 
biochemical and cellular changes important for a rapid first response 
against infections.  
 These two receptors are distributed differently among different 
cell types. Meanwhile CXCR4 is expressed on neutrophils, myeloid 
cells, and T-lymphocytes; the CCR5 receptor is found in T-
lymphocytes and in macrophages125.  
3.4 gp120-CD4/coreceptor binding 
HIV entry starts with the virion binding to the cell surface. This binding 
is enhanced and facilitated by non-covalent interactions with surface 
molecules such as mannose-binding lectins and heparan sulfate, 
although the role of this attachment factors differs depending on the 
cell type. After this initial unspecific adhesion to the cell surface the 
encounter with CD4 takes place119,124.  
 The gp120 structure can be structurally divided in a more 
conserved inner domain and an external variable domain. CD4 binding 
site (CD4bs) is placed in a depression at the limit of the inner and the 
outer domain and limiting also with the bridging-sheet, a four 
antiparallel strands-structure that lies between de V1/V2 loops. CD4bs 
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is free of glycosyl chains but it is surrounded by them. The interatomic 
contacts made in the binding site imply hydrogen bonding and van der 
Waals interactions formed between 22 CD4 residues and 26 gp120 
residues. The CD4 residues implicated range from the 22nd to the 64th 
amino acid from domain 1 (CD4D1) but in the case of gp120 the 
residues are distributed over a wide range of its sequence. The critical 
residues for binding have been identified as Phe 43 and Arg 59 for 
CD4, and Asp 368, Glu 370, and Trp 427 for gp120. CD4 Phe 43 is 
placed inside a gp120 cavity made of hydrophobic residues just in the 
interface between the inner and the outer domain of gp120 (Fig. 3.1)126. 
CD4bs constitutes a vulnerability of the viral glycoprotein for immune 
system evasion, and has been subjected to intense research for vaccine 
development. Several facts support this approach since soluble versions 
of CD4 neutralize the virus in a high extent, and broadly neutralizing 
antibodies isolated from infected patients target this same epitope127,128.  
 CD4 binding to gp120 triggers large conformational changes on 
the quaternary structure of the Env trimer, where the gp41 stalk is 
exposed and each gp120 subunit is outwardly rotated with respect to 
the Env trimer central axis. It has been suggested that activation of at 
least two gp120 subunits of the same Env trimer spike to trigger the 
changes is required for viral fusion129,130. Inside gp120 the V1/V2 stem 
is moved out from the center of the trimer to a lateral part of this, 
allowing the rearrangement of the V3 loop towards the apical end of 
the trimer. After these changes the V3 loop partially exposes the 
coreceptor binding site facing the cell membrane. The V3 loop tip 
would act as a molecular hook that sticks out from the Env trimer 
enabling the interaction with the coreceptor131. The tropism for CCR5 
or CXCR4 depends on interactions made with the coreceptor by the 
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V1/V2 and V3 loops and the bridging-sheet, with a difference in the net 
positive charge of the residues of the V3 loop what determines the 
usage of one or the other. The selectivity for CXCR4 depends, at least 
for the subtype-B virus, on the presence of a positively-charged residue 
either one or both of the 11th and 25th positions of the V3 loop119,132.   
 
Figure 3.5. gp120-CD4. Crystal structure of the first two domains of CD4 (D1D2) bound to 
one gp120 subunit. Disulfide bonds are represented as van der Waals spheres in both structures 
but with a reduced radius in gp120 for the sake of clarity. Besides the gp120 V3-loop is 
highlighted in red, and the bonds of critical residues for gp120/CD4 binding are represented in 
grey in gp120 (Asp368, Glu370, Trp427) and purple in CD4 (Phe43, Arg59) (PDB: 3JWD). 
 
 Upon coreceptor binding, membranes fusion and fusion pore 
formation occur with the insertion of the gp41 N-terminal fusion 
peptide into the cell membrane. This process relies on many other 
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drastic conformational changes in the Env spike that lead to the fusion 
of viral and cell membranes. 
 
3.4.1 Thermodynamics of gp120/CD4 
The gp120/CD4 binding entails structural changes for both molecules. 
These changes have been discovered thanks to a big effort put in the 
determination of different crystal structures of gp120, CD4, and 
complexes of both, also in the presence of antibodies. A step beyond 
the static picture provided by Structural Biology techniques was 
achieved when the thermodynamics of gp120/CD4 interaction were 
studied. The enormous enthalpic contribution of this binding was 
determined, supported by the large number of hydrogen bonds and van 
der Waals interactions formed between both molecules. Despite of the 
favorable binding enthalpy a large change in entropy is also observed 
as a consequence of the reduction of the conformational flexibility of 
the complex, whose decrease comes from the structural stabilization of 
gp120 after the rearrangements that occur after binding. This 
reorganization is supported on secondary structure changes after 
binding where the reduction of random coil parts suggests more 
structural rigidity. Besides, the slowness in the association rate constant 
between gp120 and CD4 points to a structural adaptation between both 
molecules. The high gp120 flexibility in the unbound state could be the 
reason of the lack of broadly neutralizing antibodies, whose epitopes 
are placed in discontinuous disordered parts of gp120. Only the binding 
to CD4 reduces drastically the conformational flexibility of gp120 
leading to the exposition of immunogenic sites that could be potentially 
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targeted, but prevented because of the steric hindrance imposed by the 
close proximity of the cell membrane133. 
 
3.5 CD4 mechanochemical modification during 
viral docking 
3.5.1 CD4 bending flexibility 
The gp120/CD4 complex formation suggests the stiffening of both 
molecules after binding and gp120 structural rearrangement. However 
the downstream events that lead to viral and cell membrane fusion 
require movements and flexibility in the involved molecules. As it was 
mentioned above one change after binding is the outward rotation of 
the gp120 subunits of the Env trimer, a movement that would affect 
CD4 since both are bound. In this moment the gp120 V3 loop is in a 
coreceptor binding competent state, nevertheless the cell membrane is 
still far and the gp120/coreceptor encounter is unreachable131. It has 
been proposed the requirement of CD4 bending to approach gp120 V3 
loop to the membrane coreceptor. In the unbound form of CD4 the four 
extracellular domains exhibit a semi-extended Z shape, and this 
disposition changes after gp120 binding and rotation. This gp120 
movement would induce the bending of CD4 along a hinge region 
located between its first two domains (D1-D2) and the last two domains 
(D3-D4), enabling the approaching of the gp120 V3 loop to the 
membrane coreceptor extracellular loops. Some monoclonal antibodies 
that bind in the limit between the D2 and D3 domains block the HIV 
membrane fusion but do not affect gp120/CD4D1 binding. These 
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evidences suggest that CD4 conformational flexibility, at least at the 
D2-D3 hinge region, is required for HIV fusion134,135.  
 
3.5.2 Shock absorber role of CD4 during HIV binding 
The role of CD4 structural plasticity during HIV entry gains more 
importance if the size of the virion and the receptor are considered. The 
virion is an inert spherical particle of 100 nm of diameter which 
performs random movements in fluid bodies due to thermal 
fluctuations. CD4 is, instead, a rod-shape protein of 15 nm length also 
submitted to Brownian motions as the virion but anchored to the cell 
membrane. This physical link to the membrane greatly decreases its 
degrees of freedom although lateral diffusion over the membrane is 
feasible. The viral particle and the CD4-bearing cell also experience the 
shear flow of the body fluids, such as the bloodstream136. All together 
configure a complex physical scenario for viral docking on the cell 
membrane, in which a virus could be rolling and bumping over the cell 
surface for a while, establishing and breaking bonds between the viral 
gp120 and the cell CD4. After several attempts, HIV virion could 
establish a stable bond with one CD4 receptor. Brownian motions 
would still be acting on the virus, approaching and moving away from 
the cell membrane, pushing and stretching the intermolecular weak 
contacts made in the gp120/CD4 complex and challenging the lifetime 
of this bond137–139.  
 At the same time that this viral particle is tethered to the cell 
surface through a CD4 receptor, it has its coreceptor binding site and its 
previously masked epitopes exposed and susceptible to immune 
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surveillance. The coreceptor binding would depend on the proximity to 
the cell surface and also on the probability of locating a CCR5 or 
CXCR4 coreceptor nearby the CD4 (Fig. 3.6). The structural flexibility 
of CD4 could facilitate this membrane approaching and the coreceptor 
finding due to its bending ability, but virus random movements could 
still break the gp120/CD4 interaction. The range of forces experienced 
by a CD4 receptor being pulled by the bound viral particle could lead to 
the additional extension of the protein upon domain unfolding of 
one/some of its domain/s. The unfolding of some CD4 domains would 
increase the length of the tether that keeps the virus anchored, allowing 
for the reconnaissance of a larger area of the cell membrane for 
coreceptor binding. Of course, a larger tether supposes a drawback 
since the increased virion-cell separation would facilitate the 
neutralizing antibodies access to HIV epitopes.  
 
Figure 3.6. CD4-HIV tethering. Virion is attached to CD4. The unfolding of D2 domain (here 
considered without the disulfide bond) due to the force exerted by the virus on CD4 increases 
the length of the tether allowing the virus to explore a larger area of the surface cell, 
incrementing the chances of finding a coreceptor. When the forces are reduced, D2 is able to 
refold thus acting as a spring. Representation is not at scale. 
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 However this strategy reduces the mechanical stress 
experienced by the gp120/CD4D1 bond by the unfolding of D2-D4 
domains, extending the lifetime of the interaction, increasing the 
chances of coreceptor binding and subsequent infection. Moreover the 
random movements of the virus would eventually reduce the strain on 
CD4 allowing the refolding of its domains, reducing the length of the 
tether, and bringing closer again the virus to the cell membrane. This 
hypothesis would depict CD4 extracellular domains as a shock 
absorber-like structure made of four springs arranged one after the 
other in a rod, a mechanical feature efficiently exploited for the HIV 
successful infection of the cell.  
 
3.5.3 gp120/CD4 disulfide bonds redox regulation during the 
infection 
Both gp120 and CD4 possess several disulfide bonds in their structure. 
The presence of disulfide bonds in extracellular exposed-proteins 
enhances their stability under changing environmental conditions. 
Disulfide bonds contribute also in the folding free energy of proteins, 
decreasing the entropy of the unfolded state and favoring also 
enthalpically the native state of the protein. However the spatial 
arrangement of some intramolecular disulfide bonds could affect 
negatively the thermodynamical stability of the native state of some 
proteins due to structural-strain induced by this bond. These strained 
disulfide bonds present higher dihedral energies because of the 
unfavorable angle disposition of the atoms involved in this bond, 
making these disulfides more susceptible to redox regulation. These 
potentially redox-regulated disulfides are termed as allosteric, which 
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means that rather than being involved in protein stability or catalytic 
activities they alter protein function depending on their oxidation state. 
This is the case of CD4D2 domain, whose disulfide bond geometry 
differs from those ones of D1 and D4 domains. D2 domain disulfide 
shows properties common with other disulfide redox-regulated 
proteins, and its reduction while in the cell surface could help for the 
oligomerization of CD4 receptors during TCR-MHC-II complex 
stabilization. Free thiols from adjacent CD4D2 domains could react and 
form intermolecular disulfide bonds, increasing the local colocalization 
of CD4 cytoplasmic tail-associated enzymes involved in T-cell 
activation cell signaling140,141. CD4D2 disulfide bond could be reduced 
by oxidoreductase enzymes naturally occurring inside the cell but also 
known to be secreted and associated with the cell surface, like 
thioredoxin and/or glutaredoxin. 
 Regarding gp120, nine disulfide bonds have been identified in 
its structure. These disulfides connect several loops of its structure and 
the conformational rearrangement that takes place after binding to CD4 
could include the reduction of at least two or three disulfides, located 
near CD4bs. Their reduction would make possible the reorganization of 
the V1/V2 loop and the projection of V3 loop for coreceptor binding. 
Further redox changes in some of the other disulfides could lead to the 
transformations required for gp41 fusion peptide extrusion. The gp120 
disulfide bond reduction would be potentially performed by 
oxidoreductases like PDI, also secreted to the extracellular space. 
Interestingly PDI appears to be associated to CD4D3 or D4 domains 
but it targets only gp120 disulfides, meanwhile thioredoxin would 
target CD4D2 domain and potentially also the V3 loop disulfide 
bond142–144. It has been shown the direct link between the redox state of 
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CD4D2 domain and HIV infection, not for the gp120/CD4 complex 
formation but for critical events occurring before viral fusion145. The 
reduction of CD4D2 disulfide bond could lead to conformational 
changes critical for HIV fusion. The reduction of CD4D2 domain and 
some gp120 disulfides is essential for HIV entry146, as it has been 
demonstrated by HIV entry prevention by the inhibition of the activity 
of thioredoxin, PDI and glutaredoxin 140,145,147–149.  
However the CD4D2 domain disulfide bond location is buried 
in the resolved crystal structures available. How thioredoxin access this 
disulfide remains elusive147, but the partial unfolding of D2 domain 
could expose it for enzyme induced-reduction (Fig. 3.7).  
 
Figure 3.7. CD4 disulfide bonds regulation by oxidoreductases. Thioredoxin (Trx) is 
secreted to the extracellular space and it has the ability of reducing disulfide bonds, like the 
present in CD4. CD4D2 domain possesses an allosteric disulfide which when reduced allows 
the extension of the polypeptide, thus increasing the length of the tether. Representation is not 
at scale. 
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Again the viral particle attached to CD4 could induce the 
mechanical unfolding of CD4 domains, exposing the disulfide bonds of 
the three extracellular disulfide-containing domains, which allows for 
their thioredoxin-catalyzed reduction and for a further extension if the 
domains are fully unfolded. The mechanochemical reduction of CD4 
disulfide bonds would be a way for lengthening the tether, covering a 
wider cell surface for coreceptor binding.  
 
3.5.4 Mechanical role of CD4-binding antibodies 
Due to the difficulty to develop broadly neutralizing antibodies directed 
against gp120 epitopes, antibodies binding CD4 are another therapeutic 
approach for preventing HIV infection. Targeting CD4 represents the 
advantage of a low mutation rate since it is a host protein, unlike HIV 
proteins whose rapid variability makes difficult their long-term 
effectiveness.  
 For example the monoclonal antibodies Q425 and Q428 bind to 
CD4D3 domain, blocking HIV-cell fusion but not modifying the 
interaction with gp120. It was proposed that these two antibodies block 
the hinge-like flexibility of CD4, preventing gp120 approach to the cell 
membrane134. Some anti-CD4 antibodies targeting D1 domain inhibit 
HIV infection directly competing for the binding with gp120, like 15A7 
or Leu3A150,151. Ibalizumab is an interesting broadly neutralizing anti-
CD4 antibody which targets the D2 domain, and its epitope location 
does not interfere with the binding of gp120 to CD4D1 (Fig. 3.8).  
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 Besides not hindering gp120 binding neither does it with MHC-
II binding epitope on CD4, avoiding potentially undesirable side 
effects153. Not interfering with gp120 binding, the HIV infection 
inhibition activity of Ibalizumab develops after gp120/CD4 binding, 
although the exact mechanism is not known. It has been proposed that 
the structural rearrangements experienced by CD4 upon gp120 binding 
could be blocked by Ibalizumab152. Some protein-protein interactions 
like antibody-antigen recognition could lead to the mechanical 
stabilization of the latter one41,42. In this context Ibalizumab could 
inhibit HIV entry stiffening the CD4 molecule, maybe preventing the 
mechanical unfolding of D2 domain and abolishing the reduction of its 
disulfide bond by inhibiting thioredoxin access.  
 
Figure 3.8. CD4D1D2 with Ibalizumab. Neutralizing antibody Ibalizumab bound to CD4. 
Most of the contacts are made with the B-C loop of domain D2, not overlapping neither with 
MHC-II binding site neither with gp120 binding site152. CD4D1D2 in QuickSurf representation 
and Ibalizumab in cartoon representation (PDB: 3O2D). 
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Chapter 4: A mechanical 
approach to infection 
It is clear the existence and the importance of forces at the nanoscale in 
vivo and also during the development of some diseases, including 
pathogenic infections. In this last introductory chapter the technique 
used in this thesis for the mechanical manipulation of molecules 
involved during UPEC and HIV-1 attachment is presented. It is also 
explained in which way mechanical forces affect protein unfolding and 
the knowledge that can be obtained from these studies. In the last 
section is explained how this mechanical manipulations has allowed us 
to explore force aspects involved during UPEC and HIV-1 attachment. 
 
4.1 Single molecule force spectroscopy (smFS) as a 
tool for studying force-bearing proteins 
4.1.1 smFS features 
In the previous introductory chapters several examples have been 
mentioned for illustrating the importance of physical forces in 
Physiology, highlighting the UPEC and HIV-1 attachment cases. Until 
recent times the possibility of studying the mechanical properties of 
single biomolecules was elusive. The development of single molecule 
techniques marked a turning point for elucidating the mechanical 
behavior of proteins, allowing their direct manipulation. The 
application of mechanical loads to single molecules produces 
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conformational changes along a well-defined reaction coordinate, 
different from the ones obtained from thermal or chemical denaturation 
bulk experiments. smFS techniques also offer a dynamic real-time 
picture of the force-induced conformational changes in proteins, 
meanwhile traditional Structural Biology techniques such as X-ray 
crystallography provide with static images of protein structures154. 
 SmFS allow the study of the folding/unfolding of biopolymers 
like proteins and the characterization of their folding energy landscape 
under mechanical stress. Unlike chemical or thermal denaturation 
experiments smFS techniques have a well-defined reaction coordinate 
called end-to-end extension, which is the distance between the pulled 
groups of the molecule155. This makes possible for smFS to resolve 
intermediate conformational states on proteins which detection is 
usually averaged out in bulk experiments, where the most populated 
states overlap the signal of the rare events156–158.  
The main smFS techniques used for the mechanical 
manipulation of proteins are Atomic Force Microscopy (AFM), optical 
(OT) and magnetic tweezers (MT). In all of them a biomolecule is held 
fixed on one end and on the other end to a probe. Along the experiment 
the probe position with respect to the fixed end is changed, stretching 
or relaxing the molecule, and measuring the extension and/or the force 
applied to the molecule. Each of the smFS techniques has its own 
advantages and disadvantages, regarding not only the experimental 
design but also the probe mechanical stiffness, time resolution, and the 
force-range sensitivity159. The first smFS studies conducted on 
biomolecules focused on DNA and RNA unfolding160,161, but soon the 
research was broaden to study muscle proteins like the aforementioned 
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titin31,35, and ECM proteins162. These first studies on the mechanical 
behavior of proteins were conducted mainly in AFM, the tool used in 
this thesis for the mechanical characterization of proteins.  
 
4.1.2 Effect of force on the free energy of proteins 
Before studying protein mechanical unfolding with smFS techniques it 
is necessary to understand which interactions and forces maintain 
proteins in a folded state. Proteins are polymeric chains made of 
monomers called amino acids which are connected covalently through 
peptide bonds. In solution the proteins adopt a collapsed state since this 
conformation maximizes the conformational freedom of its monomers, 
thus increasing the entropy. This means that under equilibrium the end 
points of the protein are on average spatially close between each other, 
and the mechanical extension of the protein faces the opposing 
resistance coming from this tendency to maximize the entropy of this 
system. As a consequence the existence under equilibrium conditions 
of the extended state of the protein is disadvantaged31. 
The opposing entropic and enthalpic contributions drive the 
protein folding process from the collapsed to the final folded state. 
Therein many parallel pathways are possible. The enthalpic 
contribution, together with the entropic one, determines the structure of 
the protein, mainly held by weak interactions such as Van der Waals, 
electrostatic interactions, and hydrogen bonding163,164. Besides in 
proteins two strong interactions also exist: disulfide bonds and 
isopeptide bonds165,166. All of these weak and strong enthalpic 
interactions are short-ranged thus their strength decays with distance. 
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When a protein is mechanically stretched the both contributions are 
responsible of the resistance. Once the force applied to the molecule is 
high enough the short-ranged weak interactions are broken and the 
protein goes from a compact state to an extended one. In the unfolded 
state the remaining short-ranged interactions are usually minimum, and 
the opposing force of the protein to continue to be extended is 
entropically driven158,167. 
In the simplest system a protein shows a two-state behavior 
defined by a folded state and an unfolded state. The free energy 
landscape of such a protein shows two energy wells separated by an 
energy barrier (Fig. 4.1). One deeper well is placed in an energy 
minimum which corresponds with the native folded state, and the other 
shallower well represents the unfolded state which is less energetically 
favorable. To represent the effect of the force applied in a smFS 
experiment on the folding energy landscape of a protein, the free 
energy is plotted vs the end-to-end distance of the pulling ends of the 
protein. The folded state is characterized by a short distance between 
the ends of the protein, meanwhile in the unfolded state the ends are 
separated by a larger distance. The energy barrier (∆G0 x‡) represents 
the free energy of the transition state that separates the folded and the 
unfolded states of the protein, and its height is due to the enthalpic 
interactions that keep the protein folded. The folded state and the 
transition state are separated by a distance x‡, and it is the distance 
between the ends of the protein necessary to reach the transition state. 
When a force is applied the energy landscape is tilted, lowering both 
the height of the free energy barrier of the transition state and the free 
energy of the unfolded state. When the force is high, the opposing 
entropic forces of the extended unfolded state become energetically 
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favored155. 
 
Figure 4.1. Folding free energy landscape of a two-state protein in the absence and in the 
presence of an external applied force. k(F) is the rate constant under a specific force F, A is 
an attempt frequency constant with arbitrary value, k0 is the rate constant in the absence of 
force, F is the mechanical force applied on the protein, x‡
 
is the distance to the transition state, 
kB is the Boltzmann constant and T is the absolute temperature. Lc is the contour length of the 
folded protein and ∆Lc the increment of the contour length after mechanical unfolding. 
In order to study the effect of mechanical forces on the kinetics 
of a protein and to determine its 1D energy landscape, the Bell’s model 
has been widely used. This model predicts an exponential dependency 
of the rate of bond rupture (the loss of the interactions that keep 
proteins folded) with the applied force67: 
 = exp 	
  ; 															 = 	exp 	
‡
      (1) 
Where k(F) is the rate constant under a specific force F, A is an 
attempt frequency constant with arbitrary value, k0 is the rate constant 
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in the absence of force, F is the mechanical force applied on the 
protein, x‡
 
is the distance to the transition state, kB is the Boltzmann 
constant and T is the absolute temperature. As it was noted before this 
one-dimensional representation of the energy landscape shows a two-
state protein. An increasing amount of data available about protein 
folding point to the presence of conformational intermediates between 
the folded and the unfolded state, besides the existence of different 
folding pathways157,168,169. Bell’s model was further refined by Evans 
and Ritchie who provided a theoretical framework deriving Kramer’s 
equation for considering the mechanical unfolding as the diffusion of 
the protein by Brownian motion over the 1D energy landscape, in 
which the extension of the protein the reaction coordinate. This 
consideration would place the folded protein in a harmonic well where 
the protein needs to overcome high energy barriers and the friction of 
the energy profile170. During the last years many theoretical advances 
have been achieved not only for extract valuable data accurately from 
smFS experiments but also to correct the effect of the experimental set-
up on the unfolding/folding rate of biomolecules171–175. Many of the 
advances and findings done during the last 20 years regarding protein 
mechanical folding/unfolding have been possible thanks to the data 
collected with smFS. 
 
4.1.3 AFM for force spectroscopy studies on single-molecules: 
Atomic Force Spectroscopy (AFS) 
In a typical AFS experiment the protein molecules are distributed over 
a surface placed on the top of a piezoelectric stage, the mechanical 
moving part of the tool. Above the protein sample the mechanically-
A mechanical approach to infection 
80 
 
passive element of this set-up, the cantilever, is held. The cantilever is 
the probe which “fishes” molecules from the surface, proteins may get 
attached to it due to non-specific interactions like physisorption176,177, 
keeping the protein held between the cantilever and the surface. In the 
easiest experiment the surface is moved apart from the cantilever at a 
constant speed value while stretching the protein (Fig. 4.2). Along the 
experiment the cantilever’s deflection is monitored and this signal is 
converted into force units, making it possible to know the force which 
the protein is experiencing in every moment. When the force exerted by 
the protein on the cantilever is high enough, the last one bends because 
of the opposing force produced by the protein. However as the 
piezoelectric actuator is constantly retracting, the force is increasing 
and at some force value a protein domain unfolds, releasing the amino 
acid sequence of the protein trapped in the fold and producing a sudden 
drop in the tension experienced by the cantilever, returning this to its 
resting state. Usually the proteins tested in AFS are multimodular, so 
they are single polypeptides composed of a variable number of protein 
domains arranged one after the other in the chain. In constant speed 
pulling experiments the unfolding of these protein modules generates a 
saw-tooth pattern in which both the force (monitored through the 
cantilever) and the length (monitored through the piezoelectric 
displacement) are registered. In this pattern, each peak corresponds to 
the unfolding of one protein domain. These measurements allowed for 
the determination of the mechanical stability of many proteins 
suspected to experience forces in vivo167.  
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Figure 4.2. Constant speed pulling of a multimodular protein. A three-domain protein is 
attached on one end to a surface and to the other end to the cantilever tip. Cantilever moves 
away from the surface at constant speed. The saw-tooth pattern of peaks observed corresponds 
to the sequential unfolding of the individual domains. From step 1 to 2 the protein is stretched 
and aligned with the pulling force. In step 2, the cantilever bends as a consequence of the 
opposing force generated by the protein. In step 3 one of the domains unfolds unraveling the 
protein sequence trapped in the fold domain an increasing the length of the protein, returning 
the cantilever to its resting position. In step 4 the situation in step 2 is repeated, and so on. The 
last peak corresponds to the detachment of the protein from the cantilever. Adapted from 
reference167. 
Although these constant speed experiments were useful for 
finding out the mechanical stability of proteins and for correlating this 
feature with their secondary structure composition178,179, these 
measurements are far from equilibrium and thus not physiologically 
representative. The development of the constant force measurement 
mode in smFS180 allowed the application of well-controlled constant 
forces to proteins near the equilibrium, in the range of the experienced 
ones in vivo, allowing the reconstruction of the energy landscape of 
biopolymers from the kinetics of force-dependent unfolding. Besides, 
the use of constant force measurements together with the stability of 
AFS set-ups allow monitoring the trajectory of single molecules for 
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long periods of time. The application of different force protocols induce 
first the unfolding at high force and then favors the refolding at low 
force. Hence it is possible to monitor the folding process along a single 
reaction coordinate for several cycles181. 
 
Figure 4.3. Constant force pulling of a multimodular protein. (a) A polyprotein is attached 
on one end to a surface and to the other end to the cantilever tip. Surface moves away from the 
surface, applying a constant force on the protein of 150 pN. Adapted from reference181 .(b) The 
length of the protein is registered along time (upper panel), and every time a domain unfolds 
generates a sudden increase in the total length, giving this staircase pattern. Force (lower panel) 
is kept constant during the pulling thanks to a feedback electronic controller which restores the 
force exerted on the protein after each unfolding event. Adapted from reference182. 
 
4.2 Bacterial and viral attachment, a mechanical 
target 
The current medical treatments target or interfere with the life cycle of 
the pathogen, and in many cases the drugs used are becoming useless or 
the treatments do not eradicate the problem completely. The first step 
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of infection consists in the recognition of the target cell and the 
attachment of the pathogen to its surface. Therefore the pathogen can 
use both its own proteins and the cell surface proteins of the host cell, 
establishing molecular interactions between them. Pathogen attachment 
happens in many different environments where the physical conditions 
can be very challenging, like the shear forces generated in the 
bloodstream or in the urine flow. This implies that pathogens have 
developed strategies to counteract these obstacles for the successful 
attachment and the subsequent infection. The proteins used for the 
attachment to the host are submitted to mechanical stress and as a 
consequence the pathogens have evolved surface proteins and strategies 
for counteracting the difficulties of a harsh physical environment. This 
thesis focuses on the study of the proteins used by UPEC and HIV-1 to 
attach to host cells with smFS.  
  
 Regarding UPEC, the proteins from the pilus type I used for 
urinary tract infection were studied (Fig. 4.4). Bacteria infecting the 
urinary tract are exposed to the mechanical stress imposed by the urine 
flow, and the pili are used for resisting these opposing forces. This 
appendage is interesting not only because of its mechanical role during 
infection, but also because the interactions maintaining the link 
between its hundreds of proteins is not covalent and relies on 
hydrophobic forces. With smFS we can interrogate the strength of the 
donor-strand interaction with the same geometry as the experienced in 
vivo. Our findings demonstrate that each individual subunit has a high 
mechanical stability correlated with their position in the pilus structure, 
following a mechanical hierarchy. These unfolding forces are among 
the highest ever reported, and the presence of a conserved disulfide 
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bond in these proteins plays a key role in their stability. The study of 
the strength of this hydrophobic interaction at the single molecule level 
could be a starting point for the development of drugs that 
mechanically weaken or interfere with this stable structure. A 
mechanically impaired pilus would ease the detachment of the bacteria 
from the urinary tract, being washed out during micturition.  
 
Figure 4.4. E. coli type I pilus. E. coli bacterium cells display a vast number of filamentous 
structures called pili protruding from its outer membrane (OM). A closer look into a single 
pilus shows a multiproteic structure in which hundreds of individual proteins interact head-to-
tail through non-covalent interactions along the whole chain. E. coli cells use these filamentous 
structures to attach to surfaces. In the OM, a transmembrane protein called FimD/Usher is 
involved in the incorporation of proteins during pilus biogenesis and also it acts as a scaffold 
for the whole pilus. E. coli image from Manu Forero (DOI:10.1371/journal.pbio.0040314). 
 Additionally, the process of pilus biogenesis was also 
investigated. Pilus proteins are exported to the periplasmic space in an 
extended and unfolded conformation through the SecYEG pore, and 
with smFS we can resemble this state and investigate the effect of 
DsbA and FimC proteins at the single-molecule level. Our results 
indicate that FimC only recognizes disulfide-bonded domains and it 
helps them to fold. Surprisingly, DsbA is in fact not only inducing 
disulfide bond formation but also it contributes the most to pilus 
subunits folding, a new aspect never reported before in the type I pilus 
Chapter 4 
85 
 
system. Pilus biogenesis process could be an appropriate therapeutic 
target since several protein actors and cellular compartments are 
involved during the assembly of the pilus. Interfering with the 
chaperones and enzymes required for pilus proteins maturation would 
abort the pilus assembly, making bacteria unable to attach to the host 
cells.  
 
 
Figure 4.5. HIV-1 viral particle interaction with lymphocyte T-CD4+ cell-surface proteins. 
HIV-1 viral particle exhibits macromolecular protein assemblies in its lipidic envelope, 
composed of trimers of the fusion protein gp41 and gp120. The first interaction that leads to 
viral infection implies the interaction of glycoprotein gp120 with cell-surface receptor CD4. 
The interaction of these two proteins leads later to an interaction with a membrane coreceptor 
present on the cell before membrane fusion and viral content release. This requires the 
approximation of the virus particle to the cell-membrane meanwhile attached to a CD4 protein 
through its gp120 glycoprotein. In this scenario CD4 should experience conformational 
changes for physically allow this approaching. Inspired from reference119. 
In the second part of this thesis the focus has been to study the 
nanomechanics of the first two domains of the cell surface protein 
CD4, the protein used by HIV to attach to lymphocytes T of the human 
immune system (Fig. 4.5). This is the first interaction of the virus with 
the cell and several events before virus fusion need to take place. The 
approaching of the virus to the cell membrane meanwhile bound to 
CD4 requires a high flexibility and, maybe, the mechanical unfolding 
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of some of the domains of this protein. It is not known but a viral 
particle in the fluid flow conditions of the blood or the lymphatic 
system could exert enough tension to produce the unfolding of the CD4 
domains, facilitating the following events leading to viral and cell 
membrane fusion. We have discovered a hierarchical unfolding in the 
CD4D1D2 protein tandem which can be mechanically extended at very 
low forces, like the ones expected to be exerted by a viral particle. 
Based on previous research, we developed a mathematical model 
relating infectivity with CD4 mechanical extension, proving that a 
longer CD4 increases HIV infection. Besides, the mechanochemical 
reduction of CD4 internal disulfide bonds by thioredoxin was studied 
with smFS since it has been demonstrated that this chemical regulation 
increases the infectivity. Our data shows that the internal disulfides of 
CD4D1D2 are enzymatically reduced only after unfolding, suggesting 
that in vivo the mechanical unfolding of CD4 could be a requirement 
for this event. Finally, the effect of the HIV-blocking antibody 
Ibalizumab on the nanomechanics of CD4 was tested. It is known that 
some antibodies with the ability to bind CD4 reduce the infectivity of 
HIV. This blocking activity it is not completely understood and maybe 
the increase of the mechanical stability of CD4 when bound to these 
antibodies is the explanation for the antiviral activity of these 
antibodies. We found that Ibalizumab binding mechanically stabilized 
CD4D1D2, increasing the unfolding force of these two domains.  
The mechanical study of CD4 and proteins related with its 
regulation or recognition could be a promising approach for developing 
therapies oriented to the mechanical stabilization of this protein. 
Preventing the attachment avoids the infection of new cells, having a 
potential use as a prophylactic and as a treatment for people living with 
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the infection. Not being a complete cure, it would make possible the 
restriction of the virus in the infected cells but avoiding its 
dissemination since no new infections could happen. 
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Chapter 5: Materials and 
methods 
This chapter explains in detail the experimental procedures followed in 
order to conduct this research. It is divided in four different sections. 
The first section explains the Molecular Biology techniques and 
procedures applied for obtaining the different proteins used along this 
thesis. The second section shows the AFM set-up and its operation. The 
third section details the data analysis of the experiments done with the 
AFM. Finally, the fourth section gives an insight into the SMD 
simulations and its interpretation. 
 
5.1 Molecular Biology 
To conduct this research it has been necessary to design, to express and 
to purify different proteins. During this section all the procedures used 
starting from the designing of the DNA sequence up to the final 
proteins measured with smFS will be explained. 
 
5.1.1 Protein design 
In order to study the proteins with smFS it has been necessary to create 
chimeric constructs for most of them. This chimeric protein strategy 
consists mainly in combining in a single polypeptide chain different 
protein domains, generating a so called polyprotein. In this case, the 
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sequence of the proteins of study was flanked in both ends by two I91 
protein domains. Fig. 5.1 shows a cartoon of one of the used chimeric 
polyproteins.  
 
Figure 5.1. Chimeric polyprotein. Cartoon representation of the FimG construct (green, 
modified from PDB code: 3BFQ), being flanked by two I91 domains (grey, PDB code: 1TIT) 
on both sides. In yellow is depicted the disulfide bond present in FimG. The donor β-strand of 
FimF (blue) is connected to FimG through a four amino acid flexible linker (black line). 
The I91 domain has been extensively studied with smFS hence 
its mechanical properties are well described31,180. Its unfolding when a 
single polyprotein is being pulled from its ends will produce a known 
fingerprint signal that unequivocally belongs to I91. The presence of 
this fingerprint is critical for smFS data collection and therefore it will 
be used both as a positive and a quality control of the experiments. 
Five proteins were generated with this approach (the Appendix 
contains the protein sequences of all the proteins used). With the 
exception of the protein CD4 (its first two domains, CD4D1D2), the 
proteins FimA, FimF, FimG and FimH required a more elaborated 
design. These proteins are incomplete Ig-like folds lacking the seventh 
β-strand, and are therefore unstable. They are only stable in vivo 
because of the complementation of their fold with the donation of its 
cognate subunit β-strand through a process called DSC (see Chapter 2: 
Type I pilus). In order to study the strength of this DSC interaction 
circular permutant proteins were designed (see Fig. 5.2).  
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Figure 5.2. Self-complemented FimG. (a) Top diagram shows the FimG sequence (green) 
with the donor β-strand of FimF (blue) placed in its C-terminal position with a linker in 
between (black line). Below is represented the β-strand disposition of the FimG incomplete Ig-
like fold with the FimF β-strand complementation. Disulfide bond is represented as two yellow 
circles connecting the A and B β-strands. (b) Cartoon representation of the FimG protein 
domain (green), self-complemented with the donor β-strand of FimF (blue). FimG domain and 
donor strand of FimF are covalently attached through a four amino acid linker (black). In 
yellow is depicted the disulfide bond present in FimG. 
The cognate donor β-strand sequence of each subunit was 
covalently linked to its fold through a four amino acid flexible linker 
(DNKQ) that allows for the correct anti-parallel placement of the donor 
strand with respect to the incomplete Ig-fold which complements. 
Therefore, the four amino acid linker plus the sequence of the donor 
strand were added to each C-terminal Fim protein sequence (A, F, G 
and H). This strategy was already used in the past and it produced 
stable domains in solution183,184. Besides in order to avoid competition 
with the C-terminal β-strand added, the sequence of their own N-
terminal donor β-strand was removed. In the Fig. 5.3 are depicted the 
3D structures of the self-complemented domains studied. 
Chapter 5 
91 
 
 
Figure 5.3. Self-complemented Fim proteins. (a) Self-complemented FimA (purple) with the 
donor β-strand of FimA (pink) placed in its C-terminal position with a linker in between (black 
line). (b) Self-complemented FimF (blue) with the donor β-strand of FimA (purple). (c) Self-
complemented FimG (green) with the donor β-strand of FimF (blue). (d) Self-complemented 
FimH pilin domain (red) with the donor β-strand of FimG (green). FimH lectin domain is 
covalently linked to the pilin domain in its N-terminal position. All the complementary β-
strands are placed in the C-terminal position of the domain and connected to it through a linker 
(black line). Cysteine residues are represented as yellow spheres, showing the presence of 
disulfide bonds in all of the domains. 
 
5.1.2 Genetic engineering procedures 
As a first step to study these proteins their DNA sequence is 
required. For that reason, the genes of the proteins were purchased from 
Life Technologies, which provided them inside of plasmids and with 
the sequence of the genes codon-optimized for their expression in 
Escherichia coli. Besides the genes with specific restriction sites placed 
along their sequence were ordered. These restriction sites will allow 
building the polyproteins, in several rounds of cloning and subcloning.  
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5.1.2.1 Commercial plasmid amplificationThe first step is to amplify 
the commercial plasmid containing the gene of interest. E. coli XL1-
Blue competent cells (Agilent Technologies) were transformed with 
approximately 50 ng of DNA using the manufacturer protocol185. After 
transformation, the bacteria were grown in SOC media (Invitrogen) for 
1 h at 37ºC and 250 rpm. Then, the cells were cultured over plates 
made of LB +Agar + Carbenicillin (Fisher) at 37ºC. After being grown 
overnight, single colonies were picked from the plates and grown in 5 
mL of LB with 0.1 µg/mL of Carbenicillin for 12-16 h at 37ºC and 250 
rpm. Cells were then pelleted centrifuging at 3,200xg for 10 min at 4ºC 
and plasmidic DNA was extracted from them with the QIAprep® 
miniprep kit (QIAGEN). Finally, plasmidic DNA was eluted and stored 
in nuclease-free water (Fisher) and the concentration was determined 
using the Nanodrop 2000L spectrophotometer (Thermo Scientific). Fig. 
5.4 indicates the main steps of this part.  
 
 
Figure 5.4. Commercial plasmid amplification. Commercial plasmid carrying the gene of 
interest is used for the transformation of E. coli XL1-Blue cells. Cells are grown and selected in 
the presence of antibiotic and then single colonies are isolated for growing in liquid media also 
with antibiotic. After several hours, the population of bacteria has increased and then plasmidic 
DNA extraction is performed for isolating amplified commercial plasmid in high amounts. 
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5.1.2.2 Commercial plasmid digestion 
All of our genes have a BamHI restriction site in their 5’ end and a 
KpnI restriction site in their 3’ end. At the end of the gene and just 
before the KpnI site, we have the amino acid sequence RSCC and the 
stop codon. This four amino acid sequence is flanked in its 5’ end by a 
BglII site and in its 3’ end by the above mentioned KpnI (Fig. 5.5). 
With this gene architecture, we can build our polyproteins splicing the 
different genes in several rounds of DNA digestion and ligation. 
 
Figure 5.5. Scheme of a commercial plasmid with the gene of interest. A typical 
commercial plasmid contains three main sequences. One conferring resistance to antibiotic 
treatment (AmpR, for ampicillin), another one for plasmid DNA replication (Col E1 origin) and 
the third one being the gene of interest. In our case, the gene of interest possesses three 
characteristic restriction sites in its sequence. In the 5’-end of the sequence it has a BamHI 
restriction site and in the 3’-end it has a BglII and a KpnI restriction sites. The insets show the 
DNA sequences cut by the different restriction enzymes and their translation into amino acid 
letter code. BamHI and BglII digestion produce compatible ends between the sequences. 
Between the BglII and KpnI restriction sites there are two cysteines and the codon stop. When 
building a polyprotein with different genes with these architecture, every time we splice two 
sequences only the second one (in 3’-end) will have the cysteines and the stop codon. In this 
way the last protein domain of the polyprotein (C-terminal) will have the two cysteines and it 
will help for protein immobilization over the gold substrate used in AFM experiments.  
Commercial plasmid was digested with BamHI/KpnI restriction 
enzymes (Thermo Scientific) following the FastDigest protocol186. 
Digestions were done on approximately 3 µg of total DNA in a volume 
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of 50 µL for 30’ at 37ºC. After digestion, gene insert and commercial 
plasmid were separated through electrophoresis in agarose 1% gel in 
Tris-Acetate-EDTA Buffer (Fisher) with ethydium bromide (Sigma). 
After electrophoresis, gene DNA was extracted from the agarose gel 
with the QIAquick® Gel Extraction Kit (QIAGEN) and DNA insert was 
eluted and stored in nuclease-free water and its concentration was 
determined with a spectrophotometer. 
5.1.2.3 Expression plasmid digestion 
Once the sequence of the gene of interest has been isolated, the next 
step is the opening of an expression plasmid, suitable for protein 
expression in bacteria. The expression plasmid pQE80L (QIAGEN), a 
kind gift from Julio M. Fernández (Columbia University) was used.  
Fig. 5.6 shows a scheme of the pQE80L plasmid. Besides the 
gene providing resistance to antibiotic treatment and the sequence for 
the origin of replication, the plasmid possesses the Multiple Cloning 
Site (MCS) where several restriction sites are placed for different 
restriction enzymes digestion allowing for the insertion of the gene of 
interest. Plasmid pQE80L also contains a short sequence encoding for 
six histidine residues just before the region where the gene of interest 
will be inserted. This feature will be helpful later during the protein 
purification process. 
 Upon gene of interest insertion, this gene will be under the 
control of the lac promoter. The plasmid pQE80L carries itself the gene 
that encodes the lac promoter repressor, lacI. The repressor is 
constitutively expressed by the cell and it binds to the lac promoter, 
inhibiting the expression of the gene the promoter is regulating. When 
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bacteria are grown in the presence of lactose or an analogous 
compound, the repression is interrupted, allowing for the expression of 
the gene under the control of the lac promoter.  
 
Figure 5.6. pQE80L expression plasmid. Scheme of the expression plasmid pQE80L showing 
its main features. BamHI and KpnI restriction sites are highlighted with a red circle. Gene of 
interest will be inserted in this plasmid between the sequences of these two restriction sites. 
Image generated with the software SnapGene® (Marie Fertin). 
In order to insert the gene of interest the expression plasmid 
pQE80L was opened with the same restriction enzymes used for cutting 
the gene of interest, BamHI/KpnI. The same procedure was used as 
explained for the commercial plasmid, digesting the plasmid with these 
two enzymes, separating the DNA fragments in an agarose gel 
electrophoresis and purifying the plasmidic DNA.  
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5.1.2.4 Gene of interest and expression plasmid ligation 
Both the gene of interest and pQE80L are digested with the same 
enzymes, so the ends of both DNAs are compatible between them. Like 
the restriction enzymes used generate a different cohesive end, the 
insertion of the gene will be directional and the expressed protein will 
have the desired sequence of amino acids. 
For inserting the gene of interest inside of pQE80L both DNA 
sequences were ligated. For that purpose a reaction mixture was 
prepared in which the main component is the T4-DNA ligase 
(Invitrogen), an enzyme that catalyzes the formation of the 
phosphodiester bond between two DNA fragments. Following the 
protocol specified by the manufacturer187, a molar ratio 3:1 of insert 
with respect the plasmid was used, following the next formula: 
		 !"# = 3 ∗ 	&'( )*	 ∗ + !"#	,-&'( )*	,-  
 In which ng specifies the mass in nanograms an bp refers to the 
number of base pairs in the sequence of the DNA fragments involved. 
Ligation reactions were incubated at room temperature (r.t.) O.N. and 
the ligation reaction was stopped diluting the reaction mixture five 
times with nuclease-free water. 
5.1.2.5 Expression vector-insert amplification 
 After the ligation of the gene of interest with the expression 
plasmid is done, an amplification step is needed. The same procedure 
as the one described in the subsection 2.1.2.1 was done. 
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5.1.2.6 Chimeric gene building 
In order to create a polyprotein it is needed to splice different gene 
fragments with the restriction site digestion/ligation strategy. The 
procedure used for this goal is the same as the one explained above. 
 For explaining the chimeric DNA building the polyprotein made 
for FimG will be used as an example. This polyprotein consists in four 
copies of the I91 domain flanking, two in each side, the FimG protein, 
and it is referred as (I91)2-FimG-(I91)2. Fig. 5.7 summarizes the whole 
process for creating this chimeric gene.  
 
Figure 5.7. Chimeric gene building process. In this diagram it is explained how the 
polyprotein (I91)2-FimG-(I91)2 is built by splicing the different genes that compose it. Red 
lines in between the sequences mean digestion pattern meanwhile the blue lines mean ligation 
between cohesive ends. Below the DNA sequences the codons are indicated and below the 
amino acids they code. Starting with pQE80L plasmid with one copy of the gene I91, all the 
steps consist in opening the plasmid digesting with BglII/KpnI and ligating the next gene 
previously digested with BamHI/KpnI. Every time a gene is fused to the construct the ligation 
of the cohesive ends BamHI/BglII generates a new restriction site, BstY. The last gene added to 
the sequence will be translated with the last two cysteines and the stop codon.  
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For this purpose the explanation will start with the pQE80L-
Insert construct from subsection 5.1.2.5 (pQE80L-I91), so the gene of 
interest inserted was the one encoding the I91 protein.  
For introducing another copy of the I91 gene after the first one 
the plasmid needs to be opened again with restriction enzymes. 
Digesting with BglII/KpnI enzymes generates BglII-pQE80L-I91-KpnI. 
This digestion opens the plasmid an releases a small fragment that 
encodes for the last two amino acids (two cysteines) and the stop 
codon. Digesting again the I91 gene with BamHI/KpnI will generate the 
insert BamHI-I91-KpnI. BamHI and BglII generate compatible ends, so 
two different sequences one digested with BamHI and the other one 
with BglII will have compatible ends and they can be ligated. Upon 
ligation of BglII-pQE80L-I91-KpnI with BamHI-I91-KpnI the 
pQE80L-(I91)2 construct will be generated. The ligation of cohesive 
ends between fragments digested with BamHI and BglII generates a 
new restriction site called BstY. After this, adding a new gene after the 
previous ones consists in repeating the same steps. Upon digestion of 
the FimG gene with BamHI/KpnI and the digestion of pQE80L-(I91)2 
with BglII/KpnI, these two fragment can be ligated again and so on for 
the last two copies of I91. 
When the last of the gene copies has been added to the plasmid, 
the whole construct is amplified the same way as it was explained 
before in subsection 5.1.2.1. 
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5.1.3 Protein expression and purification 
5.1.3.1 Expression test of the chimeric protein 
Once the chimeric gene has been built inside of the expression plasmid, 
the next step consisted in transforming bacterial cells suitable for 
protein expression. Around 50 ng of the plasmid were used for 
transforming E. coli BL21 (DE3) cells (Agilent) following the 
manufacturer instructions188. Bacteria then were grown with 450 µL of 
SOC medium for 1 h at 37ºC and 250 rpm. After, the cells were spread 
out over LB + Agar + Carbenicillin plates and grown O.N. at 37ºC. 
Several colonies were isolated for protein expression test and grown in 
10 mL of LB + Carbenicillin until the optical density (OD) at 600 nm 
reached a value of 0.6. Then, the volume was splitted in two and one 
the volumes was treated with 1 mM of Isopropyl-β-D-thiogalactoside 
(IPTG, Sigma) for protein expression induction. IPTG is a chemical 
compound analogous to lactose, which inhibits the suppression by the 
lac inhibitor of the lac operon under whose control is the gene of 
interest. Treated and non-treated (control) cultures were incubated O.N. 
at 37ºC and 250 rpm. After this incubation period, 1 mL of IPTG-
treated and control cultures were centrifuged and cells were pelleted. 
After discarding the supernatant, cell pellets were resuspended in 10 µL 
of Extraction Buffer (50 mM sodium phosphate pH 7.0, 300 mM NaCl) 
and then 10 µL of Laemmli sample buffer (Biorad) were added to the 
mixture. Samples were then boiled for 5 min and centrifuge at 
12,000xg for 30’. Upon this treatment bacterial proteins were released 
and denaturalized. Following with a Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) it is possible to 
separate the proteins by their size. 10-20 µL of protein sample were 
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loaded into polyacrylamide gels (stacking 4%, resolving 8-12%) and 
electrophoresis was done in the Biorad electrophoresis system for 2h at 
100 V in running buffer solution (Biorad). After separation, the gels 
were rinsed three times in milliQ water and proteins were stained with 
the Bradford solution (Thermo Scientific) for 30 min. Then the gels 
were rinsed again in water and a picture was taken with the Kodak 
Image Station 4000R. For every colony tested the control load was 
placed next to the IPTG-treated. Overexpression of the chimeric 
polyprotein appears as an intense band only in the IPTG-treated 
samples at the expected size for the construct. Fig. 5.8 summarizes the 
main steps for protein extraction.  
The colonies which display the highest protein expression were 
selected for large-scale protein production. In order to keep the colonies 
in the long-term the non-induced cultures were aliquoted an kept in 
10% v/v of glycerol (Fisher), flash frozen in liquid nitrogen and stored 
at -80ºC.  
 
Figure 2.8. Protein expression test. Diagram of protein expression test. Bacteria are 
transformed with the plasmid and then are plated in selective media. Single colonies are grown 
in liquid selective media and protein expression is induced in half of the culture, remaining the 
other half as a control. SDS-PAGE shows the molecular weight ruler (left) and then the 
controls (C) and the IPTG-treated (I) samples of four individual colonies. Orange rectangle 
indicates the control and the induced sample of a colony, highlighting the intense band at 
approximately 60 kDa, corresponding with the size of the polyprotein. 
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5.1.3.2 Large-scale protein production 
In order to conduct AFM experiments a large scale protein purification 
protocol needs to be applied. For all the proteins studied in this thesis 
the same protocol was used for protein expression and purification. 
Only (I91)2-CD4D1D2-(I91)2 was slightly different during the protein 
expression and DsbA both production and purification were completely 
different. These differences will be noted along the explanation. 
 Large-scale culture was induced with one frozen cell aliquot in 
800 mL of LB in the presence of Carbenicillin (0.1 µg/mL) and 
Chloramphenicol (0.05 µg/mL). E. coli BL21 (DE3) cells besides its 
genomic DNA and the expression plasmid introduced for polyprotein 
expression, carry another plasmid that confers resistance to the 
antibiotic Chloramphenicol. Culture was incubated at 37ºC and 250 
rpm until DO600 > 0.6 and then IPTG (1 mM) was added for protein 
expression induction ON in the same conditions.  
(I91)2-CD4D1D2-(I91)2 polyprotein was not transformed into 
BL21 (DE3) cells, instead it was transformed in E. coli NEB 5-α (New 
England Biolabs) following the instructions provided by the 
company189. This strain was chosen since it is the only one able to 
produce (I91)2-CD4D1D2-(I91)2 in a sufficient quantity suitable for 
single-molecule experiments. After NEB 5-α cell transformation and 
plating, a single colony was selected for large-scale culture in the same 
conditions as explained above but without Chloramphenicol. Upon 
IPTG adding, protein expression took place ON at 20ºC and 250 rpm. 
In the case of DsbA, the gene encoding this protein was inside of the 
plasmid pET11a. For DsbA, the large-scale culture was induced as 
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explained above and after IPTG induction the culture was incubated 
ON at 25ºC and 250 rpm. 
5.1.3.3 Protein extraction 
After o/n protein expression cells were pelleted centrifuging the culture 
at 4,000xg for 20 min at 4ºC. Supernatant was discarded and cells were 
resuspended in 16 mL Extraction Buffer (50 mM sodium phosphate pH 
7.0, 300 mM NaCl) in the presence of 160 µL of protease inhibitor 
(Merck Millipore). Then, cells were exposed to a chemical lysis at 4ºC 
with 30 min incubation in the presence of 100 µg/mL of lysozyme 
(Thermo Scientific) and gentle shaking (5 rpm). Then, cell 
resuspension was incubated for 10 min in the presence of Triton X-100 
1% (Sigma Aldrich) for cell membrane destabilization, DNAse I 
(Invitrogen) and RNAse A (Ambion) at 5 µg/mL each for enzymatic 
nucleic acid degradation, and 10 mM of MgCl2 for optimal 
performance of these nucleases. After 10 min with gentle shaking, a 
mechanical disruption of the cells was performed in order to release all 
the soluble proteins into the media. For this purpose it was used a 
French press (G. Heinemann HTU DIGI-F Press), a tool that allows for 
the application of high pressures on the cells. A valve on the bottom of 
the chamber allows for the regulation of the exit flow. Manually 
regulating the flow to the lowest speed possible (around 0.5 mL/min) 
the cells disrupted due to the high shear forces generated were 
collected. As a consequence, the cell lysis mixture obtained contains 
the proteins of interest and cell debris. In order to separate the soluble 
fraction with the proteins from the debris 1h 30 min centrifugation at 
33,000xg at 4ºC was performed. Then the pellet was discarded and the 
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supernatant was filtrated using three consecutive filters of 0.8, 0.45 and 
0.22 µm (Merck Millipore).  
 DsbA protein extraction was performed with an osmotic 
shock190,191. After protein expression, cells were pelleted (10,000xg, 10 
min, 4ºC) and resuspended in Extraction Buffer. Then cells were 
pelleted again and resuspended in Ice Cold Shock Buffer (50 mM Tris 
pH 8.0, 20% w/v Sucrose, 1 mM EDTA) and gently rocked for 10 min 
at 4ºC. After a third centrifugation, cells were resuspended and 
incubated in Ice Cold Leak Buffer (10 mM Tris pH 7.1). Then the cells 
were centrifuged and the supernatant was the periplasmic extract from 
the cells. The transference from a highly concentrated buffer to a very 
diluted one makes possible the periplasmic release of content, where 
DsbA is exported after translation in the cytoplasm.  
5.1.3.4 Protein purification 
This filtered supernatant contained the protein of interest and all the 
soluble proteins that bacteria produce constitutively. Further 
purification steps were performed taking into advantage the presence of 
six consecutive histidine residues in the N-terminal part of the protein 
of interest, added during the translation of the protein from the pQE80L 
plasmid (see subsection 5.1.2.3). Supernatant was then incubated for 1 
h at 4ºC and gentle shaking (5 rpm) in the presence of 3 mL of HisPur 
Cobalt Resin (Thermo Scientific). This resin contains cobalt divalent 
ions which bind polyhistidine-tagged proteins. After several rounds of 
resin cleaning with Extraction Buffer, the protein was released from the 
resin with Elution Buffer (50 mM Sodium Phosphate pH 7.0, 300 mM 
NaCl, 150 mM Imidazole). Elution Buffer contains imidazole, a 
compound that competes with histidine for the binding to cobalt. After 
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protein solution collection, disulfide bond oxidation or reduction was 
triggered o/n at RT in the presence of 0.1% of H2O2 or 10 mM of DTT, 
respectively (both from Sigma Aldrich).  
 A further purification step was done through a size exclusion 
chromatography in an ÄKTA pure (GE Healthcare) fast protein liquid 
chromatography (FPLC). Here a Superdex 200 column (GE 
Healthcare) was used for protein separation by size. Protein elution was 
done in HEPES buffer pH 7.2, NaCl 150 mM and EDTA 1 mM. A 
typical chromatogram from a FPLC run depicts the absorbance at 280 
nm (A280) for protein detection vs the volume eluted through the 
column (Fig. 5.9). Proteins, based on their size, elute at a particular 
column elution volume and the fractions collected coming from the 
best absorbance peak were aliquoted, flash frozen in liquid nitrogen and 
kept at -80ºC until their use in the AFM. 
 
Figure 5.9. Size exclusion chromatogram. This picture depicts a size exclusion 
chromatogram from the purification of the protein (I91)2-FimA-(I91)2. This protein elutes at 
~13.5-14.0 mL, and the fractions collected from the center of the peak are the ones used for 
AFM experiments. 
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 In the case of DsbA, after periplasmic extraction, the extract 
was loaded into a 5 mL HiTrap Q Sepharose FF column (GE 
Healthcare) for anion exchange. Instead of separating proteins by size, 
this time proteins were separated by electric charge. Negatively charged 
proteins are retained in the positively charged resin of the column. 
Upon DsbA binding to the resin, the protein was released from the resin 
with a linear increase gradient of NaCl, starting with Tris 20 mM pH 
8.0 and ending with Tris 20 mM pH 8.0, 1 M NaCl. DsbA elutes 
around 250-350 mM of NaCl. After ion exchange, the aforementioned 
size exclusion protocol was applied. 
 
5.2 Single-molecule Force Spectroscopy 
Along this section the AFM used in this thesis (Luigs & Neumann), and 
the different modes of operation applied for the mechanical study of 
single proteins will be explained. The graphical interface used for AFM 
operation, the data collection, and the analysis software were a custom-
written program for Igor Pro 6 software (Wavemetrics). 
 
5.2.1 AFM set-up 
An AFM is composed of three main parts: the piezo-electric actuator 
(PZA), the cantilever and the photodetector (PD) (Fig. 5.10). 
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Figure 2.10. AFM set-up. (a) Picture of the main AFM parts (modified from http://www.luigs-
neumann.com/sites/default/files/_DSC5708.JPG). (b) Scheme of the AFM. The laser beam is 
focused on the back of a cantilever whose back side is covered by a gold layer. The laser is 
reflected to a mirror which reflects the laser beam to a photodetector (PD). Over the PZA is 
placed the gold surface with the protein sample adsorbed over it. 
The PZA is the active part of the AFM. It is made of a material 
which shows piezo-electric effect (Fig. 5.11). Piezoelectricity is a 
property that consists in the ability of a material of generating an 
electric potential once it is mechanically stressed. This effect is related 
with the presence of electric dipoles in the crystal lattice of the 
material, and the application of a mechanical stress on the material 
changes the polarization of these dipoles. Piezoelectric materials 
exhibit also the inverse property; applying an electric field to these 
materials leads to mechanical deformation of their structure. This is 
known as the inverse piezoelectric effect192 , and it is this property the 
one exploited in an AFM. The application of a known voltage leads to a 
well-controlled mechanical disturbance. In the AFM used the PZA can 
be displaced in its X and Y directions with nm precision. Even more, 
the precision of the movement in its Z-direction is in the sub-nanometer 
range. In smFS experiments where the molecules are stretched 
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vertically this sub-nanometer resolution is crucial for the precise 
mechanical study of proteins. 
 
Figure 5.11. Inverse piezo-electric effect.  Diagram (a) depicts an unperturbed piezo-electric 
material with its dipole charge. Diagrams (b) and (c) show how the application of an opposite 
electrical potential deforms mechanically the piezo-electric material. 
The cantilever constitutes the probe with which the single proteins 
will be captured from the surface. In this thesis two types of cantilevers 
were used, MLCT and OBL-10 cantilevers (both from Bruker). Fig. 
5.12 shows pictures of both cantilevers. From MLCT, we used the 
triangular cantilevers C and D and from OBL-10 we used the 
rectangular A and B cantilevers. Both types are made of silicon nitride 
and MLCT cantilevers backside had a Ti/Au 60 nm layer, meanwhile 
OBL-10 cantilevers are covered on both sides including the tip with a 
20-30 nm Au layer. Each of the cantilevers has its own dimensions and 
properties, and they are used differently depending on the operation 
mode of the AFM used. 
Materials and methods 
108 
 
 
Figure 5.12. AFM cantilevers.  (a) Top picture shows the front side of the MLCT chip where 
the cantilevers are placed, highlighting the C and D triangular cantilevers used. Bottom picture 
shows a close view of the tip of the cantilever. (b) OBL-10 chip front view with the used A and 
B rectangular cantilevers. Bottom picture shows a close view of the tip of one of the cantilevers 
(Images from http://www.brukerafmprobes.com). 
In an AFM, the cantilever deflection is detected as a change in the 
reflection angle of the laser beam pointing to its backside. The 
reflection is detected in the PD, an optical device that converts the 
detected light (laser) into an electric signal (Fig. 5.10). The PD in fact 
is separated in two photodiodes, the upper and the lower one. Each time 
the cantilever is bent the laser beam will change its reflection angle and 
one of the halves of the PD will receive more light. The difference of 
the light registered by each half (upper PD registers a positive signal 
meanwhile de lower one is negative) generates an output electrical 
signal that corresponds with the bending of the cantilever. 
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5.2.2 AFM calibration and sample preparation 
In order to make an AFM experiment, it is necessary to place the 
protein sample over a suitable surface for protein adsorption. We 
fabricate custom-made substrates consisting of a 40-50 nm gold layer 
above a 4 nm layer of nickel over a 2 mm borosilicate substrate 
(brand). Nickel and gold layers are deposited with an Oerlikon 450B 
Evaporation System (Leybold). The gold substrate is then glued with 
vacuum grease (Dow Corning®) to the top part of the PZA (Fig. 5.10). 
Once the substrate is ready, we place a drop (10-15 µL) of the protein 
under study at a final concentration of 5-30 µM. We incubate the 
protein for 15-20 min, time during which the two last cysteines of the 
C-terminal end of the polyprotein can make a covalent bond with the 
gold surface and be immobilized (see subsection 5.1.2.6). After the 
incubation, the sample is rinsed several times with AFM buffer (10 mM 
HEPES buffer pH 7.2, 150 mM NaCl, 1 mM EDTA) to remove the 
non-attached molecules.  
The cantilever is held inside a chamber and submerged in AFM 
buffer. The liquid chamber  is a circular structure placed on a crystal 
that allows the passage of the laser beam through it. The chamber is 
laterally delimited by a silicon O-ring and the whole liquid cell is over 
a metal holder. Once the cantilever is correctly placed, the laser beam is 
focused pointing close to the end of the cantilever, near the place where 
the tip is.  
Then the PZA position is placed upside-down so now is facing 
the cantilever. The PZA is approached to the liquid cell and once it is in 
contact with the hydrophobic O-ring the liquid cell is sealed and water 
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evaporation is minimized. Now the experiment calibration can be 
started (Fig. 5.13).  
 
Figure 5.13. Sample preparation and PZA approach to liquid cell.  (a) Addition of a 10-15 
µL drop of protein on the gold substrate placed over the PZA. (b) After 15 min of incubation, 
sample is rinsed and the PZA-gold-sample set is turned upside-down, facing the liquid chamber 
where the cantilever is immobilized. Then the PZA is motor-approached to the liquid cell. (c) 
When the gold substrate is in contact with the O-ring, the chamber is sealed and water 
evaporation is minimized. 
As it was mentioned in the previous section, the PD registers the 
bending of the cantilever and converts light into an electrical signal. 
This signal is given in volts, and it is needed to convert these volts into 
force units. Assuming the cantilever deflection (zc) follows Hooke’s 
law (2), the spring-constant (k) can be calculated for small bending 
distances. 
 = −/0          (2) 
We use the Equipartition theorem (3) to calculate k193. This 
theorem relates the thermal motion of the fundamental oscillation mode 
(ω0) of the cantilever with its thermal energy  
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1
2 3/024 = 12 56  ;     = 37894                          (3) 
Were kB is the Boltzmann constant, T is the absolute temperature and 
<zc
2> is the variance of the cantilever’s Z-position registered by the PD 
at equilibrium. In order to calculate <zc2> , the power spectral density 
(PSD) of the Z-oscillations of the cantilever is calculated along a 
certain amount of time and the area under the peak of the first 
oscillation mode. <zc2> is in fact calculated as <∆V2> being ∆V=A-B 
(a difference in the registered voltage between the upper and lower 
PD).  
These calculations take place when the cantilever and the PZA 
are far away from each other (Fig. 5.14a), but in order to calculate the 
cantilever k it is required to calculate the slope that relates cantilever’s 
deflection (∆V) with the PZA displacement (zPZA). And for that, the 
PZA and cantilever have to be brought together. When they are close 
enough, a force curve is done (Fig. 5.14b). When the PZA is moved in 
Z-direction and the cantilever is pressed, this is deflected and the angle 
of the laser beam detected by the PD changes (∆V). Cantilever bending 
in Z-direction (∆zc) is the same as the PZA Z-displacement (∆zPZA). 
Now it is possible to calculate the slope (s = ∆V/∆zPZA), which can be 
used for finding out k from formula 3, 
 = 37894:9                                              (4) 
 Now, it is possible to calculate how much force (F) is being 
applied to a protein since the cantilever stiffness (k) and its 
displacement (zc) are known. 
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Each cantilever k is calculated at the beginning of each new 
experiment. Typical spring constants are: for MLCT C cantilever, 10-
20 pN·nm-1; for MLCT D, 30-60 pN·nm-1; for OBL-10 A cantilever, 9-
30 pN·nm-1; and B 2-6 pN·nm-1. MLCT C and OBL-10 B cantilevers 
are used for force-clamp measurements, which require softer and more 
sensitive probes. MLCT D and OBL-10 A cantilevers are used for 
force-extension measurements. 
 
Figure 5.14. Cantilever calibration. (a) Cantilever’s thermal spectrum is calculated at 
equilibrium and separated from PZA. For a certain time, cantilever’s Brownian movement in Z-
axis is registered in the PD as slight changes in the position of the incident light (upper 
scheme). Then, the power spectrum density (PSD) of this signal is calculated and the area under 
the fundamental oscillation mode (shaded area) is calculated too (lower graph). Finally <∆V2> 
is calculated. (b) For k calculation a force curve is done (lower graph). The PZA movement 
bends cantilever, changing the incident light on the PD (∆V). Cantilever’s Z-displacement it is 
the same as the PZA displacement (∆zPZA=∆zc) (upper scheme). Knowing the cantilever 
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displacement and the voltage change, now we can calculate the slope (s = ∆zc/∆V) (lower 
graph) and then the k of the cantilever solving the Equipartition theorem. Red arrow means the 
approach of the PZA to the cantilever, pressing it. Blue arrow means the retraction of the PZA 
from the cantilever. In the lower graph, the red approaching trace has been removed from the 
inset. In both upper schemes the liquid cell has been removed for the sake of simplicity. 
 
5.2.3 AFM operational modes 
The proteins studied with smFS in this thesis were measured in three 
different operational modes, each one of them for a specific purpose. 
These modes are called force-extension (FX), force-clamp (FC), and 
force-ramp (FR). 
5.2.3.1 Force-extension (FX) 
FX measurements consist in pulling a single protein at a constant 
speed. In this measurement the AFM is constantly doing force curves, 
with a cycle of PZA approaching to the cantilever, pressing it up to a 
specific force and then retracting. The typical FX data collected has a 
sawtooth pattern in which each peak corresponds to the unfolding of 
one domain. An example FX trace is depicted in Fig. 5.15 from a real 
measurement of (I91)2-FimF-(I91)2 polyprotein.  
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Figure 5.15. FX trace of (I91)2-FimF-(I91)2 polyprotein. The PZA approaches (red trace) to 
the unperturbed cantilever (1). Afterwards, the PZA pushes the cantilever (2). Then, the PZA 
retracts (black trace) from cantilever. When one polyprotein is adsorbed to the tip of the 
cantilever, the molecule becomes raised from the surface up to its C-terminal cysteines (3). 
Once the molecule is stretched up to its maximum length, the cantilever starts bending because 
of the tension, increasing the force (4). Force rises up to ~200 pN and one of the I91 domains 
unfolds (5). The unfolded I91 becomes completely stretched and again force starts to increase 
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until the next I91 domain unfolds, and so on. When all the I91 domains are unfolded FimF self-
complemented domain unfolds, since this domain is mechanically more stable than I91 
domains. Force rises up ~400 pN (6) and then FimF unfolding takes place (7). PZA keeps on 
retracting up to the complete stretching of the unfolded protein polymer up to the disulfide 
bond of FimF, increasing then the force again (8). Once the tension is above the strength of the 
interaction between cantilever’s tip and protein, the molecule is released from the cantilever 
and the force drops to zero. This last force peak corresponds with the detachment. 
Proteins are immobilized through their C-terminal end to the 
gold surface, so every time the PZA is pressing and bending the 
cantilever a protein molecule could get attached to the cantilever’s tip. 
When the retraction of the PZA starts, the cantilever bending gradually 
disappears, recovering its resting position. If a protein molecule got 
attached to cantilever’s tip, it will be held between the tip and the gold 
surface. As the PZA is further retracting at a constant speed and it is 
linked to the cantilever through a protein,  the PZA will start pulling the 
cantilever and bending it in the opposite direction. This bending results 
in an increment in the force registered by the PD, since the angle of the 
incident light on it changes. This force has its origin in the resistance 
made by the polyprotein while being stretched. As the PZA retracts, the 
protein is more stretched and force continuously increases. At some 
point, one of the domains of the polyprotein unfolds. Protein domain 
unfolding corresponds to the loss of the contacts that keep the protein 
in its native structure. The contacts that can be mechanically disrupted 
in a smFS experiment are weak interactions such as hydrogen bonding, 
salt bridges and hydrophobic interactions. When the unfolding of one 
domain takes place there is a sudden drop in the force and thus the 
cantilever comes back to its resting position, since the unfolding of the 
domain releases the length of the amino acid chain previously trapped 
in the native structure. After the first domain unfolds, as the PZA is 
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constantly retracting at a constant speed, the polyprotein is stretched 
again, the force rises again and then another domain unfolds and so on 
until the last domain is unfolded.  
In a homopolyprotein, a polyprotein whose domains are all the 
same, the mechanical unfolding of the domains is stochastic, happening 
in a random order one by one but around the same force for all of them. 
The last peak corresponds to the detachment of the protein from the 
cantilever, when the polyprotein is completely unfolded and the 
stretching force exerted is above the strength of the interaction between 
the cantilever tip and the protein.  
In all the FX measurements done in this thesis the polyproteins 
used were heteropolyproteins, hence not all the domains were the same. 
Specifically, each protein studied was flanked by two copies of the I91 
domain in each side. These I91 domains serve as a molecular 
fingerprint during the experiment, since their mechanical behavior is 
known. All the polyproteins of this thesis were pulled in FX at the 
constant speed of 400 nm·s-1, and CD4D1D2 was also pulled at 10 
nm·s-1. Measurements of CD4D1D2 in the presence of the antibody 
Ibalizumab were done at 400 nm·s-1, and both proteins were previously 
incubated for 1 h at RT in a 1:5 proportion before incubation over the 
gold substrate. The amplitude of the PZA approach-retract cycle was 
set to 400 nm except for FimH which was increased to 500 nm. All the 
measurements were done in the presence of AFM buffer. 
 FX operation mode allows for the study of the mechanical 
stability of protein domains when stretched at constant speed. The 
unfolding forces of a protein domain, its increment of contour length 
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and the persistence length of the protein polymer can be estimated with 
this smFS mode. 
5.2.3.2 Force-clamp (FC) 
FC measurements consist in pulling a single protein at a specific 
constant force. As in the case of the FX mode, the AFM is constantly 
doing force curves, with a cycle of PZA approaching to the cantilever, 
pressing it and then retracting. However, this time the PZA retracts in a 
way that the force applied to the protein is held constant using a PID 
feedback loop. Fig. 5.16 shows a scheme of a FC experiment. After the 
PZA pushes the cantilever, it rapidly retracts until the cantilever 
deflection is the same as the specific force (input). Once a protein 
domain unfolds, there is a drop in the force registered by the PD 
(output), since the cantilever is coming back to its resting position.  
 
Figure 5.16. FC operation mode of the AFM. An specified force (input) is sent to the 
feedback loop controller. This controller sets the PZA Z-position in order to apply a specified 
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force on the polyprotein attached to the cantilever. The real force applied is detected by the PD, 
which generates the output signal of the experiment. This system is dynamic and every time a 
protein domain unfolds the force sensed by the protein drops, so along the experiment it is 
necessary to correct the force. For that reason the output signal is also sent back to the feedback 
controller. With the information coming from the PD and from the input signal, the feedback 
loop is able to correct the PZA Z-position along time in order to keep constant the force. 
However, PD and the PZA are in constant communication 
through a feedback loop in order to keep the force constant along time. 
When a drop in force is detected, the PZA receives the signal to retract 
as much as needed in order to restore the force on the protein. Every 
time an unfolding event takes place and the force drops, the PZA will 
be retracted in order to restore cantilever’s deflection (force registered 
by PD) and maintain the force on the studied protein. In a typical FC 
trace a staircase signal is registered, in which every step is an increase 
in length which corresponds with the unfolding of one domain. Besides 
the extension of the molecule, the force is also registered. In the case of 
the force the signal oscillates around the specified value with a 10-15 
pN error and every time an unfolding event takes place there is a spike 
in the signal as a consequence of the drop in the force. The feedback 
loop restores the specified force with a response time below 5 
milliseconds. An example FC trace is depicted in Fig. 5.17 from a real 
measurement of (I91)2-FimG-(I91)2 polyprotein, 
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Figure 5.17. FC trace of (I91)2-FimG-(I91)2 polyprotein. In the left part of the figure there is 
a FC trace of (I91)2-FimG-(I91)2 polyprotein with three force regimes. First, PZA pushes 
cantilever (right side scheme, 1), and then it retracts until a pulling force of 160 pN are applied 
on the protein (2). When an I91 domain unfolds, a 25 nm step increase in length is registered, 
besides a drop in the force registered by the PD (lower left inset). Feedback loop controller then 
retracts PZA Z-position so the 160 pN are restored (3). After the unfolding of the four I91 
domains, the third force regime is applied for FimG unfolding at 300 pN (4). When FimG 
unfolding occurs, an increase of 33 nm is registered and so it is registered a drop in the force 
applied. Then, PZA is retracted again for restoring the pulling force in the molecule (5). 
 
 FC traces can be set up not only for protein unfolding but also 
for refolding. In this thesis the unfolding of CD4D1D2 and the 
unfolding and refolding of self-complemented FimG were studied 
along single trajectories.  
CD4D1D2  
The CD4D1D2 nanomechanics  were studied pulling at different forces 
ranging from 20 to 100 pN. A three-pulse force protocol was used, first 
pushing the cantilever for 0.5 s at 800 pN. CD4D1D2 has lower 
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mechanical stability than I91, so in order to isolate the unfolding of 
CD4D1D2, the aforementioned range of forces were applied for 
different times (2-30 s) in the second pulse and then the force was 
increased to 150 pN for I91s unfolding for 2-10 s. 
In the CD4D1D2 reduction experiments with human 
thioredoxin, the enzyme was diluted in AFM buffer to a final 
concentration of 10 µM in the presence of 50 nM of human thioredoxin 
reductase and 2 mM of NADPH. Thioredoxin reductase and NADPH 
(Sigma) were added for restoring the oxidation state of the thioredoxin 
along the experiment. Again a three-pulse protocol was used. The 
second pulse used was of 50-60 pN for 2-10 s.  
FimG 
With this protein, the refolding behavior of oxidized (disulfide-bonded) 
and reduced (non disulfide-bonded) FimG was studied under different 
conditions. Different force protocols were applied to FimG that 
consisted in pushing the cantilever at 800 pN for 2 s (1), unfold the four 
I91s at medium force (2), isolate the unfolding of FimG at high force 
(3), and then quenching this force to zero for different times for 
allowing protein folding (4). After these quenching times, the same 
protocol was repeated to test if FimG refolded. Besides the different 
refolding quenching times used, the role of proteins involved in Fim 
proteins maturation was approached. First, the refolding of FimG was 
studied in the presence of 10 µM of chaperone FimC. Then the same 
was done but in the presence of 100 µM of the oxidoreductase DsbA. 
Finally, the effect of both proteins was studied at the same time. A 
different pulse protocol was used for the measurements in the presence 
of DsbA, and DsbA with FimC, since the reduction of FimG by 
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reduced DsbA could be impaired at high force194. Table 5.1 
summarizes the force protocols used and the different conditions 
employed in each experiment. 
Protein under study Unfolding 
Forces 
Quenching 
forces 
Unfolding forces Other proteins 
in the media 
(I91)2-CD4D1D2-(I91)2 20/160 pN 
(20-30/2 s) 
No No -/+ thioredoxin 
(I91)2-FimG-(I91)2 160/300 pN 
(2/20 s) 
0 pN (10, 30, 
45, 60 s) 
160/300 pN (2/20 s) -/+ FimC (10 µM) 
(I91)2-FimG-(I91)2 160/300/100 
pN (2/5/2 s) 
or 
160/300 pN 
(2/7 s) 
0 pN (45 s) 160/300/100 pN (2/5/2 s)  
or 
160/300 pN (2/7 s) 
-/+ DsbA (100 
µM) 
or 
+FimC/+DsbA 
(10/100 µM) 
Table 5.1. Force protocols used in constant force smFS experiments. 
Fim proteins are exported to the periplasmic space in an 
unfolded, extended, and non-disulfided state. With constant force smFS 
experiments unfolded proteins are obtained which resemble the same 
conditions as the ones taking place during pilus proteins translocation 
and maturation in the periplasm.  
FC operation mode allows for the study of the mechanical 
stability of a protein at a specific force.  
5.2.3.3 Force-ramp (FR) 
The last operational mode used was FR. In this mode, the force applied 
to the molecule is changing linear the time. PZA constantly retracts 
increasing the deflection of the cantilever and thus the stretching force 
on the polyprotein. The loading rate is constant and the force triggers 
the unfolding of the protein domains. Again the feedback loop is in 
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charge of restoring the tension on the molecule after each unfolding 
event.  
 FR experiments were conducted on CD4D1D2 protein in the 
absence and in the presence of Ibalizumab, incubated at rt for 1h in a 
1:5 ratio. The loading rate was 33 pN·s-1.  
 
5.3 smFS data analysis 
All the experimental data was analyzed with the Igor Pro software 
(Wavemetrics). The analysis procedure employed for the analysis was 
kindly provided by Prof. Julio M. Fernández laboratory 
(AFM_Analysis_V2.40.ipf). Besides, a modification of this analysis 
procedure for force correction was kindly provided by Mariano Carrión 
laboratory (LN_AFM_Analysis_V1.1_Filtering). 
FX data 
The FX data collected had the already mentioned sawtooth pattern in 
which the unfolding peaks correspond with one domain unfolding. 
Each of the peaks of the trace is fitted to the Worm-Like Chain (WLC) 
model for polymer elasticity, 
	; = < 	 =1> ?1 − A8B
2 − 1>+ A8D                        (5) 
Where kB is the Boltzmann constant, T is the temperature, p is 
the persistence length, Lc is the contour length and x is the extension. 
The WLC model can be applied to describe the elasticity of a polymer 
submitted to a mechanical stress195–197. This model describes a polymer 
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as a string of monomers set one after the other, of a given total length. 
Polymers in solution adopt a coil conformation because this allow to all 
its monomers to maximize their entropy. When the polymer is extended 
the entropy of the monomers is reduced and this generates an opposite 
force. The persistence length p defines the flexibility of the chain. In a 
protein the value of this parameter is the length of one aminoacid (one 
monomer) being around 0.4 nm. The contour length (Lc) is the end-to-
end distance of the polymer. In a FX trace where the WLC model is 
applied to fit the unfolding of each protein domain, we can modify both 
Lc and p. The value of p was maintained fixed between 0.25 and 0.5 
nm, around the length value of an amino acid. The Lc was calculated as 
the distance between two consecutive unfolding peaks. It is denoted as 
∆Lc since the protein domains when folded already present a certain 
end-to-end distance, being around 5 nm for Ig-like domains. Fig. 5.18 
shows the fitting of the unfolding peaks from the (191)2-FimF-(I91)2 
trace depicted in Fig 5.15.  
The FX experiments yield a great amount of data; however it is 
important to select it correctly. Among this body of data the vast 
majority is constituted by incomplete stretched proteins. Working with 
homopolyproteins constituted by the repetition of the same protein 
module is not so problematic since an incomplete trace will still have 
several peaks which are the same as the missing ones. In this thesis all 
the proteins stretched were heteropolyproteins, in which the protein 
domain we wanted to study was flanked on both sides by two copies of 
the I91 protein domain. As it was mentioned before, I91 mechanical 
properties are well known thus it serves as a fingerprint for identifying 
the protein under study. I91 domains have a typical ∆Lc of ~28 nm and 
an unfolding force of ~200 pN. For that reason, in order to select only 
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the most suitable data only those traces which present the unfolding 
peaks of at least three I91 domains are accepted, and they should fulfill 
with the typical ∆Lc and unfolding forces. To identify the protein 
domains under study we first calculate theoretically their ∆Lc 
multiplying the number of aminoacids of the domain by the p of a 
polypeptide (~0.4 nm·aminoacid-1). In order to calculate the average 
∆Lc and the average unfolding force of a protein domain it is necessary 
to collect as many traces as possible to get a solid statistical support. 
Usually this number is above 50 traces but for FimH lectin domain this 
amount was below because of the difficulty to measure this protein. 
The dispersion of the data was calculated as the standard deviation. 
 
Figure 5.18. FX trace of (I91)2-FimF-(I91)2 polyprotein with WLC model fitting. Same 
trace as shown in Fig. 2.15 with the WLC fitting of the unfolding peaks. The The fitting of the 
I91 domains is showed in grey meanwhile FimF unfolding is shown in blue. ∆Lc is calculated 
as the distance between the fittings of two consecutive peaks. The red arrows indicates the 
approaching of the PZA to the cantilever (red trace) and the black arrow shows the retraction of 
the PZA (black trace). 
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FC and FR data 
The FC and FR data had a staircase pattern in which every step 
corresponds with the unfolding of one protein domain. The increase in 
length is measured as the difference in height before and after the 
unfolding of the domain. In this case the ∆Lc of the I91 is ~25 nm 
because at constant force the protein domains are not stretched to its 
maximum as it happens at constant speed. Again, in order to accept a 
trace at least three I91 domains should be present during the unfolding. 
In the refolding experiments it is expected to see at least the unfolding 
of two I91s after the quenching time. For the unfolding rates of 
CD4D1D2 and FimG calculated at a specified force, the unfolding 
trajectories were summed and averaged, and then fitted to single or 
double exponential functions. The refolding probability of the 
experiments done at constant force with FimG was calculated as the 
ratio of trajectories showing the refolding of FimG divided by the total 
amount of trajectories collected under a specific condition and 
quenching time. The standard deviation of this refolding probability 
was calculated as the one followed by a binomial distribution.  
 
5.4 Steered Molecular Dynamics simulations 
Besides the smFS experiments of the type I pilus proteins, these ones 
were also stretched in silico. The goal was to get a detailed view of the 
unfolding process at the atomic scale, since these details are 
undetectable in an AFM. For that purpose all-atom Steered Molecular 
Dynamics (SMD) simulations were done using the GROMACS 4.6.5 
package198. Self-complemented structures of the four Fim proteins 
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equivalent to the ones used in smFS experiments were used for the 
pulling experiments, based on previous 3D resolved structures and 
available in the Protein Data Bank (2JTY for the self-complemented 
FimA and 4J3O for the complex FimC-FimF-FimG-FimH). The 
subunits were isolated individually with their correspondent donor β-
strand and the DNKQ linker was manually added to each of them. In 
the case of FimF both the linker and the donor β-strand of FimA were 
manually inserted in the structure since there are no available structures 
in the PDB database. In the case of FimH we only used the pilin 
domain. 
 Also, it was tested how could affect the self-complementation 
strategy followed in the design of the Fim proteins for smFS. For that 
reason another structure of FimH pilin domain complemented with the 
donor β-strand of FimG but not covalently linked together, was 
stretched in SMD simulations. This approach allows to test if our 
experimental constructs are mechanically different from the real 
interaction that takes place in the pilus. This experiment is only 
possible in silico since non complemented Fim proteins are very prone 
to aggregation and unable to fold if they lack the complementation of 
their cognate donor β-strand or from the donor β-strand of FimC.  
 All the structures were placed in boxes of 7x7x28 nm 
dimensions with their pulling axis aligned in the z-dimension. Explicit 
solvent of TIP3P water molecules199 and 0.15 M of NaCl were added to 
the boxes. The force-field used was CHARMM27-CMAP200 and the 
systems were prepared with a steepest descent minimization and an 
equilibration simulation of 100 ps with velocity rescaling201. Upon 
relaxation and minimization steps of the structures the proteins were 
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stretched along the z-axis taking as reference pulling groups the 
nitrogen atom of the N-terminal aminoacid from the pilin domain and 
the carbonyl atom from the last C-terminal aminoacid of the donor β-
strand. The pulling was done at 1 nm·ns-1 for 10 ns with Nosé-Hoover 
temperature coupling and the timestep was 0.001 ps. At this pulling rate 
and with this simulation time it is possible to capture the complete 
ripping out of the donor β-strand from the pilin fold of each structure. 
The simulations were conducted with periodic boundary conditions in 
all directions and with the Smooth Particle Mesh Ewald (SPME) 
method for long-range electrostatics202 and a real-space cut-off for van 
der Waals interactions of 1.5 nm. No pressure coupling was used and 
the temperature of the system was set to 300 K. The hydrogen-bonding 
pattern of each donor β-strand with the pilin fold was calculated based 
on the instantaneous distances among oxygen and hydrogen atoms 
analyzed along the equilibration run and the pulling simulation. 
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Chapter 6: Results 
In this chapter all the results obtained along this thesis are detailed. 
These results are organized in two sections that approach some of the 
nanomechanical aspects involved in bacterial and viral attachment to 
target cells. 
The first part of the results is dedicated to the bacterial 
attachment system of the type I pilus. This set of results is at the same 
time divided in three sections. One is dedicated to the mechanical study 
with smFS of the Fim proteins that compose the type I pilus; the second 
one gives an atomic-level insight to the smFS experiments with 
Molecular Dynamics simulations; and the third one is focused on the 
study of the folding and the maturation of the FimG subunit for pilus 
genesis with smFS.  
The second part of the results is dedicated to the 
nanomechanical study of the first two domains of the T-cell surface 
receptor CD4. Besides, the effect of other proteins in the mechanical 
behavior of CD4D1D2 was studied and a theoretical model was 
elaborated for relating the extension of the CD4 protein with the 
infectivity of the HIV-1 virus.  
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6.1 Type I-pilus nanomechanical architecture and 
genesis 
6.1.1 Nanomechanical architecture of the type I pilus 
In order to test the mechanical resistance and stability of the type I pilus 
we designed self-complemented pilus subunits in which each protein 
domain bears the sequence of the donor β-strand of the next subunit of 
the pilus. The whole pilus structure and stability relies on this donor 
strand complementation interaction between subunits, thus pulling 
along the N-terminal to the C-terminal axis of the subunits we resemble 
the pulling direction experienced by the pilus when attached to a 
surface.  
 We pulled the different proteins at 400 nm·s-1 in FX mode. 
Most of the type I pilus is composed of FimA subunits which form the 
pilus rod, being the FimA-FimA interaction the most abundant in the 
structure. Therefore we pulled from the chimeric heteropolyprotein 
(I91)2-FimA-(I91)2 in which the FimA subunit is complemented with 
its donor β-strand but placed in the C-terminal end through the linker. 
Besides, FimA domain has a conserved disulfide bond between its A 
and B β-strands as the other Fim proteins. So the mechanical stability 
of the oxidized (disulfide-bonded) and reduced (non disulfide-bonded) 
domains was tested. In the Fig. 6.1 are shown two FX traces of FimA, 
each one in one oxidation state.  
In Fig. 6.1a after the four I91 unfolding peaks and before the 
detachment it can be seen a peak whose ∆Lc and unfolding force is 42 
nm and 500 pN respectively, corresponding with the oxidized domain 
(FimAS-S). The theoretical contour length (Lc) of FimA is ~62 nm, 
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assuming each aminoacid contributes with 0.38 nm to the Lc158 and 
knowing that FimA sequence has 163 aminoacids. However the force 
regime we can reach allows us to stretch the protein up to its disulfide 
bond, and there are 41 aminoacids enclosed between the two cysteines 
involved in the disulfide bond. This leaves the maximum Lc to ~46 nm 
(122 aminoacids). However, it is necessary to take into account that a 
folded protein domain already has an initial end-to-end distance before 
the stretching. In the self-complemented FimA with no N-terminal 
donor β-strand this length is ~4 nm between the α-carbons of the first 
and the last amino acids. Therefore the expected ∆Lc is 42 nm for 
FimAS-S, matching the value shown in the trace of the Fig. 6.1a.  
 
Figure 6.1. FX of (I91)2-FimA-(I91)2. (a) FX trace of oxidized FimA (FimAS-S) (b) FX trace 
of reduced FimA (FimASH-SH). Grey lines are the WLC fitting of the I91 unfolding peaks. The 
purple one represents the fitting to FimA unfolding. (c) Increment of contour length (∆Lc) vs 
unfolding force. Oxidized (n=63) and reduced FimA (n=68) populations differ clearly both in 
∆Lc and force. The cartoon figure has two arrows showing the pulling axis of the self-
complemented FimA domain, where the yellow spheres represent the cysteine residues and the 
blue strand represents the donor β-strand of FimF. Linker appears in black. 
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On the other hand, reduced FimA does not have the 
intramolecular bond so the whole sequence can be stretched, leaving us 
a ∆Lc of ~58 nm. Fig. 6.1b shows a FX trace of reduced FimG 
(FimASH-SH). The ∆Lc is 57 nm as expected but the unfolding force is 
decreased (300 pN) when compared with the oxidized domain. The 
absence of the disulfide bond makes the protein weaker when this is 
mechanically unfolded. Fig. 6.1c shows ∆Lc vs unfolding force plot of 
all the unfolding peaks collected for FimA both in the absence and in 
the presence of the disulfide bond. The calculated average for ∆Lc was 
42 ± 2 nm (mean±SD) and for the unfolding force was 516 ± 49 pN 
(mean±SD). Meanwhile, for FimASH-SH the ∆Lc was 57 ± 1 nm and for 
the unfolding force was 307 ± 25 pN. This represents a 33 % decrease 
in the mechanical stability of the reduced domain. 
 Following the type I pilus architecture, after the pilus rod 
composed of hundreds of FimA subunits we find the pilus tip fibrillum. 
This structure is composed of the array of FimF-FimG-FimH although 
two subunits of FimF could be present instead of only one. FimF and 
FimG constitute what is known as the hinge region of the pilus, 
bridging the pilus rod with the lectin binding protein. Therefore we 
pulled the oxidized and reduced domains of both proteins. In the case 
of FimFS-S, the ∆Lc was 42 ± 2 nm and the unfolding force was 409 ± 
39 pN. The theoretical ∆Lc is 42.5 nm since in the oxidized domain 
there are 125 aminoacids available for stretching and the Lc is ~5 nm. In 
the reduced domain, the ∆Lc was 55 ± 1 nm and the unfolding force 
was 272 ± 25 pN (Fig. 6.2).  
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Figure 6.2. FX of (I91)2-FimF-(I91)2. (a) FX trace of oxidized FimF (FimFS-S) (b) FX trace of 
reduced FimF (FimFSH-SH). Grey lines are the WLC fitting of the I91 unfolding peaks. The blue 
line represents the fitting to FimF unfolding. (e) Increment of contour length (∆Lc) vs unfolding 
force. Oxidized (n=150) and reduced FimF (n=40). (c) The cartoon figures show the pulling 
axis of the self-complemented FimF domain (in c) where the yellow spheres represent the 
cysteine residues and the purple strand represents the donor β-strand of FimA. Linker is shown 
as a black line. 
 In the case of FimG, the oxidized domain displayed an ∆Lc of 
40 ± 2 nm and an unfolding force of 440 ± 36 pN, meanwhile the 
reduced one had an ∆Lc of 52 ± 1 nm and an unfolding force of 339 ± 
27 pN (Fig. 6.3). Again, we observe a pronounced decrease in the 
mechanical stability of the non-disulfided proteins, ~50 % in the case of 
FimF and ~30 % in the case of FimG.  
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Figure 6.3. FX of (I91)2-FimG-(I91)2. (a) FX trace of oxidized FimG (FimGS-S) (b) FX trace 
of reduced FimG (FimGSH-SH). Grey lines are the WLC fitting of the I91 unfolding peaks. The 
green line represents the fitting to FimG. (c) Increment of contour length (∆Lc) vs unfolding 
force. Oxidized (n=83) and reduced FimG (n=69). The cartoon figures show the pulling axis of 
the self-complemented FimG (in c) where the yellow spheres represent the cysteine residues 
and the blue strand represents the donor β-strand of FimF. Linker is shown as a black line. 
 FimH is the last of the pilus subunits. It is divided in two 
connected domains, the N-terminal lectin domain involved in the 
recognition and binding to the sugars present in the cells of the bladder, 
and the C-terminal pilin domain. The pilin domain is complemented by 
the donor β-strand of FimG, thus it shares the same characteristics as 
the other Fim proteins. Both pilin and lectin domains have conserved 
disulfide bonds near their N-terminal sequence. In Fig. 6.4 are shown 
FX traces of the polyprotein (I91)2-FimH-(I91)2. In the oxidized state 
the unfolding of FimH is detected as two independent peaks, one 
corresponding to the lectin domain (FimHL) and the other 
corresponding to the pilin domain (FimHP). FimHL is the weakest 
domain in the polyprotein thus it unfolds at the beginning of the 
stretching. After it, the I91 domains unfold and then FimHP unfolds just 
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before the detachment peak. The average ∆Lc is 40 ± 2 nm and the 
unfolding force is 122 ± 24pN, for FimHL. In one third of the traces the 
unfolding of FimHL domain takes place through an intermediate with 
two peaks, one with an ∆Lc of 6 ± 1 nm and 95 ± 30 pN and the other 
with ∆Lc of 35 ± 2 nm and 116 ± 19 pN (Fig. 6.4b). When reduced, the 
pilin domain presents a ∆Lc of 47 ± 2 nm and a mechanical stability of 
235 ± 37 pN, following the trend observed in the other Fim proteins. 
Capturing the unfolding of the reduced lectin domain was elusive only 
being possible to register it in two traces, probably due to the 
misfolding or instability of the domain in the reduced state.  
 
Figure 6.4. FX of (I91)2-FimH-(I91)2. (a) FX trace of oxidized FimH, with both lectin 
(FimHLS-S) and pilin domains oxidized (FimHPS-S) (b) FX trace of oxidized lectin domain 
showing an intermediate (FimHLS-S). (c) FX trace of reduced pilin domain (FimHLSH-SH) (d) 
Increment of contour length (∆Lc) vs unfolding force. Oxidized FimHPS-S (n=48), oxidized 
FimHLS-S (n=29) and FimHLS-S with an intermediate (n=13). The cartoon figure shows the 
pulling axis of the self-complemented FimH. FimHL (brown) and FimHP (red) present both a 
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disulfide bond, showed as yellow spheres. The green strand represents the donor β-strand of 
FimG. Linker is shown as a black line. (e) FX trace of reduced FimHL (FimHLSH-SH). Grey lines 
are the WLC fitting of the I91 unfolding peaks. The red one represents the fitting to FimHP 
unfolding, the brown one represents the fitting to FimHL. 
 In Fig. 6.5 is shown the unfolding forces of the Fim subunits 
both in the oxidized and reduced state. It is clear there is an 
unequivocal decreasing trend in the mechanical stability of the domains 
as we approach to the tip of the type I pilus. The FimA subunit is the 
most stable domain followed by FimG and FimF and then by FimHP  
and
 
FimHL. This trend is reproduced at lower forces by the reduced 
domains of each Fim protein. It seems clear the type I pilus architecture 
and its mechanical properties are intimately related, yielding a very 
resistant structure which relies on non-covalent interactions and 
submitted to challenging shear forces. 
 
Figure 6.5. Hierarchical unfolding forces of type I pilus subunits. (a) Histogram showing 
the values of the unfolding forces of both oxidized and reduced pilus domains. Bars show the 
mean value and the error bars show the SD (b) Summary table of the unfolding forces and the 
increment of contour length values of the subunits in their oxidized and reduced state. Data 
showed as mean±SD. 
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6.1.2 Molecular Dynamics pulling simulations of type I pilus 
subunits 
smFS experiments show a general view of the unfolding mechanism of 
the pilus subunits. However a detailed description of the events taking 
place during the unfolding is unreachable with the AFM. For that 
reason, Molecular Dynamics simulations are a useful tool for exploring 
atomic-level events that fall outside the reachable experimental range. 
This computational study was done in collaboration with Dr Fabiano 
Corsetti and Dr Emilio Artacho. 
 
Figure 6.6. Force vs Extension plots of the SMD simulations of the type I pilus subunits. 
From top to bottom, FimA-DSFimA (a), FimF-DSFimA (b), FimG-DSFimF (c) and FimHP-DSFimG 
(d). The cartoon insets show the proteins at different extensions during the pulling. N and C 
terminal aminoacids are highlighted as grey beads, except for FimA whose N-terminal 
aminoacid is a cysteine, shown with a van der Waals representation. The four aminoacid linkers 
(DNKQ) are represented in black. 
Steered Molecular Dynamics (SMD) simulations were 
performed in the four self-complemented Fim proteins. Proteins were 
Chapter 6 
137 
 
pulled from their N-terminal end at a constant speed (1 nm·ns-1), 
mimicking the FX experiments done in the AFM. The proteins were 
stretched during 10 ns, a time window long enough for β-strand 
removal from the protein fold. Fig. 6.6 shows the force vs extension 
plots of the SMD simulations of the four pilin proteins. At first sight 
the force traces look very similar and the force peaks observed coincide 
at similar protein extensions. Most of the force builds up from the 
strength of the interaction between the donor β-strand and the rest of 
the fold.  
 Several hydrogen-bonds connect the donor β-strand with two β-
strands, one running parallel and the other one in an antiparallel 
disposition. Fig. 6.7 shows the hydrogen bonds between the donor β-
strands and the fold of the protein they are complementing. The 
hierarchical forces observed in the AFM are somehow conserved in the 
simulations although FimH climbed two positions (FimA: 673 
KJ·nm·mol-1 > FimH: 652 KJ·nm·mol-1 > FimG: 626 KJ·nm·mol-1 > 
FimF: 434 KJ·nm·mol-1). The pulling rate used in the SMD simulations 
is six orders of magnitude faster than the attained experimentally in the 
AFM, a possible explanation for this rearrangement in the forces.  
 Nevertheless the differences in the force maximums are 
negligible at the force ranges registered. What is common to the four 
proteins is that the force peaks disappear once the correspondent donor 
β-strand is ripped out from the protein fold and the force drops to near 
zero once this event takes place, pointing to the fact that all the 
mechanical resistance of the pilus domains lies on the strength of the 
interactions between the donor β-strand and the protein fold. 
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Figure 6.7. Hydrogen bond pattern of the self-complemented Fim proteins. The bonding 
pattern is recovered by examining the fluctuation of O-H bond lengths in the equilibrated 
structure before the start of the pulling. Each circle represents a residue (specified in letter 
code), and a single line connecting two circles shows a hydrogen bond between them. Double 
lines indicate two hydrogen bonds within the same pair of residues. The dotted line indicates a 
weak bond. Within each protein, the top strand and donor strand exhibit parallel β-sheet 
bonding (given by the zig-zag bonding pattern), while the bottom strand and donor strand 
exhibit antiparallel β-sheet bonding (given by the row of double bonds). 
In the case of FimA, 20 hydrogen bonds are stitching the fold; 
FimG and FimF show 18 and 19 bonds respectively, and FimH shows 
17. Based on this finding, we can infer that FimA shows the highest 
unfolding force in smFS experiments since it presents the highest 
number of hydrogen bonds between the donor β-strand and its 
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surroundings. FimG and FimF show a similar number and FimH shows 
the lowest number, something we can relate with the different 
unfolding forces registered in the AFM in which FimH pilin domain 
shows the lowest unfolding force among the all pilins. 
In order to validate the experimental design of the self-
complemented domains, a SMD simulation with the same conditions 
was done on the FimH pilin domain complemented with the donor β-
strand of FimG but not covalently linked to it. Fig. 6.8 shows the 
comparison between the pulling simulations of the complemented (688 
KJ·nm·mol-1) and the self-complemented (652 KJ·nm·mol-1) FimH 
pilin domains. The force-extension plot shows almost no difference 
between pullings, validating our experimental constructs and the data 
obtained in the smFS experiments. In the complemented protein the 
force drops to zero after the removal of the donor strand of FimG since 
no physical connection links strand with the rest of the fold, as it 
happens in the self-complemented structure. 
 
Figure 6.8. Force vs time of the Steered Molecular Dynamics simulations of the self-
complemented FimH pilin domain and the FimH pilin domain with the donor β-strand of 
FimG. The self-complemented FimH shows the same unfolding pattern and the same 
mechanical stability as the FimH domain complemented with the donor β-strand of FimG. 
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6.1.3 FimG subunit maturation and folding for pilus incorporation 
smFS experiments allowed us to study the mechanical stability of the 
Fim proteins. Besides, it allows us to study at the single-molecule level 
the process of maturation of the pilus subunits. Fim proteins are 
exported to the periplasmic space in an extended and non-disulfided 
conformation. Under these conditions they cross the inner membrane 
through the SecYEC pore and once in the periplasm an orchestrate 
process takes place for the formation of their disulfide bond, their 
correct folding and their transport to the outer membrane FimD/Usher 
protein platform for incorporation to the pilus.  
 With the AFM we can unfold and extend the protein mimicking 
the same conditions as the ones the pilus proteins face when they are 
exported to the periplasmic space. In the in vivo process, it is known 
that the first actor involved after the subunit exportation to the 
periplasm is DsbA, the oxidoreductase enzyme involved in the 
formation of the conserved disulfide bond present in the Fim proteins. 
Upon oxidation, the chaperone FimC donates a β-strand to the 
incomplete folds of the Fim proteins. The established model stipules 
that once the FimC-Fim complex is formed, the Fim protein folds with 
the help of FimC. The complex (i.e. FimC-FimF) is then recruited in 
the outer membrane by the FimD platform where there is an exchange 
between the N-terminal donor strand of the incoming subunit (i.e. 
FimF) and the one of FimC of a previously incorporated Fim protein 
(i.e FimG). When the donor strand complementation (DSC) between 
subunits is done, the FimC (i.e. the FimC from the complex FimG-
FimC) chaperone is released and ready for the interaction with a new 
incoming Fim protein. When a new Fim complexed with the chaperone 
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arrives to the FimD (i.e. FimA-FimC), DSC takes place and the FimC 
from the previous subunit (FimF-FimC) is released, and so on. 
 We tested this process with the self-complemented FimG 
domain using the force-clamp (FC) mode of the AFM. In the case of 
FimG, the DSC between FimG and its cognate donor β-strand from 
FimF is already formed in the protein structure since it is covalently 
linked to it. However, the unfolding of the protein yields an extended 
polypeptide, separating the FimF donor strand from the rest of the 
protein fold. When the protein is held in an extended state for a period 
of time it enables the intervention of third parties such as FimC or 
DsbA. 
FimG assisted refolding in the presence of FimC 
Under these considerations, a constant force protocol was designed in 
order to test the ability of FimG-DSFimF to refold after its mechanical 
unfolding. First, a pulse of 160 pN for 2 s was applied for the I91 
unfoldings, and then the force was increased to 300 pN for 20 s in order 
to unfold FimG. Then, the force was quenched to 0 pN for different 
times ranging from 10 to 60 s for allowing protein refolding. After, the 
same two pulses of the beginning were applied to test if protein 
refolding took place. We tested this ability to refold both in the absence 
and in the presence of the chaperone FimC. Besides, we wanted to test 
the ability of FimC to discriminate between oxidized and reduced 
FimG domains, since it has been suggested the need of the disulfide 
bond for FimC binding and Fim subunits maturation previous to pilus 
incorporation203.  
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Figure 6.9. Force-clamp refolding experiments of FimG. The figure shows two example 
traces from unfolding and refolding experiments of FimG at 45 s of quenching time. In each 
trace I91 unfoldings are detected as 25 nm increase in length, meanwhile FimG is detected as 
an increase of 33 nm (when disulfide-bonded, (a)) or  45 nm (reduced, (b)). Dotted brown line 
indicates the stretched molecule has the same height on both sides. The different gray scale of 
the shaded areas indicates the constant force applied along the experiment (grey, 160 pN for 2 
s; dark grey, 300 pN for 20 s; and light grey, 0 pN for different times). 
In a FC experiment both the force applied and the PZA 
displacement are registered. The unfolding of one protein domain is 
captured as a step increase in length and a sudden drop in the force 
applied. The feedback loop then corrects and restores the constant force 
value retracting the PZA as much as needed for restoring the force 
value. Fig. 6.9 shows two traces of FimG-DSFimF, one oxidized (step 
size ~33 nm) and the other reduced (step size ~45 nm), in which the 
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refolding of FimG did not take place after the quenching time at 0 pN. 
We know FimG did not refold since there is no any step length increase 
in the second part of the experiment, but the total extension of the 
protein is the same before and after the quenching time. We do not 
know if the FimC recognition of the FimG domain occurs when the 
protein is extended or once it is collapsed during the quenching time. 
For that reason we tested a wide range of quenching times (10, 30, 45 
and 60 s). Fig. 6.10 and Fig. 6.11 shows oxidized and reduced refolded 
traces at 10, 30, 45 and 60 s of quenching time.  
 
Figure 6.10. Force-clamp refolding experiments of oxidized FimG in the presence of 
FimC. The figure shows four example traces from unfolding and refolding experiments of 
FimG in the presence of FimC at different quenching times. In each trace I91 unfoldings are 
detected as 25 nm increase in length, meanwhile is FimG is detected as an increase of 33 nm. 
Oxidized FimG (FimGS-S) at 10 s (a), 30 s (b), 45 s (c) and 60s (d) of quenching time. The 
different gray scale of the shaded areas indicates the constant force applied along the 
experiment (grey, 160 pN for 2 s; dark grey, 300 pN for 20 s; and light grey, 0 pN for different 
times). 
 
 
 
Results 
144 
 
 
Figure 6.11. Force-clamp refolding experiments of reduced FimG in the presence of 
FimC. The figure shows four example traces from unfolding and refolding experiments of 
FimG in the presence of FimC at different quenching times. In each trace I91 unfoldings are 
detected as 25 nm increase in length, meanwhile is FimG is detected as an increase of 45 nm. 
Reduced FimG (FimGSH-SH) at 10 s (a), 30 s (b) 45 s (c) and 60 s (d) of quenching time. The 
different gray scale of the shaded areas indicates the constant force applied along the 
experiment (grey, 160 pN for 2 s; dark grey, 300 pN for 20 s; and light grey, 0 pN for different 
times). 
 
 After collecting a significant number of traces under each 
different condition, we calculated the refolding probability of oxidized 
and reduced FimG in the absence and in the presence of FimC for four 
different quenching times. Fig. 6.12 shows the refolding probability of 
FimG under different conditions and the single-exponential fitting of 
the data.  
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Figure 6.12. Single-exponential fitting of the Probability of refolding of FimG in the 
presence and in the absence of FimC. (a) Fitting to a single-exponential function of the 
Probability of refolding of oxidized FimG in the absence (green, for ∆t=10s, n=22; ∆t=30s, 
n=18; ∆=45s, n=15 and ∆t=60s, n=11) and in the presence of FimC (yellow, for ∆t=10s, n=36; 
∆t=30s, n=14; ∆t=45s, n=23 and ∆t=60s, n=16). Refolding rates were determined to be 0.021 ± 
0.008 s-1 (-FimC) and 0.022 ± 0.006 s-1 (+FimC). (b) Fitting to a single-exponential function of 
the Probability of refolding of reduced FimG  in the absence (green, for ∆t=10s, n=15; ∆t=30s, 
n=15; ∆t=45s, n=16 and ∆t=60s, n=22) and in the presence of FimC (yellow, for ∆t=10s, n=23; 
∆t=30s, n=15; ∆t=45s, n=14 and ∆t=60s, n=14). Refolding rates were determined to be 0.137 ± 
0.034 s-1 (-FimC) and 0.027 ± 0.011 s-1 (+FimC).  
 On one hand, the refolding probability of the oxidized FimG in 
the presence of FimC increases moderately if we compare it with the 
non-treated protein. However, this trend is not observed in the reduced 
FimG. This form of the protein, both in the absence and in the presence 
of FimC refolded in a lower extent than the oxidized form. In fact, the 
presence of FimC did not change the refolding probability at all. This 
indicates that FimC only acts on disulfide bonded subunits, being this 
feature crucial for the refolding process. On the other hand, the 
refolding kinetics of FimG does not change in the presence of FimC 
(~0.02 s-1), neither in the oxidized (~0.02 s-1) neither in the reduced 
forms of FimG (~0.03 s-1). In fact, the fastest refolding rate is observed 
in reduced FimG (~0.14 s-1), but the maximum is reached very early. 
This last finding could be counterintuitive since it was expected a 
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higher rate of refolding in the presence of FimC. However it looks like 
FimC helps in the refolding of oxidized FimG but does not accelerate 
it.  
 Besides the folding/refolding of FimG, other interesting features 
can be deduced from constant force experiments. As we discovered in 
the FX measurements the reduced domain unfolds at lower force 
(339±27 pN) than the oxidized one (440±36 pN), so it is plausible that 
at constant force the reduced domain should unfold faster than the 
oxidized one. Fig. 6.13 shows the cutted, summed, and averaged traces 
of FimG oxidized and reduced when submitted to a constant force of 
300 pN. As expected and in good agreement with the FX data, the 
reduced FimG unfolds at a faster rate (1/τ1~10 s-1 and 1/τ2~182 s-1) than 
the oxidized one (1/τ1~0.5 s-1 and 1/τ2~10 s-1). The data shown in this 
figure is well fitted by a double-exponential function. A reasonable 
explanation for this behavior could be that the molecule is first 
submitted to a 160 pN pulse for 2 s and then the force is clamped at 300 
pN for 20 s. This first pulse at 160 pN could be biasing the unfolding 
rate of FimG at 300 pN, triggering the early unfolding of some 
domains. However even if these measurements cannot be assumed as 
“pure” dwell-times, it is clear reduced FimG is less mechanically stable 
not only at constant pulling speed but also at constant force. This trend 
is expected to be the same for the other Fim proteins from the type I 
pilus. 
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Figure 6.13. Unfolding rate at 300 pN. Double-exponential fitting of the summed and 
averaged traces of the unfolding of oxidized (FimGS-S, n=29) and reduced FimG (FimGSH-SH, 
n=58) at 300 pN (FimGS-S: 1/τ1~0.5 s-1 and 1/τ2~10 s-1; FimGSH-SH: 1/τ1~10 s-1 and 1/τ2~182 s-
1). 
FimG oxidation and refolding in the presence of DsbA 
Now that we know in which extent FimC contributes to the folding of 
FimG, we decided to study the whole process of subunit maturation 
before being incorporated to the pilus. The main actors involved in this 
process are FimC and DsbA. Combining them at the same time we can 
have a clearer and more complete picture of the maturation process. 
But before testing if they cooperate and have a synergistic effect on the 
folding of FimG, we need to test first the effect of DsbA on FimG. 
 A similar protocol to the one followed for FimC was used for 
DsbA. The oxidation state of both FimG and DsbA were difficult to fix 
along the experiments.  
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Figure 6.14. FC traces of FimG in the presence of DsbA and in the presence of DsbA and 
FimC. (a) Force-clamp trace of FimG in the presence of DsbA. Protein was submitted to a 4-
pulse protocol (or 3-pulse protocol). First it was stretched at 160 pN for 2 seconds (I91 
fingerprint detection) and then the force was increased to 300 pN for 5 seconds (or 7 seconds) 
for FimG unfolding. After that, for some traces (the ones submitted to 5 seconds at 300 pN) the 
force was quenched for 2 seconds to 100 pN in order to ease the reduction of the protein by 
DsbA. Then, force was quenched to 0 pN for 45 seconds. In order to test if FimG refolded and 
if its disulfide bond was reformed, we applied the same pulse protocol. I91 unfolding steps 
appear as a 25 nm increase in length meanwhile oxidized FimG yields a 33 nm step size 
increase, and its reduction produces a 12 nm increment in length. (b) Force-clamp trace of 
FimG in the presence of both FimC and DsbA. The same force protocols as for FimG with 
DsbA experiments were applied.  
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 At least a 20% of the FimG molecules stretched are in the 
opposite oxidation state of the expected one. This means that oxidized 
molecules could be detected even if the protein came from a 
purification in which DTT was added for disulfide bond reduction, and 
vice versa with the oxidized samples. Besides, along the experiment the 
oxidation state of the molecules oscillates since every time an oxidized 
DsbA induces disulfide bond formation on a FimG, a reduced DsbA is 
generated so the opposite reaction (disulfide bond reduction) can be 
also detected later. For that reason, after the fingerprint detection with a 
force pulse at 160 pN for 2 s, we applied either a pulse of 300 pN for 7 
s or two sequential pulses of 300 pN for 5 s followed by a pulse of 100 
pN for 2 s. This second pulse of 100 pN was used in order to ease the 
reduction of oxidized FimG by reduced DsbA, since it has been 
demonstrated that the enzymatic mechanochemical reduction of 
disulfide bonds is impaired at high forces194. After these force pulses, 
the force is quenched to 0 pN for 45 s and then the same pattern is 
repeated for checking both the refolding and the oxidation state of the 
FimG.  
 Ideally the experiments are done with reduced FimG and 
oxidized DsbA. Fig. 6.14a shows one trace of the unfolding and 
refolding of FimG in the presence of DsbA. Upon the unfolding of the 
I91 domains, the unfolding of oxidized FimG (~33 nm) is detected. 
Then, the reduction of the disulfide bond of FimG takes place even 
before the force is quenched to 100 pN, releasing the previously 
sequestered sequence (~12 nm). During 45 s it is allowed the refolding 
of FimG in the presence of DsbA. When the force pulse protocol is 
repeated, we observe that FimG appears again oxidized (~33 nm) and it 
is reduced by DsbA once more meanwhile held at 300 pN (~12 nm). 
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From this trace we can see that FimG’s disulfide experienced three 
oxidation states changes. First it was registered oxidized, and then it 
was reduced by DsbA. After the 45 s allowed for refolding, we detected 
that DsbA oxidized the disulfide and upon unfolding it reduced it again. 
DsbA is able to both oxidize and reduce disulfide bonds, depending on 
its own oxidation state. From this kind of experiments it is difficult to 
say if it is the same DsbA molecule involved in all of these 
oxidoreduction events. Most probably, two populations of different 
oxidation states of DsbA molecules live together since the beginning. 
Also during the experiment these two populations shift from one state 
to the other as long as they are reacting with the FimG molecules. Also, 
we detected the disulfide bond reduction during the 100 pN quench, but 
apparently the enzyme catalyzed reduction of FimG was not impaired 
at 300 pN and for that reason we extended the 300 pN pulse for 2 
seconds more and remove the 2 s at 100 pN.  
 
Figure 6.15. Refolding probability and percentage of disulfide reformation of FimG in the 
presence of DsbA and in the presence of DsbA and FimC. (a) Refolding probability of 
FimG after 45 seconds of quenching time under different conditions (FimGSH-SH, n=16 FimGSH-
SH + FimC, n=14, FimGSH-SH + DsbA, n=16, FimGSH-SH + FimC + DsbA, n=21). (b) Percentage 
of disulfide bond reformation of FimG after 45 seconds of quenching time under different 
conditions (same dataset as specified in (a)). 
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 Fig. 6.15a shows the refolding probability of FimG under 
several circumstances. Above all the maximum refolding probability is 
achieved when in the presence of DsbA (~60 %), indicating that DsbA 
is increasing the refolding probability of FimG in a greater extent than 
FimC does.  
 In Fig. 6.15b is represented the percentage of bond reformation 
under different conditions. We assume bond reformation when FimG is 
detected in its reduced state before the quenching time (~45 nm or ~33 
+ ~12 nm) and it is detected in the oxidized state after the quenching 
(~33 nm). This implies DsbA formed the disulfide bond during the 0 
pN quench. Only in the presence of DsbA it is possible to detect the 
bond formation, since FimC it is unable to induce its formation. 
FimG maturation both in the presence of DsbA and FimC 
As it was explained the maturation of pilus subunits implies the 
sequential action of DsbA followed by FimC. As the Fim preproteins 
are exported to the periplasmic space, DsbA should recognize their free 
thiols as they appear in the periplasmic side of the inner membrane. 
Once the disulfide is formed the protein is then delivered for FimC, so 
this chaperone can stabilize the preproteins before their incorporation 
into the pilus. We tested both the refolding probability and the disulfide 
bond formation as we did with the experiments in the presence of only 
DsbA. Fig. 6.14b shows an example trace of FimG, which is reduced 
by DsbA and oxidized again during the quenching time, being detected 
oxidized in the second part of the trace. In this case, the refolding 
probability is increased to almost ~50 % (Fig. 6.15a), and the bond 
reformation is on the same range as the previously detected with DsbA 
only (Fig. 6.15b). These experiments resemble the natural process of 
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pilus subunit maturation for pilus biogenesis. More importantly, these 
experiments uncover DsbA as the true chaperone of this system, being 
able by itself to increase the ability of refolding of FimG. Also proves 
that the presence of both proteins do not have a synergistic effect on the 
refolding probability of FimG, being greatly determined by DsbA more 
than from FimC. 
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6.2 Nanomechanics of cell-surface protein CD4 
This part of the results is part of a publication from 2014 in the journal 
ACS nano204. The results presented here are part of the research 
conducted by Raul Perez-Jimenez, Alvaro Alonso-Caballero, Ronen 
Berkovich, David Franco, Ming-Wei Chen, Patricia Richard, Carmen 
L. Badilla and Julio M. Fernandez. Specifically, my contribution to this 
work was the study of CD4D1D2 at low pulling speed and low constant 
force. From the latest it was possible to obtain unfolding rates at the 
lowest tested constant force, making possible to extrapolate an 
unfolding rate value at zero force. 
 
6.2.1 Nanomechanics of the HIV binding domains of CD4: D1D2 
In order to study the mechanical properties of the first two domains of 
CD4, a polyprotein was designed. The sequence of CD4D1D2 was 
flanked on both sides with two copies of the I91 protein, as we did with 
the Fim proteins. Same conditions as before were used for studying the 
mechanical stability of CD4D1D2 when stretched at constant speed. 
The kind of pulling velocities exerted in vivo by a HIV-1 particle bound 
to a CD4 molecule are unknown, so besides pulling CD4D1D2 at 400 
nm·s-1, we decided to pull it also at a lower speed of 10 nm·s-1, in order 
to test more physiological conditions. Pulling at lower speed yields 
lower unfolding forces, following a lineal relation, something that has 
been already demonstrated in other proteins and in I91 too155.  
Fig. 6.16 shows the data collected for both conditions and some 
example FX traces.  
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Figure 6.16. Mechanical stability of CD4D1D2 domains. (a) (I91)2-CD4D1D2-(I91)2 
polyprotein in the AFM set-up. (b) FX trace of (I91)2-CD4D1D2-(I91)2 pulled at 400 nm·s-1. 
The unfolding peaks of the two domains are fitted with the WLC model (D2 in blue, D1 in red). 
(c) ∆Lc (nm) vs unfolding force (pN) scatter plot of (I91)2-CD4D1D2-(I91)2 pulled at 400 nm·s-
1
 (D1, n = 132; D2, n = 125). (d) FX trace of (I91)2-CD4D1D2-(I91)2 pulled at 10 nm·s-1. (e) 
∆Lc (nm) vs unfolding force (pN) scatter plot of (I91)2-CD4D1D2-(I91)2 pulled at 10 nm·s-1 
(D1, n = 56; D2, n = 51). 
Both CD4 domains are weaker than the I91 domains, in contrast 
to the results obtained for type I pilus proteins. Interestingly and 
independent of the pulling speed, a mechanical hierarchic behavior is 
observed since D2 domain most of the times unfolds before D1 
domain, but even more interestingly is the fact that D2 unfolding force 
(119 ± 32 pN, 16 ± 4 nm, the theoretical value up to the disulfide bond 
is 20 nm) is greater than the one of D1 (101 ± 30 pN, 10 ± 1 nm, the 
theoretical value up to the disulfide bond is 12 nm). This 
counterintuitive mechanical behavior could be explained by the 
existence of a shared β-strand between D1 and D2. D1 mechanical 
stability probably is compromised upon the unfolding of D2 and the 
loss of this shared structural element. With this design D2 would be 
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acting as a mechanical protector of the D1 domain. As expected, when 
pulling at 10 nm·s-1 the unfolding forces of both domains decrease (D1, 
57 ± 21 nm; D2 75 ± 23 nm). It would be expected that a viral particle 
could exert these kind of pulling forces more probably than the forces 
obtained at higher pulling rates, resembling more accurately and 
realistically the initial stage of the infection. 
The mechanical extension of CD4 could be important for HIV-1 
infection, but we do not know how this event could happen. Besides the 
constant speed, we decided to apply a constant force to trigger the 
extension of CD4D1D2, in order to know at which time scale this could 
be happening. We used a double pulse force protocol: first we applied a 
pulse of forces ranging from 20 to 100 pN, and then we increased the 
force to 150 pN for the I91 fingerprint detection. We decided to cover 
again this wide range of forces since we do not know how much force a 
virus particle could exert meanwhile attached to CD4. Fig. 6.17a shows 
an example trace obtained when applying 20 pN for 30 s. After 
collecting enough traces under each force tested, the CD4D1D2 
unfolding traces were summed and averaged and the data is fitted with 
a single-exponential function, as can be seen in Fig. 6.17b. From these 
fittings the unfolding rate of both domains is calculated at each 
different force. Fig.6.17c plots the unfolding rate of CD4D1D2 vs 
force. Using Bell-Evans-Ritchie model it can be extrapolated the 
unfolding probability at zero force (0.08 s-1 at 0 pN). This could mean 
that CD4 could be mechanically extended at very low forces, in the 
range of what a viral particle could exert. The CD4 extension at low 
forces could even happen through intermediates, as we observed for the 
unfolding of the D2 domain in approximately 5% of the traces.  
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Figure 6.17. Mechanical stability of CD4D1D2 domains. (a)  FC trace of (I91)2-CD4D1D2-
(I91)2 pulled at 20 pN for 30 s and then pulled at 150 pN for the fingerprint detection. (b) 
Summed and averaged unfolding traces of CD4D1D2 at different forces fitted with a single-
exponential function (At 100, n = 11; at 80 pN, n = 8; at 60 pN, n = 26; at 50 pN,  n = 11; at 20 
pN, n = 23). (c) Unfolding rate vs constant force of CD4D1D2. An unfolding rate of 0.08 s-1 is 
observed if an extrapolation to zero force is done. Data shown is the unfolding rate determined 
from the single-exponential fittings of panel (b) and the error was calculated with the bootstrap 
method. 
 
6.2.2 CD4 extension correlation with HIV-1 Infectivity 
Experiments done on 293T cells demonstrated a strong dependency 
between the extension of CD4 and the infectivity by HIV-1152. Cells 
expressing variants of the CD4D1D2 domains connected to the cell 
membrane with flexible linkers of 2, 6, 12 and 18 nm allowed the 
infectivity with an increasing efficiency related with the length (Fig. 
6.18a). The total length of this constructs was the length of the flexible 
linkers plus the length of the folded domains D1D2, which was 
determined to be around 6 nm based on the X-ray structure of CD4 
(PDB code: 1WIP). Fig. 6.18b shows the relative infectivity vs the 
contour length of the construct with the different linkers. Longer linkers 
are correlated with higher infectivity, however the folded wild-type 
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CD4 (CD4WT, black dot) does not follow this trend. If we assume that 
two of the domains of CD4WT are unfolded the extension is increased 
(CD4WT, red dot) and the correlation between the infectivity and the 
total extension is well fitted by a single-exponential function. 
 
Figure 6.18. Correlation between HIV-1 infectivity and the total extension of CD4. (a)  
Schematic representation of the constructs used in152, with the wild-type CD4 (CD4WT) and 
four constructs made of flexible linkers of different length that connect the cell membrane with 
the domains CD4D1D2. The linkers are made of repetitions of the peptide GGGGS. The 
relative infectivity (relative light unit, RLU) in SC42266 isolates is indicated below each 
construct, being maximum for CD4WT. Data extracted from152. (b) Relative infectivity vs 
contour length extension for the different constructs. In all of them is considered that the total 
contour length comes from sum of the folded CD4D1D2 domains and the complete extension 
of the linkers assuming a contribution of 0.4 nm per aminoacid. The black dot corresponds with 
the infectivity of the CD4WT assuming its folded. The red dot for CD4WT assumes that two 
domains are unfolded, following the same trend as the Linker-CD4D1D2 constructs follow. 
 The mechanical extension of a protein is well described in the 
low force regime by the freely jointed chain (FJC) model for polymer 
elasticity. During the hypothesized mechanical unfolding of CD4 
triggered by a HIV-1 viral particle one or several domains may be 
unfolded, contributing to the final extension of CD4. We applied the 
FJC model to predict the final length of the four Linker-CD4D1D2 
constructs when different forces are applied. First the relation between 
the extension and the force, x(F), is described by the FJC model: 
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in which xc is the total contour length of the molecule taking into 
account both folded and unfolded domains, F is de applied force, a is 
the Kuhn length, kB is the Boltzmann constant and T is the temperature. 
Now the infectivity relationship with the force-induced extension of 
CD4  
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The maximum value of infectivity for CD4WT is 57 RLU (I0) and in 
this model is considered an asymptote (see Fig. 6.19). A is the length of 
the folded protein at zero infectivity as x0ln(I0/A) ~ 5.3 nm, and x0 is a 
length-scale coefficient of the infectivity at a given force. Fig. 6.19 
shows the behavior of the different linkers with CD4D1D2 and the 
CD4WT at different forces. Also is shown how the unfolding of the 
domains affects the final extension. It is clear that at least two domains 
of CD4WT should be unfolded in order to follow the same correlation 
as the Linker-CD4D1D2 variants do, as it can be seen in Fig. 6.19a 
and b.  
 
Figure 6.19. Infectivity vs extension of CD4 constructs calculated from the FJC model. (a) 
Infectivity vs calculated extension at 5 pN for the different constructs, both folded and 
unfolded. (b) Same as (a) but at 25 pN. In both panels the grey bars indicate the extension of 
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unfolded domains. (c) Infectivity vs extension at 5, 15, 25 and 40 pN of aplied force. In the 
three panels the lines are exponential fittings of the function that relates infectivity with the 
force-induced extension of the protein. In panels (a) and (b) it can be seen that at least the 
unfolding of two domains of CD4WT are necessary in order to follow the same correlation as 
the other Linker-CD4D1D2 constructs follow. 
 
6.2.3 Mechanical effect of the HIV-1 neutralizing antibody 
Ibalizumab on CD4D1D2 domains 
The previous subsection suggests that a longer extension of CD4 
improves the infectivity by HIV-1 virus. This hypothesis suggests that a 
mechanically more stable CD4 in which the unfolding of its domains 
requires higher forces would reduce the chances of infection. 
Ibalizumab is a humanized monoclonal anti-CD4 antibody that blocks 
HIV-1 infectivity binding to the interface between domains D1 and D2 
of CD4 with a very high affinity, and it is not clear why it is such a 
good inhibitor of HIV-1 infection. We decided to test if the mechanical 
stability of the polyprotein (I91)2-CD4D1D2-(I91)2 changes in the 
presence of the antibody Ibalizumab.  
FX measurements at 400 nm·s-1 revealed that CD4D2 domain 
was stabilized in ~20 pN by the presence of Ibalizumab, meanwhile the 
CD4D1 domain mechanical stability remained unchanged (CD4D1, 
101 ± 30 pN; CD4D1+Iba, 100 ± 24 pN; CD4D2, 119 ± 32 pN; 
CD4D2+Iba, 138 ± 23 pN). A striking feature of the FX traces is the 
position of the unfolding peaks of CD4D1D2 domains (Fig. 6.20b, c 
and d), where we are able to detect them after the unfolding of one, 
two or even three I91 domain unfoldings. The mechanical stabilization 
exerted by the presence of Ibalizumab is not very different when it is 
Results 
160 
 
not present and one would expect that the weaker domains are the first 
ones unfolding when the protein is stretched, but the fact that the 
unfolding peaks of CD4D1D2 appear after the unfolding of I91 
domains whose unfolding forces are ~200 pN indicates that clearly 
Ibalizumab is altering the mechanical properties of CD4D1D2.  
 
Figure 6.20. Mechanical stability of CD4D1D2 in the presence of the antibody Ibalizumab. 
(a)  Cartoon representation of CD4D1D2 with the Ibalizumab antibody bound to it (PDB: 
3O2D). (b) FX trace of (I91)2-CD4D1D2-(I91)2 pulled at 400 nm·s-1 in the presence of 
Ibalizumab. (c and d) Position of CD4D1D2 unfolding peaks in the FX traces in the absence (c, 
n = 123) and in the presence (d, n = 50) of Ibalizumab.  
The force-ramp (FR) experiments in which we pull the protein 
at a constant force rate of 33 pN·s-1 (Fig. 6.21a and b) revealed the late 
simultaneous unfolding of the CD4D1D2 tandem in the presence of 
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Ibalizumab. In Fig. 6.21c and d is shown the step length increases of 
CD4D1D2 in the absence and in the presence of the antibody. Both 
domains present a tendency to unfold in a single ~22 nm step at 
elevated forces (up to ~250 pN), opposite to the unfolding behavior 
with no antibody where both domains unfold separately at low forces. 
The initial unfolding forces (Fig. 6.21e) under each condition confirm 
that the Ibalizumab presence shifts the forces from ~80 pN to ~150 pN. 
 
Figure 6.21. Mechanical stability of CD4D1D2 in the presence of the antibody Ibalizumab.  
(a and b) FR trace of (I91)2-CD4D1D2-(I91)2 pulled at 33 pN·s-1 in the absence (a) and in the 
presence (b) of Ibalizumab. (c and d) Step size length increase histograms in the absence (c, n = 
72) and in the presence (d, n = 76) of Ibalizumab. In the presence of the antibody there are 
more events of CD4D1D2 unfolding in one single step of ~22 nm. (e) Initial unfolding forces in 
the absence (n = 37) and in the presence (n = 54) of Ibalizumab. 
 
6.2.4 Mechanochemical extension of CD4D1D2 through the 
reduction of its disulfide bonds by thioredoxin 
Disulfide bonds tend to increase the thermodynamic stability of 
proteins166. From the mechanical point of view, the presence of 
disulfide bonds increases the robustness of proteins however this 
depends on the position and the structural features of the protein that 
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the disulfide in bridging. Three out of four of the extracellular domains 
of CD4 present a disulfide bond in its structure, being CD4D3 domain 
the only one lacking this bond. It looks important during HIV-1 
infection the fine tuning of the oxidation state of the disulfides both 
from CD4 and gp120 viral protein149. The inhibition of oxidoreductase 
enzymes apparently prevents HIV-1 infection, and the regulation of the 
disulfide of CD4D2 domain seems to be managed by thioredoxin141,148. 
Besides, HIV-1 is prone to infect cells where CD4D2 domain disulfide 
is reduced146. However, the disulfide of CD4D2 is buried in the inner 
core of the protein so thioredoxin is not able to reach it. We 
hypothesized that mechanical unfolding of CD4 triggered upon the 
attachment of the HIV-1 viral particle could expose this cryptic 
disulfide and make it available for disulfide/thiol exchange by 
thioredoxin.  
 In Fig. 6.22b it is shown a FC trace of the construct in the 
presence of thioredoxin. Upon the unfolding of CD4D1D2, the buried 
disulfides of both domains are exposed and susceptible of being 
reduced by thioredoxins. CD4D2 reduction is detected as a ~8 nm step 
that overlaps with the length observed for the oxidized CD4D1 (in Fig. 
6.22c, the first distribution of the histogram highlighted with a grey 
Gaussian curve), and then the reduction of CD4D1 is detected as an 
increase of ~20 nm. In some of the traces it was possible to register the 
unfolding of CD4D1D2 but only the reduction of CD4D2. This could 
be related with a different dependency of force for the enzymatic 
cleavage of the disulfide of these two domains. The unfolding of 
CD4D1D2 domains already reduced would yield length increments of 
~29 nm and ~22 nm, respectively. However these events are rare, 
supporting the idea that their disulfide bonds remain oxidized in the 
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core of these two domains and are only available for reduction upon 
their mechanical unfolding. 
 
Figure 6.22. Force-induced exposition of CD4D1D2 cryptic disulfides and reduction by 
thioredoxin. (a)  (I91)2-CD4D1D2-(I91)2 polyprotein in the AFM set-up in the presence of 
human thioredoxin (PDB code: 1UVZ). (b) FC trace of (I91)2-CD4D1D2-(I91)2 pulled at 60 
pN in the presence of thioredoxin. After the extension of the oxidized domains of CD4D1D2, 
the reduction of CD4D2 takes place followed by the reduction of CD4D1. Then the force is 
increased to 150 pN to detect the fingerprint (c) Histogram of the step size increase in length of 
CD4D1D2 in the presence of thioredoxin (n = 25). Three population of steps are detected. The 
first one of 8 ± 1 nm corresponds both with the unfolding of CD4D1 and the step size increase 
produced after the reduction of the disulfide of CD4D2. The second one of 13.4 ± 0.7 nm 
corresponds with the unfolding of CD4D2 and the third one shows the reduction of CD4D1 
domain with 20.2 ± 1.8 nm. 
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Chapter 7: Discussion  
In this final chapter the results obtained in this thesis will be discussed 
and compared with the most recent available literature for the two 
issues covered. A final section is used to conclude and connect the 
main ideas and findings achieved. Finally a focus on the prospective 
research which could be conducted in the Mechanomedicine 
framework for the development of new therapeutic strategies is given. 
 
7.1 Nanomechanical architecture and biogenesis of 
the type I pilus  
UPEC type I pilus is a filamentous multiproteic structure used by 
bacteria as a virulent factor for uroepithelium attachment. UTIs develop 
under chemical and physical harsh conditions which pathogenic 
bacteria have to fight against to in order to colonize the urinary tract. 
Bacteria ascend from the urethra to the bladder, and then to the ureters 
and kidneys. Along this path, but especially from the urethra to the 
bladder, bacteria have to advance and avoid to be dragged away during 
micturition. Type I pili provide mechanical anchors that help bacteria to 
remain attached when the shear forces generated by the urine flow push 
their cell bodies out of the urinary tract.  
 Type I pilus has been widely studied as it is one of the reasons 
of the persistence and recurrence of UTIs, and it represents a potential 
target for therapeutic treatment. These appendages are highly adapted 
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for their task and for the environment where they are required, and 
several features are responsible for this specialization.  
 First, the presence of FimH protein at the pilus tip end. 
UPEC/Uroepithelium attachment occurs as a protein-ligand interaction 
between mannose-containing proteins from the epithelium and FimH 
lectin domain. This bond is allosterically regulated by FimH pilin 
domain, whose interfacial contacts with the lectin domain down-
regulate the affinity for the mannose205,206. This behavior permits the 
colonization and spreading of bacteria along the urinary tract since the 
lectin-mannose interaction is weak and the bond rupture rate is high, 
allowing bacteria rolling and spreading. But in the event of an urine 
flow burst the lectin affinity for mannose increases as a consequence of 
the tensile force experienced by FimH65. As urine flow pushes bacteria 
cells their pili, establishing weak contacts with the epithelium through 
their tip-end FimH, start to be stretched. This stretching force finally is 
transmitted to the mannose-lectin bond and then to the interfacial 
contacts between the lectin and pilin domain of FimH. A 
conformational rearrangement induced by the tensile stress aligns both 
domains along their longitudinal axis, disrupting the inhibitory effect of 
the pilin domain and leading to a lectin high affinity state for mannose. 
This finger trap-like toy mechanism is known as a catch-bond and it is 
optimized for bacterial spreading in the urinary tract meanwhile 
prevents bacteria detachment64,68,71. 
 Second, the pilus rod quaternary structure provide with an 
additional mechanical feature which favors both pilus and catch-bond 
integrity. Although the whole pilus is a passive structure its architecture 
is dynamic and experiences conformational changes upon the 
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application and removal of tensile force74. Almost the entire pilus is 
made of FimA subunits which form the rigid pilus rod. These domains 
arrange in a right-handed helical configuration forming a 7 nm 
diameter structure, presenting 3.6 stacked subunits per helix turn. The 
rod helical conformation is stabilized through the turn-to-turn weak 
interactions made between the residues of non-sequential subunits, 
occurring between the i domain and the i + 3 domain77,207. Upon tensile 
stress application the pilus is completely stretched and the tension is 
finally transmitted to the lectin-mannose catch-bond. Catch-bonds 
experience an increased affinity for the ligand and an increased bond 
life time up to an optimal force, but above that force the bond rupture 
probability increases. Before the catch-bond interaction is broken, pilus 
rod uncoiling takes place and the different layers of stacked FimA 
subunits start to break the weak contacts that held their configuration. 
The rod starts unraveling in the closest stacked layer to the pilus tip, 
and progresses along it extending the length up to 5 to 6 times77,208,209. 
This unraveling behavior protects the catch-bond from being broken 
during the shear flow of the urine, maintaining an optimal force at the 
protein-ligand interface210,211. It is important to bring the attention to 
the fact that each bacteria cell is surrounded by hundreds of pili. Many 
of these appendages can be attached to the uroepithelium through 
catch-bonds and the tensile force can be distributed among several of 
them, protecting the structural integrity of the individual pilus76. Once 
the tensile force is removed, i.e. when the urine flow finishes, the 
unraveled pili recoil reforming the turn-to-turn contacts of the subunits 
that lead to the quaternary structure. This re-stacking process shortens 
the length of the extended pilus and this contraction enables the 
bacteria to advance and recover their pre-stress position76,210.  
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 All these features confer elastic tether properties to the type I 
pilus whose overextension and recoiling behavior is optimized for 
extending the bond lifetime at its tip-end, ensuring bacteria attachment 
to the uroepithelium but also allowing the spreading and rolling at low 
or zero shear force. One of the most surprising qualities of these 
structures is the fact that the proteins which form the pilus are 
connected head-to-tail through non-covalent interactions, donating each 
subunit an N-terminal β-strand to the incomplete Ig-like fold of the 
previous subunit in the assembly. This interaction is also specific for 
each subunit protein, being what finally determines the order of 
assembly during pilus biogenesis. It has been demonstrated that this 
hydrophobic interaction is one of the strongest found in nature, 
conferring high kinetic stability against dissociation or unfolding once 
the antiparallel β-strand complementation is done96,97. High energy 
barriers against unfolding guarantee the integrity of the pilus structure 
preventing its disassembly. Hundreds of subunits form the pilus and the 
spontaneous rupture of only one single donor-strand interaction would 
lead to tether breakage and detachment.  
 In this thesis we have explored the mechanical stability of the 
four Fim proteins that form the type I pilus. We designed self-
complemented proteins where the cognate donor β-strand of each 
subunit was placed in its C-terminal sequence. In the tertiary folded 
structure of the domain this design ensures the correct antiparallel 
insertion of the β-strand, forming the native contacts made in the 
mature pilus. During pilus stretching in vivo, after the pilus quaternary 
structure has been completely unraveled, the force is transmitted along 
the head-to-tail axis of the subunits. This longitudinal pulling is what 
finally challenges the resistance of the hydrophobic interaction between 
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proteins. With smFS we could resemble the geometry of the force 
experienced by the pilus and interrogate the mechanical strength of the 
donor-strand interaction. Although the thermal stability of these 
proteins has been explored, their evident exposition to mechanical 
forces has not been addressed, and a mechanical description of them is 
required for the development of new therapeutical strategies oriented to 
target bacterial attachment. 
  We first applied constant speed experiments pulling at 400 
nm·s-1 to these constructs finding strikingly high unfolding forces for 
all of them, standing out as some of the most mechanically resistant 
proteins discovered until today, in the range of the values obtained for 
cohesin I modules of scaffoldin212. In the case of FimA (Fig. 6.1), the 
most abundant protein in the pilus, the mechanical stability was above 
500 pN being the most stable type I pilus Fim protein. This is in 
agreement with the values obtained for other shaft pilus proteins (most 
abundant proteins forming a pilus) for Gram-positive bacteria, where 
SpaA from Corynebacterium diphteriae and FimA from Actinomyces 
oris showed the highest unfolding forces ever reported for globular 
proteins213. Unlike type I pilus subunits, these two examples of Gram-
positive pili are assembled through interdomain isopeptide bonds, 
forming a continuous covalent backbone along the whole pilus. In our 
case the mechanical strength builds from the self-complemented FimA 
fold (FimA-DSFimA), in which the donor-strand of another FimA 
subunit is included and mimics the native fold. Taking into account that 
almost the whole pilus is made of an array of hundreds of FimA 
subunits, we suggest the strength of this complementation evolved in 
order to reduce the probability of pilus disassembly due to FimA-FimA 
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interaction rupture. A mechanically strong pilus rod is mandatory for 
the UPEC attachment to the urine tract. 
 We observed an even more interesting property of the type I 
pilus when we realized that the mechanical stability of Fim domains 
follows a hierarchical trend. After FimA, FimG and FimF showed the 
highest unfolding forces (Fig. 6.2 and Fig. 6.3) followed by FimH pilin 
domain, and finally by the weakest FimH lectin domain (Fig. 6.4). This 
mechanical hierarchy matches the pilus architecture, becoming less 
stable as we approach to the pilus tip. FimG and FimF are part of what 
is known to be the hinge region of the pilus. It adopts a hook-like shape 
in the non-attached pilus which serves the FimH lectin domain to 
explore the surface for mannose recognition. FimF is complemented 
with the FimA donor-strand and the first pilus tip protein after the rod. 
The FimF donor-strand complements the FimG fold. Both Fim proteins 
have similar unfolding force values, which gives them a similar role 
when bridging the two very different parts formed by the lectin and the 
pilus rod. At the end of the pilus tip we find FimH protein, formed by 
two domains connected by a peptide linker. The pilin domain is 
complemented by the FimG donor-strand, in the same way as FimA, 
FimF and FimG. Of all the pilin domains this is the less mechanically 
stable one, although its values are above the not negligible quantity of 
300 pN. Following both the mechanical trend and the pilus architecture, 
the lowest force value corresponds to the FimH lectin domain, the 
ligand-recognizing protein of the pilus which sometimes unfolded 
through an intermediate (Fig. 6.4b). This lowest value is not surprising 
since the lectin domain possesses a jelly-roll topology, an elongated β-
barrel made of 11 strands and which conformation changes depending 
on the allosteric regulation exerted by the pilin domain. It tightly 
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clamps the mannose ligand when the down-regulation exerted by the 
pilin domain is removed after tensile force application. 
 Our findings reveal a high mechanical stability for the four pilin 
domains and the lectin domain, hierarchically decreasing from the pilus 
rod to the pilus tip. Although protein-ligand interaction breaks at values 
below the least mechanically stable domain (FimH pilin domain), we 
think these donor-strand interdomain connections are designed for 
guaranteeing pilus integrity in the harsh conditions of the urinary tract. 
We think this strength is based on the surface complementarity between 
the residues of the donor-strand and the residues of the fold it 
complements. The mechanical hierarchy observed in the experiments 
was partially affirmed by the SMD simulations, which showed a 
slightly different order of mechanical stability (Fig. 6.6), but supported 
the force hierarchy observed in smFS experiments due to the different 
number of hydrogen bonds made in the self-complemented proteins 
(Fig. 6.7). The simulations also confirmed us that the self-
complemented strategy was suitable for testing the mechanical strength 
of the complementation, since covalently and non-covalently self-
complemented FimH pilin domains showed the same unfolding pattern 
(Fig. 6.8). Although this same design has been used before in bulk 
experiments in the past183,184,214, this simulation validates our self-
complemented constructs as pilus native-like interactions.  
  All these previous findings where obtained with disulfide-
bonded domains, and the mechanical contribution of this bond to these 
proteins has not been addressed before. All pilus type I proteins contain 
conserved disulfides in their structure, including the FimH lectin 
domain. In the lectin case, the disulfide is placed near the mannose-
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binding pocket and its presence has been demonstrated to be crucial for 
the protein-ligand interaction215. In the reduced form, capturing the 
unfolding of the lectin domain was elusive (Fig. 6.4e), and a possible 
explanation could be the lack of stability or misfolding. But more 
importantly is the fact that all four pilin domains exhibited decreased 
unfolding forces in their reduced states, with a lost in the mechanical 
stability up to 50 % (Fig. 6.5). The position of the disulfides is not only 
conserved among type I pili subunits but also in the proteins from the 
Dr fimbriae and P pilus, highlighting the stabilizing effect of this bonds 
in adhesive organelles79. In all these fimbrial proteins the disulfide 
bond bridges A’ and B antiparallel strands and confers high 
thermodynamical and kinetic stability, which together with the strength 
of the donor-strand interaction confer high resistance to the domains. 
These configuration places two mechanical clamps on each pilus 
subunit. On the one hand the disulfide bond, and on the other hand the 
hydrophobic interaction and the hydrogen bond network made between 
the donor-strand and the A and F-strands of the fold. When a tensile 
force is applied, domain unfolding starts from the C-terminal end of the 
protein which consists in removing the donor β-strand from the fold, as 
it can be seen in the SMD simulations performed where the force 
maximums were reached just before the donor-strands are ripped out 
(Fig. 6.6). In the absence of the disulfide bond clamp, the mechanical 
unfolding pathway shifts and it starts from the N-terminal end, the 
weakest part of the protein. This different unfolding pathway was 
revealed in coarse-grained simulations performed and published by our 
group on oxidized and reduced self-complemented FimG, which 
showed the mechanical locker effect of the disulfide bond216. It is clear 
that disulfide bonds are relevant for the structural integrity of adhesive 
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structures and they confer not only thermodynamical stability but also 
mechanical resistance.  
 These findings highlight the importance of both the disulfide 
bond and the strand complementation between domains as the main 
contributors to pilus mechanical integrity. Hence, these two elements 
are potential targets for bacterial attachment ablation. The use of 
reducing agents would break disulfide bonds, and the usage for 
example of small peptides with the ability of competing with the strand 
complementation interaction would lead to pilus disassembly. However 
targeting the mature pilus is not the only option available for disrupting 
bacterial attachment. The process of pilus assembly in vivo is another 
interesting target for drug therapy, since several events occur before the 
pilus secretion. We wanted to study even deeper the attachment system 
of UPEC approaching the process of pilus biogenesis in the bacterial 
periplasm. For this purpose we used the FimG construct and we 
monitored its unfolding/folding behavior with constant-force 
experiments within single trajectories. With this approach we resemble 
the extended state of the protein when is exported to the periplasmic 
space through the SecYEG pore system. We observed the refolding 
probability of disulfide-bonded FimG was greater than the one of 
reduced domain (Fig. 6.9), showing that the disulfide bond as expected 
contributes to the folded state both enthalpically and reducing the 
entropy of the chain217. It is necessary to consider the residual structure 
existing in the oxidized FimG, which also contribute to ease the 
refolding of the stretched protein.  
 Our next step was to identify how much FimC contributes to the 
folding of FimG, as this chaperone has been identified as the main actor 
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for pilus subunits folding in the periplasm. FimC contributed 
moderately in the refolding of oxidized FimG but its effect was null for 
the reduced version (Fig. 6.10, Fig. 6.11 and Fig. 6.12), supporting the 
already proposed additional function of FimC of acting as a quality 
control system which only supplies disulfide-bonded domains to the 
assembly platform FimD203. Unfolding kinetics of both states of the 
protein revealed a higher rate of unfolding for the reduced protein (Fig. 
6.13), which directly connects with the lower mechanical stability 
observed in the FX experiments. Considering the lower mechanical 
stability of the reduced domains, we think FimC would ensure the 
incorporation to the pilus of only properly folded and oxidized 
domains.  
 It is important to remember that the design of our FimG 
contains the cognate antiparallel donor-strand provided by FimF (cis-
DSE), an interaction more favorable than the parallel G1-strand 
donated by FimC (trans-DSC). After quenching to zero force the 
refolding of FimG can happen without an external help, and this design 
could be masking the real performance of FimC. However the lack of 
activity on the reduced domains suggests that FimC recognizes and 
helps to fold oxidized FimG. 
 The modest folding effect of FimC was puzzling since previous 
extensive research has always supported this chaperone as the only 
factor contributing to pilus proteins folding in the periplasm. We 
wanted to explore in detail pilus protein maturation involving DsbA 
oxidoreductase, the enzyme responsible for disulfide bond formation in 
Fim proteins. Surprisingly, DsbA not only contributes in thiol-pair 
oxidation but also contributes, and in a greater extent than FimC, to 
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FimG folding (Fig. 6.14 and Fig. 6.15). We believe this newly 
uncovered behavior corresponds to a real chaperone effect of DsbA not 
only enhanced by disulfide-bond formation.  Although this is the first 
time DsbA has been directly identified as a chaperone in type I pilus 
biogenesis, previous studies already suggested that oxidoreductases 
from the thioredoxin family could be involved in more tasks than 
disulfide bond formation.  
 When the crystal structure of DsbA was reported some 
structural elements were identified as being capable of binding partially 
folded proteins218. Later a chaperone-like activity of DsbA during the 
oxidative folding and maturation of the periplasmic chaperone PapD (P 
pilus type equivalent of FimC) was proposed. Native PapD chaperone 
possesses a disulfide bond, being its correct formation and the PapD 
folding critical events for P type pilus assembly105. This study could not 
verify if PapD folding was being facilitated only by thiol-pair oxidation 
or if there was a chaperone activity in DsbA. Zheng et al.219 identified 
the chaperone-like activity of DsbA on proteins lacking disulfide 
bonds, separating it from the thiol-oxidoreductase activity. Therein, 
DsbA was able to help in the refolding of chemically-denatured protein 
substrates, binding to unfolded intermediates and preventing 
aggregation. In the presence of small peptides the DsbA-assisted 
refolding of these denatured proteins was diminished as a consequence 
of the competition between the small peptide and the protein substrate, 
demonstrating the peptide-binding ability of DsbA. DsbA, as its 
eurkaryotic counterpart PDI, possesses a thioredoxin-like domain 
which presents a hydrophobic groove just below the active site, which 
would allow the binding of partially folded proteins before the disulfide 
bond formation.  
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 Frech et al.220 demonstrated the establishment of non-covalent 
interactions between DsbA and a protein substrate during the 
intermolecular disulfide bond complex generated between both species 
before complete oxidative folding. The fact that DsbA-catalyzed 
disulfide exchange with unfolded proteins is much faster than the 
provided one by small molecules like glutathione, suggests that the 
increased rates are favored by non-covalent interactions between DsbA 
and the protein substrate. Non-covalent interactions are usually made 
with chaperones which provide suitable molecular surfaces for the 
correct folding of the protein substrates, as it happens with the 
periplasmic chaperone Spy221,222. Proteins secreted to the periplasmic 
space usually contain few disulfide bonds and frequently they can fold 
before oxidation. It is important that DsbA rapidly recognizes and binds 
to these proteins meanwhile they are being secreted to the periplasm, 
thus catalyzing oxidative folding as it is required for each pilus subunit. 
The mixed disulfide intermediates stabilized through non-covalent 
interactions would be solved once the protein substrates fold in the 
surface of DsbA. This would decrease the affinity of the folded protein 
for DsbA, which would be released in an almost complete folded state 
or competent for FimC-assisted folding220.  
 The fact that when together DsbA and FimC do not increase 
even more the refolding probability of FimG suggests that DsbA 
delivers almost completely mature subunits to FimC. In our design 
folded self-complemented FimG is stable by itself but in vivo FimC 
would stabilize more than helping to fold, the different subunits 
through parallel DSC and facilitate DSE during pilus incorporation at 
the FimD platform. Moreover FimC would discriminate between 
correctly folded and oxidized subunits from the reduced ones, and 
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forming complex with the individual subunits would prevent subunit 
oligomerization and aggregation in the periplasm through donor-strand 
donation.  
 In summary our results suggest the type I pilus is a 
mechanically stable structure. This stability is built on the interdomain 
non-covalent interactions that hold the structure, and this strength 
decreases hierarchically from the pilus rod to the pilus tip. The 
presence of disulfide bonds in each of the proteins mechanically clamps 
the domains, increasing even more their stability. The importance of 
this intramolecular covalent bond is shown during pilus biogenesis, 
where chaperone FimC discriminates between oxidized strong domains 
and reduced weak domains. In our experiments, DsbA was not only 
inducing disulfide bond formation but also demonstrated to be a true 
chaperone. This new scenario strongly supports DsbA as the real 
chaperone during pilus proteins maturation, and FimC as the 
stabilization chaperone which prevents aggregation and addresses the 
correct oxidation state of the subunits. 
 
7.2 Nanomechanics of CD4 receptor 
CD4 protein is a cell-surface receptor with a crucial role during the 
adaptive immune response, involved in the stabilization of the 
interactions between the TCR and MHC-II, and in the triggering of the 
T-cell activation. HIV uses this receptor to attach to CD4+-
lymphocytes, to infect them and to replicate. Therefore the 
consequence is the destruction of the immune system cells leading to 
the host immunodepression, leaving it vulnerable to opportunistic 
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infections and cancer. Targeting the same cells that should be fighting 
the virus is one of the several reasons of the success of the infection. 
Another important reason is the virus ability to integrate into the host 
genome and hide from immunologic surveillance, remaining latent for 
future replication. This Trojan horse strategy is complemented with 
morphological features of the virion that make it undetectable to the 
immune system. The only viral-origin protein exposed on the surface of 
the virus is the glycoprotein complex Env. This protein is extensively 
glycosylated, making it invisible to the immune system, and its 
potential epitopes are subjected to high sequence variability because of 
the errors made during the retrotranscription of the viral genome. All 
together, these strategies shape the arsenal of a pathogen which 
produces a persistent and incurable infection which when non-treated 
leads to a poor prognosis of the patient. 
 Since the onset of the world pandemic huge efforts have been 
done to find a cure and crucial achievements have been accomplished, 
turning a deadly disease into a chronic one with a significant 
improvement of the life expectancy of those who live with the 
infection. Thanks to the knowledge acquired about the virus biology it 
has been possible to develop drugs that interfere with different steps of 
its life cycle, however it remains unreachable the complete eradication 
of the infection once it is started, with the only possibility of 
maintaining a low baseline viremia load and to avoid further spreading 
of the infection.  
 Especially relevant are those drugs used to prevent infection in 
the first instance. These drugs interfere with the fusion of the virus 
disrupting conformational changes required for membranes fusion, like 
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enfuvirtide, or with events taking place before fusion such as the 
binding of gp120 to the coreceptor, like maraviroc124. There are several 
antibodies targeting the most conserved sites of gp120, the CD4bs and 
the coreceptor binding site in the V3 loop127. The success of these 
antibodies greatly varies, some of them are effective in vitro with 
laboratory adapted strains but not useful against strains isolated from 
patients, and others show different effectiveness in vivo depending on 
the isolate. The coreceptor binding site and other gp120 susceptible 
regions become exposed after CD4 binding, and they are termed as 
CD4 induced epitopes (CD4i). Several antibodies target this site like 
17b, E51, or m36, but again they only exhibit mild neutralization 
potency223,224. The treatment with these antibodies in clinical trials 
usually is effective for a short period of time, after which resistant 
strains appear and are positively selected225. The successful viremia 
suppression comes when the antiretroviral therapy combines several 
neutralizing antibodies225. 
 The problem about targeting the viral spikes is not only the 
glycan masking of the epitopes but also the high mutation rate. This 
mutability generates virus quasispecies varying up to 5% in their 
genetic content inside the same host226. A reasonable approach is to 
interfere with the receptors used in viral attachment, like CD4 and the 
chemokine receptor151. Being host proteins they are not exposed to a 
high mutation rate thus they can be targeted with the certainty of not 
becoming obsolete due to sequence variability227. Some problems may 
arise from this strategy since the binding of antibodies to these two 
receptors could alter their natural function. This requires inhibitory 
molecules able to prevent HIV infection but to not interfere with the 
performance of these receptors228.  
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 The effect of forces on proteins has not been approached until 
recently and, as it was indicated in the Introduction chapter, their 
relevance in human diseases cannot be underestimated. In the same 
way that bacteria attachment is strongly influenced by forces, the viral 
attachment process also experiences mechanical stress. During HIV 
entry, CD4 conformational flexibility is required for viral particle 
approaching to the membrane coreceptor135,229. This malleability 
implies structural changes on CD4 which could be triggered due to the 
forces exerted by the bound virion. A stiffer CD4 molecule would 
complicate downstream events required for HIV entry. Understanding 
the mechanics of CD4 under small stretching forces which resemble the 
viral attachment in vivo, constitutes the first step for designing a 
strategy to stiffen CD4 and block HIV infection.   
 In this thesis the mechanical behavior of the first two domains 
of CD4 under different conditions has been investigated. For this 
purpose we studied CD4D1D2 protein with smFS. In the first set of 
experiments the mechanical stability of CD4D1D2 was studied with 
constant velocity experiments. Two pulling speeds were tested, 400 
nm·s-1 and 10 nm·s-1 (Fig. 6.16). The first speed has been widely used 
for determining the mechanical stability of proteins like I91 and 
constitutes a reasonable starting condition for identifying the protein 
mechanical stability230, but the second lower speed reflects the attempt 
of resembling the hypothetical moving speed of a viral particle attached 
to the cell surface in vivo. Under both pulling speeds both CD4 
domains exhibited a lower mechanical stability than the I91 domains of 
the polyprotein, and D2 showed a higher unfolding force than D1. 
Counterintuitively the strongest domain, D2, unfolds before the weaker, 
D1, when the expected behavior is just the opposite31. This trend is 
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observed at low and high pulling speed indicating a mechanical 
hierarchy in the behavior of CD4D1D2 protein. D1 and D2 are 
connected through a β-strand shared by both domains (termed as G-
strand in D1, and as A-strand in D2). This shared structural element 
would confer to the D1-D2 tandem a common mechanical response, 
acting as one unit. After D2 unfolding D1is left unprotected, easing its 
mechanical unfolding. Once D2 is unfolded the force would be 
propagated through the shared strand between domains, breaking the 
hydrogen bonds made between D1 A-strand and G-strand (the strand 
shared with D2). This intimate interdomain connection has been 
suggested as a proof of modularity in CD4, since the same kind of 
relationship exists also between D3 and D4 domains231.  
 In the set of FC experiments different constant forces where 
tested to unravel the kinetics of CD4D1D2 unfolding, from 20 to 100 
pN (Fig. 6.17). Following Bell-Evans-Ritchie model67,232, the unfolding 
rate of both domains increased exponentially with the force applied 
(Fig. 6.17c). The force range used allows for the extrapolation of the 
unfolding rate at force-values close to zero, in the range of forces 
expected to be exerted by a viral particle attached to CD4. These 
measurements demonstrated that CD4D1D2 extension is possible at 
very low forces, like the ones HIV could exert in vivo. This extra length 
would increase the chances for coreceptor binding on the cell surface, 
since a longer tether permits the exploration of a larger area 
surrounding the anchoring point provided by CD4. Again the 
hierarchical unfolding of the tandem was reproduced as it occurred in 
the FX measurements. Moreover D2 was observed to be able to unfold 
through an intermediate, a feature that could be related with the redox 
regulation of its allosteric disulfide bond. This intermediate could 
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expose the buried disulfide making it available for reduction by 
thioredoxin enzyme, enabling a further extension of the tether.  
 Longer tethers support greater HIV infectivity, as it can be 
deduced from the experiments of Freeman et al.152. In this work four 
constructs where expressed on the surface of 293T cells, presenting all 
of them the tandem CD4D1D2 followed by polypeptide linkers of 
different length. We developed a mathematical expression that relates 
the infectivity data from this work with the length of the different 
CD4D1D2 constructs. This expression accounts for the force-induced 
extension of CD4 under different loads. The infectivity levels of the 
four constructs were correlated with the length of the tether and this 
trend follows a single-exponential function (Fig. 6.18 and Fig. 6.19). 
Wild-type CD4 provides the maximum infectivity level but it falls out 
from the exponential fit if we assume this infectivity is achieved 
without the extension of any of its domains. Nevertheless if the 
unfolding of one or two domains is considered, the extra extension 
would place wild-type CD4 in the exponential trend. This suggests the 
unfolding of CD4 D3 and D4 would help HIV to infect the cells, and 
the unfolding of D2 also cannot be ruled out from this behavior. 
 From these findings it is feasible that HIV virion could trigger 
the partial unfolding at low forces of CD4 supporting the infection. 
Several antibodies interfere with the infection, and those ones 
recognizing CD4 are of special importance since they provide an 
opportunity for targeting a host element instead of the highly mutable 
epitopes of the virus134,150,151. It has been hypothesized that some of 
these antibodies that do not compete with the binding site of gp120, 
could interfere with the conformational rearrangements required for 
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viral entry. Among these antibodies is Ibalizumab, a strong inhibitor of 
HIV infection but whose neutralizing mechanism is unknown153. It has 
been demonstrated that protein-protein interactions can lead to 
mechanical stabilization41,42, and Ibalizumab binding to CD4 could 
mechanically stabilize CD4 hindering its force-induced extension. For 
this reason we performed smFS experiments on CD4D1D2 in the 
presence of Ibalizumab. First, FX experiments did not show remarkable 
differences in the unfolding force of the tandem CD4D1D2, only with a 
slight increase in the case of D2 domain. Ibalizumab contacts are 
placed mainly in D2 domain and some in D1 domain, and a greater 
stabilization effect was expected. However although forces did not 
increase significantly, the FX traces showed a change in the position of 
the CD4D1D2 unfolding peaks suggesting the stabilization of the 
tandem. In the absence of Ibalizumab both CD4 domains unfold first 
followed by the unfolding peaks of the fingerprint I91 domains. When 
Ibalizumab is present the tandem unfolding was detected even after the 
unfolding of the four I91 domains (Fig. 6.20d). A possible explanation 
for this behavior could be that Ibalizumab stabilizes mainly D2 domain, 
which protects D1 domain from mechanical unfolding, but under 
increasing tensile stress the antibody unbinding occurs and leaves D2 
domain susceptible of mechanical unfolding. FR experiments provided 
a better understanding of this behavior since unlike FX they make 
possible the application of constant loading rates. FR traces in the 
presence of Ibalizumab showed again a change in the position of the 
unfolding steps of CD4D1D2, occurring after the I91 unfolding (Fig. 
6.21b). If the initial unfolding forces (the first unfolding step coming 
from any of the domains of CD4D1D2) are compared it is possible to 
see a shift to higher forces when the antibody is present. In this case the 
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average unfolding force increased around 80 pN (Fig. 6.21e), four 
times the values detected in FX experiments. We also detected this 
stabilization effect in the length increase of CD4D1D2, whose 
simultaneous unfolding was more probable in the presence of 
Ibalizumab (Fig. 6.21d). This could be explained in the context of the 
force range where the unfolding of the tandem takes place. Ibalizumab 
delays the unfolding of D2 domain meanwhile the tensile force 
increases, but when it unbinds it leaves the tandem submitted to forces 
way higher than the ones the CD4D1D2 tandem is able to resist by 
itself. At this high force the unfolding of both domains occurs in one 
single step that reveals that Ibalizumab binding mechanically stabilizes 
CD4. During HIV entry Ibalizumab could prevent CD4 unfolding 
decreasing the success of coreceptor binding because of the rigidity of 
the linker.  
These results suggested us that CD4 extension and flexibility 
play a significant role for the HIV successful infection. Another 
important feature of HIV infection is the redox regulation of the 
proteins involved147. CD4 domains possess intramolecular disulfide 
bonds whose presence imposes mechanical inextensibility beyond a 
certain point. In the force range we can apply with smFS these bonds 
are unbreakable due to their covalent nature. Besides, the virus could 
never pull at such high forces without breaking the weak contacts made 
with D1 domain. It is known that several oxidoreductases are secreted 
to the extracellular space for signaling and also for the regulation of 
membrane and extracellular proteins, and it has been demonstrated that 
the reduction of disulfide bonds present in gp120 and in CD4 are 
required for viral entry148,233. Specifically the disulfide bond reduction 
of CD4D2 domain is apparently required for the successful infection146. 
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This disulfide presents some particularities that make it different from 
the disulfide bonds of domains 1 and 4. For example in D1 the disulfide 
bond connects the B and F-strands, bridging the two β-sheets that form 
the β-sandwich structure of the domain. This is the typical architecture 
of Ig-like domains which present disulfide bonds. However in D2 the 
disulfide bond bridges the C and F-strands and both are part of the 
same β-sheet. This kind of disulfides are unusual and are related with 
the allosteric regulation of the protein231. In the case of CD4 the 
reduction of the disulfide bond of D2 domain would allow the 
dimerization of CD4 molecules through the formation of intermolecular 
disulfides between D2 domains of neighboring receptors234. Dimers of 
CD4 would help to stabilize the interaction with the MHC-II during 
antigen presentation and also would amplify the downstream signals 
that lead to T-cell activation.  
During viral attachment thioredoxin oxidoreductases secreted to 
the extracellular space could reduce D2 disulfide, making possible the 
total extension of this domain. Despite of being different from D1 and 
D4 disulfides, as in them D2 disulfide is buried in the hydrophobic core 
of the domain. As it is hidden, oxidoreductases cannot access the 
disulfide thus cannot reduce it. Nevertheless the viral particle bound to 
CD4 could unfold partially D2 domain making its disulfide solvent-
exposed and available for thioredoxin catalytic activity. We 
hypothesized that CD4 viral-induced extension could be 
mechanochemically enhanced by cell enzymes. In order to test this 
hypothesis we conducted FC experiments in the presence of 
thioredoxin. FC measurements are best suited for mechanochemical 
experiments since oxidoreductase activity is impaired when the 
substrate is held at high forces194, thus maintaining a constant 
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intermediate force guarantees the optimal catalytic performance of the 
enzyme. The data collected shows the unfolding of both domains up to 
its disulfide bonds and its posterior reduction as a consequence of the 
action of thioredoxin (Fig. 6.22). In very rare events was possible to 
unfold completely the domains showing no disulfide. Along the 
experiment thioredoxin could reduce the disulfide bonds of CD4D1D2 
molecules before stretching, but the low number of events registered 
suggests that their disulfides are inaccessible for the enzyme and only 
after mechanical extension of the protein they become available. In 
some occasions after the initial unfolding we detected the reduction of 
D2 domain disulfide but not the one from D1, suggesting that this 
disulfide is more prone to be regulated by thioredoxin.  
D2 domain disulfide bond shares the same configuration as the 
one of gp120 V3-loop, with two antiparallel β-strands connected235. 
This configuration, termed as –RHStaple, is typical of allosteric 
disulfides and provides the adequate positioning of the three sulfur 
atoms involved in the reaction, forming a 180º angle between 
thioredoxin Cys32 and CD4D2 Cys130 and Cys159, which favors 
reduction143. Moreover the –RHStaple configuration imposes an 
unfavorable conformation of the χ angles of the disulfide, generating a 
mechanical strain in the protein structure which destabilizes the bond. 
These topological constraints modulate the disulfide reactivity and 
stretching forces facilitate their reduction236. Therefore  external 
applied forces (like the exerted by the virus) induce a conformational 
distortion which affects the redox potential of the disulfide, lowering its 
activation energy237,238. Once the disulfide is reduced, the prestress 
topology of the protein could be released triggering conformational 
changes in both gp120 and CD4, which are required in the subsequent 
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events of infection143,235. This scenario strongly supports the 
mechanochemical regulation of CD4, where the virus could exert force 
enough for unfolding CD4 domains, destabilizing the oxidized state of 
the disulfide and easing the access of thioredoxin. Again the extra 
lengthening provided by a reduced and an unfolded CD4 domain would 
increase the chances of the virus for binding to its coreceptor, covering 
a larger area of the cell surface.  
 We propose that HIV takes advantage from CD4 
conformational malleability in order to commit a successful infection. 
Once bound, the virion remains attached to CD4 through weak 
interactions but the random movements of the particle can exert forces 
on CD4 high enough for inducing its mechanical extension. The 
unfolding of some of CD4 domains exposes buried disulfide bonds 
which are susceptible of redox regulation by thioredoxin, an 
oxidoreductase secreted to the extracellular space as part of the normal 
cell physiological processes. CD4 D2 domain is highlighted as a 
potential target for this redox regulation since its disulfide bond 
presents features proper of allosterism, facilitating the dimerization of 
CD4 molecules on the cell surface. This would allow HIV to extend 
CD4 even more, covering larger areas of the cell surface and increasing 
the probability of coreceptor encounter. CD4 dimerization could also 
help HIV binding, securing the attachment of one Env spike with two 
gp120/CD4 interactions. However we think the mechanochemical 
extension of CD4 during HIV binding contributes more to the infection 
than CD4 dimerization. Mechanically extended proteins are able to 
refold in the presence of low forces, and we think that viral Brownian 
motions can both extend and collapse CD4, hopping around the folding 
equilibrium of the domains of the receptor.  
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 Taking into account all of these features we propose CD4 
behaves as a shock-absorber element during HIV binding, a structure 
able to extend and contract at low forces due to the motion of the virus. 
The ability of releasing the tension experienced by the contacts of the 
gp120/CD4 interface would prevent the viral detachment from the 
receptor, as it happens with the unraveling mechanism of the type I 
pilus rod. Together with the hinge-like flexibility of CD4 and its 
mechanochemical extension, the opportunities for coreceptor binding 
of HIV increase. Our results using Ibalizumab show that the 
mechanical stabilization of CD4 could be the reason of the inhibitory 
effect of this antibody. This finding supports our hypothesis of the 
flexible spring-like structure hijacked for infection, and also highlights 
the mechanomedical research as a field full of possibilities for the 
future of Medicine.  
 
7.3 Conclusions and outlook 
In the presented work we have approached the mechanochemical 
aspects involved during UPEC and HIV-1 attachment to their target 
cells on the single molecule level. Our work strongly highlights the 
importance of forces on processes occurring at the nanoscale like 
bacterial and viral attachment, where single molecules and protein-
protein/ligand interactions govern the fate of these two pathogenic 
infections. 
 We think these findings are exportable to other models of 
pathogenic infection and that the nanomechanical properties of the 
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molecules involved in the attachment should be explored and 
considered for medical treatment development. 
 In the case of UPEC smFS has been proven to be useful for 
probing the mechanical stability of pilus proteins, and to resemble the 
extended state of pilus subunits for interrogating the maturation process 
in the periplasm. As it can be seen from our results, the redox state of 
pilus subunits disulfide bonds can be targeted for mechanical 
destabilization. Also, designed small peptides or molecules able to 
compete/disrupt for the donor-strand complementation in the mature 
pilus could be used for triggering pilus disassembly. This last strategy 
should be oriented to target specially the donor-strand interactions from 
the pilus tip, since the quaternary structure of the pilus rod would shield 
the access to FimA-FimA linkage unless it is mechanically uncoiled. 
Besides targeting the mature pilus, the main actors involved during 
pilus proteins periplasmic maturation and incorporation offer 
alternative approaches. DsbA defective mutants display problems for 
type I and P pilus maturation105. DsbA/DsbB system is widely spread 
across species, and targeting it affects several functions of the bacteria, 
many of them related with the assembly and secretion of virulence 
factors such as Tcp pili, cholera toxin and enterotoxin239. 
 Other potential targets for drug development could be the 
blockage of FimD secretion pore, which would inhibit pilus secretion. 
This target has some advantages since it is located in the OM of 
bacteria and it is easier to access. The blockage of SecYEG channel for 
avoiding periplasmic importation of proteins, or disrupting the 
favorable molecular surfaces provided by the periplasmic domains of 
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FimD, responsible of chaperone/subunit complex management during 
pilus assembly, could be more alternatives. 
 SmFS can be helpful in the developing and testing the effect of 
new drugs, as it was done with the CS20 fimbriae. In this research the 
mechanical effect of antibody binding to these adhesive structures of 
enterotoxigenic E. coli was tested with smFS experiments, showing that 
antibody binding decreased pilus elasticity hindering uncoiling. Higher 
forces were required to uncoil these pili because of the stabilization 
effect of the antibody, and also extended pilus recoiling was hindered 
due to this protein-protein interaction240. Peptides or molecules with the 
ability of disrupting pilus proteins mechanical stability could be also 
approached with smFS, and experiments on whole purified pilus should 
be conducted in order to test their effect on higher order structures.   
 Regarding CD4 and HIV infection we observed strong 
parallelisms with the UPEC attachment. The redox regulation of 
CD4D2 disulfide bond by thioredoxin, as DsbA does on pilus proteins, 
could be a potential target for viral infection prevention. However other 
oxidoreductases like PDI or glutaredoxin could substitute thioredoxin 
and also interfering with them probably would alter many cellular 
processes. In the case of CD4, the mechanical stabilization of its 
domains through antibody binding could be the better approach. 
Ibalizumab has shown us that its neutralizing activity could be 
explained in the context of CD4 stiffening due to antibody binding.  
 In the future the four extracellular domains of CD4 should be 
tested in order to obtain a complete description of the nanomechanics 
of this receptor. The glycosylation of D3 and D4 domains prevented us 
to produce this protein in our bacterial expression system, but as we 
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proved the first two domains of CD4 already gave us an interesting 
picture of how forces could be affecting them during infection. Future 
work involving smFS would require measurements of CD4 mechanical 
extensibility at forces close to the range of thermal motions, like for 
example using OT or MT setups. An interesting experiment would be 
to functionalize MT probes with gp120 and pull from full extracellular 
CD4 molecules attached to the surface. After gp120/CD4 binding, 
pulling at very low forces would reveal us the kinetics of CD4 domains 
unfolding when pulled from the specific binding site of HIV, 
resembling the in vivo interaction. These experiments should test also 
the effect of thioredoxin and Ibalizumab on this system, and see how 
these two proteins separated and in combination affect CD4 mechanical 
unfolding. 
 Our findings provide a framework for mechanomedical 
research. Research focused towards to find molecules able to bind to 
CD4, increasing its stiffness, and preventing its mechanical extension, 
could be the therapeutic strategy of the future to avoid HIV entry in 
cells. The same situation is applicable for UPEC pilus attachment 
where instead of protein stiffening, the mechanical weakening of its 
individual domains could be the best approach.  The 
Mechanopharmacology field may develop as the future strategy for the 
designing of fine-tuned drugs able to mechanically affect proteins 
involved in human diseases. 
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Appendix 
Protein sequences 
(I91)2-CD4D1D2-(I91)2 
LIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEI
IEDGKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKELIEVEKPLY
GVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHIL
ILHNCQLGMTGEVSFQAANAKSAANLKVKERSRSGSSKKVVLGKKG
DTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADS
RRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDT
HLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSG
TWTCTVLQNQKKVEFKIDIVVLAFQKASSRSLIEVEKPLYGVEVFVGE
TAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHILILHNCQLG
MTGEVSFQAANAKSAANLKVKELIEVEKPLYGVEVFVGETAHFEIELS
EPDVHGQWKLKGQPLTASPDCEIIEDGKKHILILHNCQLGMTGEVSFQ
AANAKSAANLKVKERS 
 
(I91)2-FimA-(I91)2 
LIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEI
IEDGKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKELIEVEKPLY
GVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHIL
ILHNCQLGMTGEVSFQAANAKSAANLKVKERSRSACAVDAGSVDQT
VQLGQVRTASLAQEGATSSAVGFNIQLNDCDTNVASKAAVAFLGTAI
DAGHTNVLALQSSAAGSATNVGVQILDRTGAALTLDGATFSSETTLN
NGTNTIPFQARYFATGAATPGAANADATFKVQYQDNKQAATTVNGG
TVHFKGEVVNARSLIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQW
KLKGQPLTASPDCEIIEDGKKHILILHNCQLGMTGEVSFQAANAKSAA
NLKVKELIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLT
ASPDCEIIEDGKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKERS 
 
(I91)2-FimF-(I91)2 
LIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEI
IEDGKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKELIEVEKPLY
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GVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHIL
ILHNCQLGMTGEVSFQAANAKSAANLKVKERSRSDGNGCSVAAEST
NFTVDLMENAAKQFNNIGATTPVVPFRILLSPCGNAVSAVKVGFTGV
ADSHNANLLALENTVSAASGLGIQLLNEQQNQIPLNAPSSALSWTTLT
PGKPNTLNFYARLMATQVPVTAGHINATATFTLEYQDNKQAATTVN
GGTVHFKGEVVNARSLIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQ
WKLKGQPLTASPDCEIIEDGKKHILILHNCQLGMTGEVSFQAANAKSA
ANLKVKELIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQP
LTASPDCEIIEDGKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKE
RS 
 
(I91)2-FimG-(I91)2 
LIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEI
IEDGKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKELIEVEKPLY
GVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHIL
ILHNCQLGMTGEVSFQAANAKSAANLKVKERSRSVVAKPCTVSTTNA
TVDLGDLYSFSLMSAGAASAWHDVALELTNCPVGTSRVTASFSGADS
TGYYKNQGTAQNIQLELQDDSGNTLNTGATKTVQVDDSSQSAHFPVR
ALTVNGGATQGTIQAVISITYTYSDNKQADSTITIRGYVRRSLIEVEKP
LYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKK
HILILHNCQLGMTGEVSFQAANAKSAANLKVKELIEVEKPLYGVEVF
VGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHILILHNC
QLGMTGEVSFQAANAKSAANLKVKERS 
 
(I91)2-FimH-(I91)2 
LIEVEKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEI
IEDGKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKELIEVEKPLY
GVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHIL
ILHNCQLGMTGEVSFQAANAKSAANLKVKERSRSFACKTANGTAIPIG
GGSANVYVNLAPVVNVGQNLVVDLSTQIFCHNDYPETITDYVTLQRG
SAYGGVLSNFSGTVKYSGSSYPFPTTSETPRVVYNSRTDKPWPVALYL
TPVSSAGGVAIKAGSLIAVLILRQTNNYNSDDFQFVWNIYANNDVVVP
TGGCDVSARDVTVTLPDYPGSVPIPLTVYCAKSQNLGYYLSGTTADA
GNSIFTNTASFSPAQGVGVQLTRNGTIIPANNTVSLGAVGTSAVSLGLT
ANYARTGGQVTAGNVQSIIGVTFVYQDNKQADVTITVNGKVRSLIEV
EKPLYGVEVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIED
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GKKHILILHNCQLGMTGEVSFQAANAKSAANLKVKELIEVEKPLYGV
EVFVGETAHFEIELSEPDVHGQWKLKGQPLTASPDCEIIEDGKKHILIL
HNCQLGMTGEVSFQAANAKSAANLKVKERS 
